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ABSTRACT 
Implantable cardioverter defibrillators (ICDs) reduce mortality in patients with 
ischaemic cardiomyopathy at high risk of ventricular arrhythmias (VA). 
However, the current indication for ICD prescription needs improvement. 
Telomere length and telomerase activity in leukocytes have been shown to 
correlate with biological aging and pathogenesis of cardiovascular diseases. 
Their role in arrhythmias, however, is unknown. 
I examined telomere biology in ischaemic cardiomyopathy patients and 
established its association with VA. This study stemmed from the primary 
hypothesis that telomere shortening at the time of the index event (myocardial 
infarction), results in poor myocardial repair process and predisposes patients 
to greater arrhythmic tendency. Hence there would be a correlation between 
leukocyte telomere length, load-of-short telomeres and telomerase activity with 
VA occurrence in these patients. I also investigated the effect of genetic 
variation on telomerase activity and VA. From a basic science perspective, 
different mechanisms of telomere shortening were studied by using a novel 
method for measuring critically short telomeres. 
90 ischaemic cardiomyopathy patients with primary prevention ICDs 
were recruited. 35 had received appropriate therapy from the ICD for 
potentially-fatal VA while the remaining 55 patients had not. No significant 
differences in baseline demographic data were seen between the two groups. 
There was no significant difference in the age and sex adjusted mean telomere 
length analysed by qPCR between the groups (p=0.66). In contrast, the load-
of-short telomeres assessed by Universal-STELA method and telomerase 
activity by TRAP assay were both higher in patients who had appropriate ICD 
therapy and were significantly associated with incidence of ICD therapy 
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(p=0.02, p= 0.02). Genetic variation in telomerase activity was observed with a 
significant correlation between telomerase and VA in C/C genotype only. 
These data collectively suggest that telomere biology is a promising area 
of exploration for further research in risk stratification for ICD prescription.
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Chapter 1 – INTRODUCTION 
1.1 Sudden Cardiac Death (SCD) and Ischaemic 
Cardiomyopathy 
1.1.1 Sudden Cardiac Death 
Sudden cardiac death (SCD) is defined as unexpected death from cardiac 
causes within one hour of symptom onset in a person with or without pre-
existing heart disease. Because the duration of symptoms preceding the 
terminal event usually defines the sudden nature of death, World Health 
Organization defines SCD as unexpected death within 1 hour of symptom 
onset if witnessed or within 24 hours of the person having been observed alive 
and symptom-free if unwitnessed. Exclusion of a non-cardiac cause is critical.[1] 
SCD is a major health problem affecting 50,000 – 70,000 lives in the 
United Kingdom and 250,000 – 300,000 in the United States every year and 
represents the largest proportion of deaths attributable to coronary artery 
disease (CAD) and caused by an arrhythmic event. [2,3] It accounts for more 
than 50% of all CAD deaths and 15-20% of all deaths. [4] Despite the recent 
advances in cardiopulmonary resuscitation and post resuscitation care, survival 
to hospital discharge for out of hospital cardiac arrests is approximately 5 - 8%. 
Moreover, the small proportion of people who do survive a cardiac arrest are at 
a higher risk of further arrest. Approximately 85–90% of SCD is due to the first 
recognised arrhythmic event; the remaining 10–15% is caused by recurrent 
events. [2,3] It poses a major challenge to the clinician as the vast majority of 
SCDs occur unwitnessed at home, a significant proportion in seemingly low risk 
individuals with no known cardiac disease. [3,5] 
The incidence of SCD increases markedly with age, independent of 
gender or ethnic background. [6,7] Despite this observation, the proportion of 
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deaths that are sudden is larger in the younger age group with a large 
socioeconomic impact. Men have a three fold higher risk of SCD than women, 
which might be a reflection of the lower incidence of CAD in the latter. Racial 
differences in SCD have also been reported with the relative risk of cardiac 
arrest being higher in Afro-Carribeans than Caucasians. [6,7] 
SCD is a complex disorder with varied etiology. It is believed to be 
caused by a dynamic interaction between a trigger event and underlying 
pathological substrate leading to a fatal ventricular arrhythmia (VA), which 
causes haemodynamic collapse resulting in cardiac arrest. The commonest 
primary electric event (contributing to the initiation of a fatal arrhythmia) 
recorded at the time of SCD is ventricular tachycardia (VT) in patients with 
CAD. [6,8] 
The various underlying disease processes implicated in causality of 
SCD include CAD, cardiomyopathies (dilated, hypertrophic and arrhythmogenic 
right ventricular cardiomyopathy) and channelopathies (long QT, short QT, 
brugada, catecholaminergic polymorphic ventricular tachycardia). Despite the 
varied etiology, CAD remains the commonest substrate accounting for nearly 
75% of all SCDs. [4,9,10] Hence it is one of the important subgroups to target with 
the aim to reduce the incidence of SCD.  
1.1.2 Sudden Cardiac Death and Coronary Artery Disease 
CAD is the most common and frequent cause of SCD in the Western world 
responsible for ~ 75% of all SCDs.[4,7] CAD can result in SCD in mainly three 
clinical scenarios: (1) acute myocardial infarction (MI) (2) myocardial ischaemia 
without infarction and (3) myocardial structural changes in the form of scarring 
or ventricular dilatation following prior infarction or chronic ischaemia. [4,7,9,10]  
Evidence from autopsy studies in sudden death victims indicates that stable 
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plaques and chronic atherosclerotic changes were the pre-dominant findings in 
the vast majority. [11] 
CAD, with its current prevalence, has a significant impact on the risk of 
SCD. Data from the Framingham heart study show that CAD was responsible 
for a 2.8- to 5.3- fold increase in risk of SCD. The risk of SCD post MI has a 
temporal trend and is maximum in the first 30 days, remaining significant at 6 
months and gradually decreasing with time with a plateau phase at two 
years.[12] 
 The mechanism underlying SCD post MI is believed to be an electrical 
event due to a VA triggered by an arrhythmogenic stimulus on the background 
of an ischaemic substrate. VT degenerating into ventricular fibrillation and then 
asystole is the commonest pathophysiological cascade involved in fatal 
arrhythmias. Bradyarrhythmias and electromechanical dissociation have been 
recorded at the time of SCD in patients with advanced heart failure. [6,8] 
In this subset of SCD victims, VT can be triggered by acute myocardial 
ischaemia resulting from abrupt changes in regional myocardial blood flow due 
to alterations in coronary artery structure and/or function, such as spasm, 
platelet thrombi, dissection, or plaque rupture. Alternatively, it can be in the 
context of an anatomical substrate in the form of myocardial scarring in the 
absence of acute myocardial ischaemia. Mechanisms leading to cardiac arrest 
in the absence of acute ischaemia include the generation of re-entrant circuits 
as a result of fibrosis on the border of an infarct zone, triggered activity in scar 
tissue, worsening heart failure and metabolic/electrolyte disturbances. In 
addition, certain genetic polymorphisms may predispose individuals to a 
greater chance of developing VAs in the presence of an initiating insult. [13,14,15] 
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 Preventive strategies to reduce the global burden of SCD can take the 
form of primary prevention of CAD by minimising the associated risk factors or 
primary prevention of SCD by risk stratification and intervention in those 
individuals with established cardiovascular disease placing them at higher risk 
than the general population. Although it might seem obvious that reduction of 
cardiovascular risk factors would result in reduction of CAD and SCD, robust 
evidence supporting this notion is currently lacking. [3] 
For prevention of SCD in CAD patients, better identification of risk 
factors and pathogenesis of SCD in CAD is essential. It is critical to know who 
is likely to remain stable for months or years after the index event (MI) and who 
has a likely substrate for fatal VAs. Timely and accurate identification of 
individuals likely to suffer an arrhythmic event in the general population lacks a 
widely accepted, highly sensitive and specific predictive model. Current 
parameters for risk stratification of patients with CAD for SCD include medical 
history (presence of non-sustained ventricular tachycardia or syncope), family 
history of MI, New York Heart Association Class (NYHA), left ventricular 
ejection fraction, ECG criteria (QRS duration, QT interval, QT dispersion), 
signal averaged ECG, heart rate variability and baroreflex sensitivity. 
Candidate gene and genome wide association studies have helped identify 
single nucleotide polymorphisms (SNP) associated with SCD in CAD patients. 
However, the sensitivity and specificity of these parameters needs to be 
established in large-scale population studies for them to be used as 
independent risk predictors. Also, the heritability of SCD in this subgroup 
remains poorly understood. Although the above parameters have been used in 
combination in various risk prediction algorithms, the only one established as 
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an independent risk predictor of SCD in CAD is left ventricular ejection fraction 
(LVEF). [1] 
Interventions and therapies directed towards CAD in general and SCD in 
particular have been tried to reduce the incidence of SCD in the general 
population. Pharmacological therapy including beta-blockers, anti-arrhythmics 
and statins have shown some potential. However, amongst all medications 
tested, only beta-blockers have shown definite reduction in incidence of SCD in 
patients who survived a MI. The Beta-Blocker Heart Attack Trial (BHAT) study 
showed that β-blockade with propranolol reduced all-cause mortality by 25%, 
especially in patients with diminished LV function and/or VAs. [16] The most 
effective of all interventions to date is the implantable cardioverter defibrillator 
(ICD). Multiple randomised control trials (RCTs) have shown a marked survival 
benefit with ICD therapy in patients with poor left ventricular function on the 
background of prior MI. In this subgroup of patients, ICD therapy has been 
associated with a 23%–55% mortality reduction, due almost exclusively to a 
reduction in SCD. [1] 
1.2 Implantable Cardioverter Defibrillators (ICD) in Ischaemic 
Cardiomyopathy 
1.2.1 Implantable Cardioverter Defibrillator – The Evolution 
The implantable cardioverter defibrillator (ICD) is recognised as an effective 
therapeutic modality for termination of malignant VAs and hence prevention of 
SCD. Multiple prospective, randomised, multicenter clinical trials have 
documented its efficacy in improved survival by reduction of SCD in patients 
with CAD.  
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Figure 1: Image showing the implantable cardioverter defibrillator with pulse 
generator and atrial and ventricular leads in the heart 
 
     (Taken from JAMA. 2006;296(23):2839-2847) [17] 
 The concept of an ICD first emerged in late 1960s with the advent of 
external defibrillation and the first clinically applicable, ICD implant was 
performed in 1980 by Mirowski. [18] Initial clinical acceptance was slow, but 
improved substantially after the Food and Drug Administration (FDA) approval 
was granted in 1985.  
Since its initial conception, the ICD has undergone phenomenal change 
in structure and function with advances in technology. The very early devices 
were short lived, could provide shock only therapy, weighed 250 g and required 
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thoracotomy and abdominal generator implants. The current devices have 
become smaller and are suitable for pre-pectoral implants. They have extended 
longevity, endocardial/epicardial lead systems with capacity for multi-
programmable tiered therapy with advanced rhythm discrimination.  
 The current data supporting ICDs (primary and secondary indications) 
have been derived from several RCTs, the vast majority of which were 
published between late 1996 and early 2005, in a period of less than 10 years. 
The evidence from these trials started to get consideration and support from 
the larger scientific community after the publication of the initial results of the 
CAST (Cardiac Arrhythmia Suppression Trial) study in 1989. [19,20] CAST had 
an indispensable influence on arrhythmia management by concluding that anti-
arrhythmics (flecainide/encainide) should not be used in patients with minimally 
symptomatic VA after MI due to increased risk of arrhythmic deaths. [19,20] The 
paradigm for preventive therapy of SCD drifted away from anti-arrhythmic 
therapy, providing a boost to the potential of device therapy. The role of ICDs in 
arrhythmia detection and the evidence base for the benefits of primary 
prevention ICDs and their efficacy in preventing SCD, especially in ischaemic 
cardiomyopathy, is presented next.  
1.2.2 ICD as a Tool for Arrhythmia Detection and SCD prevention  
The role of ICDs in SCD prevention is largely based on their ability to detect 
and treat arrhythmias. ICD generators have advanced programmability and 
internal circuitry, which is designed to deliver high-energy shocks within 
seconds of arrhythmia detection. They have detailed data logging capabilities 
and can record precise measurements of arrhythmia rates, time of occurrence 
and response to therapy. The stored electrograms provide beat-to-beat interval 
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data for VA detection and are an important diagnostic to assess the 
appropriateness of therapy and any malfunction of the system.  
Arrhythmia detection requires effective sensing of the intrinsic cardiac 
activity and fulfillment of the programmed detection algorithm. The 
programmed algorithms help the ICD to differentiate between supraventricular 
and ventricular arrhythmias and hence prevent inappropriate therapy. After 
each delivered therapy, the ICD determines whether the tachycardia was 
terminated and the need for any further therapy. 
Therapies delivered for VAs can be antitachycardia pacing (ATP) and 
shock therapy. ATP refers to high-rate, overdrive pacing to terminate VT and 
has shown to be more effective in terminating spontaneous VTs (slower) rather 
than induced VTs (faster). [21] ATP can be unsuccessful in the setting of poor 
LVEF and very rapid ventricular rates (>200bpm). [22] However, ATP still 
remains the preferred mode of initial therapy as it has >90% success rate in 
terminating VT, [23] is painless and contributes to preservation of battery life 
when compared to cardioversion. Failing ATP or as a first line therapy for VF, 
ICDs can deliver high-energy shocks for cardioversion. Although effective, this 
drains the battery quickly, can be pro-arrhythmic and has a negative impact on 
the patients QOL. 
Device programming to detect VAs is central to the delivery of 
appropriate and inappropriate therapies and should be based on a good 
understanding of the patient’s arrhythmias, underlying pathophysiology and 
indication (primary/secondary) for ICD implant. Most devices allow for multiple 
zones of VA detection based on heart rate. Whereas a shock box programmed 
to detect and treat VF in a single zone works to reduce SCD, the use of VT 
zones allows for the use of ATP and SVT discriminators to avoid both 
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inappropriate and appropriate shocks. Careful device programming is key to 
achieve the primary aim of reduction of SCD while minimising the adverse 
effects of shock therapy. 
1.2.3 ICD For Prevention of SCD – The Evidence Base 
On a background of optimal medical therapy, RCTs have shown a risk 
reduction of sudden death following ICD implantation in patients with left 
ventricular dysfunction post MI to be approximately 25 - 50%. [1,24,25] These  
were primarily designed to test the efficacy of defibrillator therapy against 
pharmacological therapy alone for “protection” against SCD. Primary 
prevention trials investigating role of ICDs in potentially reducing the burden of 
SCD are summarised as follows: 
MADIT I (Multicenter Automatic Defibrillator Implantation Trial I); 1996: was the 
first RCT designed to test if ICD therapy would result in improved survival in 
patients with CAD at high risk of SCD when compared to conventional medical 
therapy. 196 patients with ischaemic cardiomyopathy and a LVEF ≤ 35%, a 
documented episode of non-sustained ventricular tachycardia (NSVT) on holter 
monitoring and inducible VT by programmed stimulation (with failure of 
intravenous procainamide to prevent inducibility) were randomised to receive 
an ICD (n=95) versus conventional medical therapy (n=101). ICD therapy was 
associated with a 59% relative risk reduction of death after a mean follow-up of 
27 months. This led to the approval of ICD for MADIT I indication 1996. [26] 
MADIT II (Multicentre Automatic Defibrillator Implantation Trial II); 2002: 
following on from MADIT I results, this trial aimed to identify patients with 
ischaemic cardiomyopathy who are at high risk of SCD, before the actual 
manifestation of VAs. Patients with CAD with previous MI with LVEF ≤ 30% 
and on optimal medical therapy, were randomised to receive an ICD (n=742) or 
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no ICD (n=490). Results indicated a 31% relative risk reduction in mortality 
(SCD) in the ICD group over a 20-month follow-up. The FDA approved ICD 
prescription for MADIT II indication in 2002. Also, the American College of 
Cardiology and European Society of Cardiology rendered level IIA 
recommendation for prophylactic implantation of ICDs in MADIT II type 
patients. [26,27] 
Trial	   Year	   Patients,	  
(n)	  
LVEF	  
(%)	  
Enrolment	  Criteria	   Outcome	  
MADIT	  I	   1996	   196	   ≤35	   Prior	  MI,	  LVEF≤35%,	  
NSVT	  on	  Holter,	  
inducible	  VT	  and	  failure	  
of	  VT	  suppression	  with	  
i.v.	  procainamide	  
54%	  reduction	  
in	  total	  
mortality	  with	  
ICD	  therapy	  
MADIT	  II	   2002	   1232	   ≤30	   Prior	  MI	  and	  LVEF≤30%	   31%	  reduction	  
in	  total	  
mortality	  with	  
ICD	  therapy	  
MUSTT	   2000	   1397	   ≤40	   Prior	  MI	  and	  LVEF≤40%	   31%	  reduction	  
in	  total	  
mortality	  with	  
ICD	  therapy	  
SCD-­‐HeFT	   2006	   1676	   ≤35	   Ischaemic	  and	  non-­‐
ischaemic	  
cardiomyopathy,	  
LVEF≤35%,	  NYHA	  class	  
I/II	  
23%	  reduction	  
in	  mortality	  with	  
ICD	  therapy	  
DEFINITE	   2004	   485	   ≤35	   Non-­‐ischaemic	  dilated	  
cardiomyopathy,	  
LVEF≤35%,	  NSVT	  or	  
PVCs	  
35%	  reduction	  
in	  arrhythmic	  
mortality	  with	  
ICD	  therapy	  
CABG-­‐PATCH	   1997	   900	   ≤36	   CAD,	  undergoing	  non-­‐
emergent	  CABG,	  
LVEF≤36%	  and	  
abnormal	  SAECG	  
No	  reduction	  in	  
total	  mortality	  
with	  ICD	  
therapy	  
DINAMIT	   2004	   674	   ≤35	   MI	  within	  past	  40	  days,	  
LVEF≤35%,	  depressed	  
HRV,	  average	  24hr	  
HR≥80bpm	  
50%	  reduction	  
in	  arrhythmic	  
deaths	  with	  ICD	  
therapy	  
COMPANION	   2004	   1520	   ≤35	   NYHAIII/IV,	  LVEF≤35%,	  
QRS≥120ms,	  
hospitalisation	  for	  CHF	  
within	  12	  months	  
24%	  reduction	  
in	  total	  
mortality	  with	  
CRT	  alone	  
MADIT-­‐	  CRT	   2009	   1820	   ≤30	   Ischaemic	  or	  non-­‐
ischaemic	  
cardiomyopathy,	  
LEVF≤30%,	  
QRS≥130ms,	  NYHAI/II	  
34%	  relative	  risk	  
reduction	  in	  risk	  
of	  total	  morality	  
 
Table 1: Summary of primary prevention ICD clinical trials [19] 
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[Trial names, year in which trial carried out, number of patients recruited, their 
LVEF, enrolment criteria and trial outcomes have been shown. MADIT I: 
Multicenter Automatic Defibrillator Implantation Trial I, MADIT II: Multicentre 
Automatic Defibrillator Implantation Trial II, MUSTT: Multicentre Unsustained 
Tachycardia Trial, SCD-HeFT: Sudden Cardiac Death in Heart Failure Trial, 
DEFINITE: Defibrillators in Non-ischaemic Cardiomyopathy Treatment 
Evaluation, CABG-Patch: Coronary Artery Bypass Graft Patch, DINAMIT: 
Defibrillator in Acute MI Trial, COMPANION Trial: Comparison of Medical 
Therapy, Pacing, and Defibrillation in Heart Failure, MADIT-CRT: Cardiac-
resynchronisation therapy for prevention of heart failure events] 
 
MUSTT (Multicentre Unsustained Tachycardia Trial); 1999: tested the value of 
electrophysiologically guided antiarrhythmic drug therapy against no therapy in 
high risk CAD with poor LVEF ≤ 40% and NSVT. Risk assessment was carried 
out by testing inducibility of a sustained ventricular tachycardia. Patients with a 
history of MI, LVEF ≤ 40%, NSVT, and inducible VT despite antiarrhythmic 
drug use were randomly assigned to receive an ICD, electrophysiologically 
guided antiarrhythmic therapy, or no antiarrhythmic therapy. At 5 years, 
patients in the ICD group had a 31% absolute and 58% relative risk reduction. 
Electrophysiologically guided antiarrhythmic therapy did not reduce the rate of 
cardiac arrest, death from arrhythmia, or the overall mortality rate in 
comparison with no antiarrhythmic therapy. These results confirmed inducibility 
testing as the most accurate risk-stratifying marker and demonstrated no 
benefit in serial EP drug testing and highlighted the risks associated with stand 
alone antiarrhythmic drug treatment. [28] 
SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial); 2005: was designed 
to evaluate whether amiodarone or a conservatively programmed shock-only, 
single-lead ICD decreases the risk of death from any cause in a broad 
population of patients with mild-to-moderate heart failure. The trial enrolled 
2521 patients with NYHA II/III chronic heart failure and LVEF ≤ 30% due to 
ischaemic or non-ischaemic etiology. Patients were randomised to receive 
	  	  
31	  
optimal medical therapy alone (n=847), optimal medical therapy along with 
amiodarone (n=845), or optimal medical therapy along with a ICD (n=829). 
Placebo and amiodarone were administered in a double-blind fashion. Results 
indicated a 23% reduction in mortality in the ICD group over a mean follow up 
of 3.8 years. The benefit of ICD was similar in both the ischaemic and non-
ischaemic group. Optimal medical therapy and amiodarone lead to no survival 
benefit. [25] 
DEFINITE (Defibrillators in Non-ischaemic Cardiomyopathy Treatment 
Evaluation); 2004: trial enrolled 458 patients with non-ischaemic dilated 
cardiomyopathy, LVEF ≤ 36%, and premature ventricular complexes or NSVT. 
Patients were randomised to receive standard medical therapy (n=229) or to 
receive standard medical therapy plus a single-chamber ICD (n=229). Results 
indicated a mortality rate of 14.1% in the standard medical therapy group and 
7.9% in the ICD group at 2 years of follow up. The largest benefit was seen in 
NYHA class III patients. The results of this trial expanded the prescription of 
primary prevention ICDs to the non-ischaemic cardiomyopathy. [29] 
CABG-Patch (Coronary Artery Bypass Graft Patch); 1997: trial investigated the 
benefit of ICDs in patients with CAD who underwent elective coronary artery 
bypass surgery and who also had a LVEF ≤ 36% and abnormal signal 
averaged electrocardiograms. 1055 patients were enrolled and randomly 
assigned to therapy with ICD (n=446) or to the control group (n=454). The 
primary end point of the study was overall mortality, and the two groups were 
compared in an intention-to-treat analysis. Contrary to other primary prevention 
trials, results indicated no survival benefit associated with ICD therapy. [30] 
DINAMIT (Defibrillator in Acute MI Trial); 2004: examined the utility of early ICD 
implantation post MI in CAD patients with LVEF ≤ 35% and impaired cardiac 
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autonomic function (manifested as depressed heart-rate variability or an 
elevated average 24-hour heart rate on Holter monitoring). Patients were 
randomised to ICD therapy (n=332) or no ICD therapy (n=342), 6 - 40 days 
post MI. At 2.5- year follow-up, there was no survival benefit from early ICD 
implantation, which was associated with lower arrhythmic mortality rates but 
with an unexplained increase in non-arrhythmic death, in comparison with the 
outcomes after conventional therapy. The results of this trial lead to the 
recommendation that ICD implants should be delayed for at least 40 days 
following an acute myocardial infarct. [31] 
COMPANION Trial (Comparison of Medical Therapy, Pacing, and Defibrillation 
in Heart Failure); 2004: is the only trial in which ICD therapy was evaluated in 
patients with advanced heart failure, NYHA class IV. The trial investigated the 
utility of prophylactic cardiac-resynchronisation therapy (with or without a 
defibrillator) in reduction of risk of death and hospitalisation among patients 
with advanced chronic heart failure and intra-ventricular conduction delay. 1520 
patients who had advanced heart failure due to ischemic or non-ischaemic 
cardiomyopathies and a QRS interval of at least 120ms were randomly 
assigned in a 1:2:2 ratio to receive optimal medical therapy alone or in 
combination with cardiac-resynchronisation therapy with either a pacemaker or 
a pacemaker-defibrillator. The primary composite end point was the time to 
death from or hospitalisation for any cause. Results indicated that heart-failure 
hospitalisation and all-cause mortality rates were lower in both the CRT and 
CRT-D groups (24% versus 36%) than in the group that received no device 
therapy with a similar benefit across ischaemic and non-ischaemic 
cardiomyopathy patients. The results of this trial established a case for CRT-D 
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implants in patients with advanced heart failure and wide QRS interval with 
view to improve heart failure symptoms and reduce mortality. [32] 
MADIT-CRT (Cardiac-resynchronisation therapy for prevention of heart failure 
events); 2009: was designed to evaluate the utility of CRT-D therapy in patients 
with mild heart failure. 1820 patients with ischaemic or non-ischaemic 
cardiomyopathy, LVEF ≤ 30%, QRS duration ≥ 130ms and NYHA class I/II 
were randomly assigned in a 3:2 ratio to receive CRT plus an ICD (n=1089) or 
an ICD alone (n=731). The primary end point was death from any cause or a 
nonfatal heart failure event. During a follow-up of 2.4yrs, a relative risk 
reduction of 34% was noted in the CRT-D group largely driven by a decrease in 
non-fatal heart failure events. Since CRT-D significantly reduced the incidence 
of the trial primary end point (without conferring a survival benefit from SCD 
prevention), it is now indicated in patients with NYHA class I/II. [33] 
These trials provide conclusive evidence for mortality reduction from SCD and 
survival benefit provided by ICD therapy in ischaemic cardiomyopathy patients. 
Of note, different risk factors have been used to determine patient eligibility 
(and hence risk of SCD) for enrolment across trials. The unifying risk predictor 
appears to be a poor LVEF. A better understanding of various risk stratification 
markers used for primary prevention ICD implants and the evidence behind 
their utility in clinical practice is essential.  
1.2.4 Current Risk Stratification for Primary Prevention ICDs 
It is intuitive that the benefit derived from ICD therapy would be a balancing act 
between a patient receiving lifesaving appropriate therapy from the device or 
being lost to death in the absence of any device therapy. The key to achieving 
the former lies in timely and precise identification of patients with CAD who are 
likely to be at the highest risk of malignant VAs and hence SCD. 
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 As evident from the various clinical trials discussed in the previous 
section, acute MI survivors are currently risk assessed and selected for primary 
prevention ICD implants largely on the basis of their LVEF. However, it is also 
apparent from these trials and more recent evidence that other variables in 
addition to LVEF, help refine risk of SCD.  
These risk stratifying markers detect: (1) slow conduction (QRS 
duration, Signal averaged electrocardiogram – SAECG), (2) heterogeneities in 
ventricular repolarisation (QT interval, QT dispersion, T-wave alternans), (3) 
imbalance in autonomic tone (heart rate variability, heart rate turbulence, heart 
rate recovery after exercise, baroreceptor sensitivity), (4) extent of myocardial 
scar formation (LVEF, 6 minute walk), and (5) ventricular ectopy (long term 
ambulatory monitoring). [34] The current evidence for the use of these risk -
stratifying markers is presented here.  
 Left ventricular ejection fraction (LVEF): is the most widely used 
measure of left ventricular systolic function. It is the single major parameter that 
has been most consistently studied in clinical trials and reported to reliably 
define risk for SCD in ischaemic cardiomyopathy. RCTs have demonstrated 
that LVEF is the strongest predictor of SCD in acute MI survivors. [25,26,28,29] The 
MADIT trial demonstrated a 50% reduction in mortality with ICDs compared 
with medical therapy alone. [26] Subsequent analysis of the MADIT data 
demonstrated that this benefit was greatest in patients with LVEF ≤ 26%. [35] 
These results were reinforced in MADIT II which demonstrated a 31% risk 
reduction of death in patients (with LVEF ≤ 30% and prior MI) who were 
randomised to the ICD arm. [26] Likewise, it was noted in the MUSTT trial that 
the frequency of arrhythmic deaths was higher in patients with LVEF ≤ 30%. [28] 
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Similar reduction in mortality with ICD therapy in patients with poor LVEF were 
seen in the SCDHeFT trial. [25]  
 LVEF is commonly measured by 2-dimensional echocardiography and 
has several advantages. It is readily available and routinely performed in 
patients post MI. The accuracy of LVEF is in excess of ± 10% for both visual 
estimation and calculation by Simpson’s rule with echocardiography. Current 
international guidelines for prophylactic ICD implants are predominantly based 
on LVEF. 
QRS duration: on a 12 lead electrocardiogram (ECG) quantifies the duration of 
ventricular depolarisation and is a reflection of intra-ventricular or inter-
ventricular conduction delay or block. It is highly reproducible with a coefficient 
of variation of < 5%. [36] QRS prolongation has been shown to be associated 
with worse outcome in patients with poor LVEF due to CAD in observational 
studies. [37] QRS prolongation could be a surrogate marker for more advanced 
myocardial disease, but it may also contribute directly to increased mortality, 
because dys-synchronous ventricular activation may cause depression of 
cardiac function. [34] The CASS (Coronary Artery Surgery Study) registry 
showed that patients with left bundle branch block (LBBB) had more extensive 
CAD and worse LVEF than patients with a normal QRS. Moreover, LBBB was 
a strong predictor of arrhythmic mortality independent of degree of heart failure 
and extent of CAD. [38] The presence of fragmented QRS (fQRS) has been 
shown to be associated with myocardial scar in CAD patients and evidence 
suggests that it is a significant predictor of mortality and SCD in CAD. [39]  
 The utility of QRS prolongation as a predictor of SCD has been tested in 
subgroup analysis of various RCTs. An independent analysis of MADIT II data 
revealed that a prolonged QRS was significantly associated with survival 
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benefit from ICD therapy. [40] Prolonged QRS (>120ms) was also shown to 
correlate with appropriate ICD therapy and a higher hazard ratio of SCD (ICD 
therapy). [25] MUSTT results demonstrated that LBBB and non-specific 
intraventricular conduction delay (IVCD) were associated with increased total 
mortality risk, although there was no significant link between LBBB and 
inducible monomorphic VT. [28] 
 The simplicity, ease of measurement, cost-effectiveness and easy 
reproducibility on each follow up visit make QRS duration an attractive 
candidate for further investigation. It is not currently used as an independent 
parameter for risk stratification of SCD in ischaemic cardiomyopathy. 
QT interval and QT dispersion: QT interval represents the time required for 
both ventricular depolarisation and repolarisation to occur and hence is a 
reflection of summed ventricular action potential duration. It shortens with 
increasing heart rate and is commonly corrected (QTc) by using the Bazett’s 
formula. Although, QT-interval measurements have been shown to be highly 
reproducible, [41] the need for rate correction with suboptimal formulas limits the 
comparability of QT data in populations. [34]  
 Observational studies have shown association of QT prolongation with 
mortality in patients with moderate and severe left ventricular dysfunction. [42] 
However, this association was not reproducible in other studies. [43,44] Some 
population studies have demonstrated QT prolongation to independently effect 
the prognosis of cardiovascular mortality, [45] but its clinical utility (in the 
absence of congenital long QT syndrome) is at best limited to a risk association 
with increased mortality in CAD. [46] 
 QT dispersion represents the difference between maximum and 
minimum QT interval on a 12-lead ECG. It is thought to measure cardiac 
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electrical heterogeneity and hence of value in arrhythmia risk prediction. It has 
been associated with increased mortality in some observational studies. [42] Yet, 
others have found no association between this parameter and cardiovascular 
outcome. [43,47] 
 The utility of QT interval and QT dispersion in ischaemic cardiomyopathy 
has not been tested in any large RCT. They are not used as independent risk 
stratifiers in this context. The inter- and intra-observer variability reduce the 
reproducibility of these parameters, which further challenges their utility for risk 
stratification. 
Holter Analysis: Ventricular ectopy and NSVT – ventricular premature beats 
and NSVT have been shown to have prognostic importance in patients with 
CAD especially in the presence of left ventricular impairment. An increased 
relative risk of SCD in patients post MI with ≥ 10 VPB/hour and NSVT has been 
demonstrated. [48-51] This observation was reproducible in the modern era of 
interventional cardiology and early re-perfusion. [49,52,53] NSVT was found to be 
an independent predictor of SCD post MI. [53] The European MI Amiodarone 
Trial (EMIAT) investigators showed a higher mortality in patients with frequent 
or complex arrhythmias on AECG than in those without (20% versus 10%) on 
the background of poor LVEF ≤ 40% post MI. [54] 
 In combination with an impaired left ventricular function, ventricular 
ectopy and NSVT are very strong risk factors for mortality in CAD.  
Unfortunately, the sole use of conventional 24-h Holter monitoring for the 
prediction of VAs is significantly limited by its low sensitivity and specificity. 
 
Heart rate variability (HRV) – provides a surrogate for the autonomic effects in 
the ventricle that are postulated to be important in the pathogenesis of VAs. It 
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has been proposed that an analysis of HRV, particularly its parasympathetic 
effects on the sinus node, can potentially predict mortality. [34]  
 HRV reflects changes in cardiac autonomic tone that occur post 
MI. It tends to decrease early after an infarct and a steady increase towards 
normality is observed within 6 – 12 weeks. [55] The Multicentre Postinfarction 
Study (MPS) showed that HRV was a significant predictor of mortality in acute 
MI patients, and remained so even after adjusting for LVEF. [56] The ATRAMI 
(Autonomic Tone and Reflexes after MI) trial provided clinical evidence that 
after MI, patients with low HRV had a relative mortality risk of 3.2 having 
accounted for a poor LVEF. However, it also demonstrated that other markers 
of autonomic dysfunction were superior to HRV in prediction of mortality in 
context of a poor LVEF (≤ 35%). [57] In the DINAMIT and ALIVE trials, patients 
with low HRV had a higher non-arrhythmic mortality, which was believed to be 
a reflection of advanced haemodynamic compromise. [31,58]  
HRV can be automatically recorded using the standard holter. Overall 
low HRV has been shown to be a predictor of overall mortality rather than 
being specific for arrhythmic deaths. This alongwith its futility in patients with 
atrial fibrillation and its variability with external factors like age, gender and 
functional status of sinus node, limits its use as an independent risk predictor in 
ischaemic cardiomyopathy. 
Heart rate turbulence (HRT): is a marker of baroreceptor sensitivity that 
quantifies mainly the reflex vagal activity. It is a measure of fluctuations in sinus 
rhythm cycle length following a single premature ventricular ectopic. In normal 
healthy individuals, a premature ventricular ectopic is followed by a biphasic 
response (acceleration followed by deceleration) of sinus rhythm. This pattern 
is absent in high-risk patients. HRT has been shown to be a powerful 
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independent predictor of risk following a MI. The REFINE (Non Invasive Risk 
Assessment Early after a MI) study results concluded that impaired HRT in 
patients with LVEF ≤ 50%, beyond 8 weeks after a MI could reliably identify 
patients at a high risk of arrhythmic death. [59] HRT in combination with 
deceleration capacity was shown to identify high-risk individuals amongst post 
MI patients with LVEF ≤ 30%. [60] Moreover, a relative risk of ~ 4 for fatal and 
non-fatal cardiac arrest post MI was attributable to a low HRT in an ATRAMI 
substudy. [61] 
 HRT has primarily been examined in patients with ischaemic etiologies. 
It can be automatically recorded with a standard holter. However, it cannot be 
reliably assessed in patients with atrial fibrillation and an optimal time post MI 
to perform the test has not been established. Given the results so far and the 
ease with which it can be performed, it is a potentially attractive risk 
stratification tool.  
Signal Averaged ECG (SAECG): calculates an average of consecutive QRS 
complexes (usually around 300) to produce a filtered QRS complex that 
provides useful information on the presence of ventricular late potentials 
(VLPs). VLPs represent slowed conduction through a diseased myocardium, 
which may serve as a substrate for subsequent VAs, and have been 
documented in 25-50% of patients soon after MI. [62] Various studies have 
looked into the prognostic value of SAECG in predicting mortality post MI. 
SAECG has a sensitivity of 15% to 75% (over a follow up period of 6 – 24 
months) to predict arrhythmic events with a negative predictive value of >90% 
and hence its utility in identifying very low risk patients. [62,63]  
The MUSTT investigators found that a filtered QRS >114ms was 
associated with a 28% risk of arrhythmic events during a 5-year follow-up 
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period compared with a 17% risk of events for those with shorter filtered QRS 
durations. [64] The CABG-Patch trial used SAECG as an enrolment criteria in 
addition to poor LV function but did not find it useful in defining arrhythmic 
risk.[30] 
 SAECG is easy and quick to perform and can be utilised in patients with 
atrial fibrillation. However, it has a very low positive predictive value and hence 
limiting its utility in identification of high-risk patients. Also, it is better at 
predicting ventricular tachycardia rather than ventricular fibrillation and a 
standardised measurement in the presence of bundle branch block is not 
available. It is currently not used as a sole risk stratification marker and is 
recommended as a class IIB risk stratification tool in post MI patients. [65] 
T wave alternans (TWA): is a heart rate dependent measurement of beat-to -
beat changes in the amplitude of the T-wave on an ECG. It is thought to reflect 
dispersion of ventricular repolarisation and has been shown to be associated 
with fatal VAs. [66,67] TWA can be assessed during exercise (microvolt T-wave 
alternans, MTWA) or during ambulatory Holter-based recordings (modified 
moving average analysis). MTWA has been shown to be a strong predictor of 
fatal arrhythmias and SCD post MI, with and without left ventricular impairment. 
[66,67] The ABCD (Alternans before Cardioverter Defibrillator) trial was a 
prospective trial in ischaemic cardiomyopathy patients (LVEF ≤ 40%) and 
demonstrated that risk stratification using MTWA versus invasive 
electrophysiology studies are comparable at 1 year and complementary when 
used in combination. The positive and negative predictive values of MTWA at 1 
year were 9% and 95% respectively. [68] Another similar trial, the MASTER 
(Microvolt T wave Alternans Testing for Risk Stratification of Post-Myocardial 
Infarction Patients) trial in ischaemic cardiomyopathy patients showed that 
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MTWA testing did not predict arrhythmic events. However, MTWA non-
negative patients (positive and indeterminate) had significantly higher mortality 
than MTWA negative patients. [69]  
 TWA currently has a class IIa indication for risk stratification of primary 
prevention ICDs in ischaemic cardiomyopathy. Its high negative predictive 
value makes it valuable for identification of low risk individuals. However, a 
significant proportion of tests are indeterminate due to inability to achieve a 
target heart rate with regular R-R intervals; secondary to atrial fibrillation, 
frequent ectopic activity or failure to reach a target heart rate. Its value may be 
enhanced in combination with other risk predictors.  
Baroreceptor sensitivity (BRS): is used for assessment of autonomic control of 
the cardiovascular system. It refers to the adaptation of R-R intervals to 
changes in blood pressure. [70] BRS is most commonly measured in clinical 
practice during a brief period of controlled blood pressure change while 
administering an intravenous bolus of phenylephrine.  
BRS has been shown to be strongly associated with a risk of fatal VA. In 
a prospective study of 78 post MI patients, BRS was found to be significantly 
lower in the deceased patients (including SCD) than in the survivors. [71] These 
results were found in other studies as well. [72,73] The multicenter ATRAMI study 
also helped establish BRS as a risk stratification marker in ischaemic 
cardiomyopathy. [57] Depressed HRV or BRS were shown to have a significant 
risk of cardiovascular mortality and this risk was further increased if both 
parameters were depressed. Also, further analyses showed that in conjunction 
with a poor LV function (LVEF<35%), a depressed BRS conferred a 
significantly worse two-year survival than a preserved BRS in these patients.[57] 
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BRS may be useful in risk stratification for SCD in ischaemic cardiomyopathy, 
but it is not yet established as an independent marker. 
 
It is evident from the above discussion that left ventricular dysfunction remains 
the key investigation in determining which patients should be offered an ICD. A 
number of non-invasive investigations have been shown to help in risk 
stratification. However, these have not found a place in the current international 
guidelines. 
 With an increasing number of patients surviving acute MIs, the number 
of ICD implants has substantially increased in this group of patients at a high 
risk of VAs. [2,3,5] Subjecting an increasingly large population to an invasive ICD 
implant requires more thought as it has clinical implications for the patients and 
financial implications for the healthcare providers. To be able to use resources 
efficiently for the greatest clinical benefit, it is important to understand not just 
the clinical benefits of an ICD implant but the associated clinical procedural 
risks and financial implications.  
 Without doubt, the ICD has proven its utility in reducing mortality in a 
very high-risk population. But do ICD implants come with their own risk? Or is 
there a dark side to life with an ICD implant? Or perhaps, do we need to and 
can we, better identify patients who would derive maximum benefit from an 
ICD? 
1.2.5 Problems with ICD Implantation  
Although ICDs are the most effective means of preventing SCD, they remain 
expensive and are associated with significant co-morbidity. The major 
challenges that health care providers and the patient population are faced with 
are: 
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Procedural risks: ICD implantation is an invasive procedure that comes with its 
attendant risks. Recorded risks/complications include pain, bruising, radiation 
exposure, haematomas, infection, pneumothorax, lead displacement and 
cardiac tamponade. Procedural complications associated with ICD implantation 
occur in 11% of patients and around 1% patients develop a device infection 
requiring risky lead extraction. [74] 
Cost-Effectiveness: NICE has estimated the average cost of an ICD implant in 
the UK at approximately £9692 excluding hospitalisation and follow up costs. 
The initial treatment of patients at increased risk of SCD with ICDs in 
combination with optimal medical therapy had an incremental cost-
effectiveness ratio (ICER) of £19,479 per QALY gained compared to optimal 
medical therapy alone. The ICERs in other groups including chronic heart 
failure due to ischaemic and non-ischaemic causes ranged between £14,231 
and £29,756 per QALY gained. [2]  
 Buxton et al conducted a cost-effectiveness model for primary 
prevention ICD implants in the UK. Mean discounted gain from ICD implant (at 
a high financial cost) over a 20yr horizon was 1.24 years or 0.93 QALYs. They 
concluded that ICDs, as currently applied in the UK, are not cost-effective by 
conventional standards. [75] Similar concerns over cost-effectiveness of ICDs 
have been raised by other investigators as well.[74,76] It has been suggested that 
the best utilisation of finances for maximum clinical benefit can be achieved by 
better risk stratification in order to implant ICDs in high risk patients without 
associated co-morbidities that limit life expectancy to 10 years and by reduction 
of follow up costs. [77]   
Psychological Impact and Quality of Life (QoL): While many patients feel 
secure and comforted by having the ICD implant as a “safety-net”, others 
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commonly have ICD related fears including impending shocks, public 
embarrassment and death. Shocks (both appropriate and inappropriate) have 
an adverse psychological impact that has been well documented in the QoL 
analysis from various trials including AVID and DEFINITE. [76] 
 QoL studies have demonstrated that patient concerns about the ICD are 
an important indicator of psychosocial adjustment. Although patients who had 
experienced a shock scored higher on ICD concerns, ICD concerns was the 
only independent determinant of anxiety and depressive symptoms adjusting 
for shocks and all other factors. [78] Anxiety levels and depression have been 
found to be high post ICD implant and shock therapy and decrease over time 
from the primary event. [79] 
Inappropriate device therapy: Out of all primary prevention ICD implants only 
20-30% patients ever get treatment from it and not all device therapies are life 
saving. [80] A vast majority of patients experience inappropriate shocks from the 
ICD, their incidence varying between 15 – 35%. [81] Inappropriate ICD shocks 
have a negative impact on the patients’ QoL, increase health care resource 
utilisation and can lead to other adverse sequelae. Not only are these painful 
and psychologically damaging but have been found to be associated with a 
worse prognosis with a hazard ratio for death of 1.98. [82]  
 Supraventricular arrhythmias with a rapid ventricular response are the 
commonest cause of inappropriate device therapy. Statistically significant 
predictors of inappropriate ICD interventions in the MADIT II study included 
atrial fibrillation (AF), smoking, and diastolic blood pressure > 80 mm Hg. Other 
factors contributing to inappropriate therapies include abnormal ICD sensing 
(R/T oversensing, far field electrograms, diaphragmatic potentials), ICD failure 
and electromechanical interference. [83] The potential of ICDs being pro-
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arrhythmic has been reported. [84] Device pro-arrhythmia can be attributed to 
local effects from leads, direct and indirect effects of ventricular pacing, and 
problems associated with improper device function. While the concept of local 
irritability is supported by a relatively higher incidence of VAs in the first week 
after transvenous and epicardial ICD implantation, local fibrosis can occur at 
any time after lead implantation and is more difficult to demonstrate. Change in 
electrical activation associated with ventricular pacing is another plausible 
mechanism for pro-arrhythmicity of ICDs. [85] 
Hardware malfunction: despite advances in ICD system technology and 
manufacturing, structural failure of an implanted device is not unheard of. The 
estimated survival rate of ICD leads was noted to be 85% at 5 years and 60% 
at 8 years after implantation. [86] Advisories on potential for ICD malfunction 
were issued by all major device companies in the year 2005. This was followed 
soon after by the recall of the Sprint Fidelis lead due to lead fractures resulting 
in an increased risk of inappropriate shocks. [87,88] While the impact of this on 
patients is intuitive, it was particularly challenging for the clinicians as well who 
were left to manage these patients based on individual experience.  
1.2.6 Need for Improved Risk Stratification of SCD 
The vast majority of patients who qualify for an ICD implant represent a very 
high-risk group, with multiple co-morbidities at an advanced age. Numerous 
clinical features have been shown to be predictive of or associated with a 
higher risk of VAs. And yet, the most clinically useful and accepted in 
international guidelines is only one – LVEF. Despite the proven survival benefit 
of ICD prescription, only a minority of patients (<1/3rd) [80] ever use it; while still 
being subject to the challenges associated with ICD implant. In order to 
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improve the risk stratification process for ICD implants, the current practice 
trends and guidelines defining ICD prescription need to be examined. 
Limitations of LVEF as risk stratification marker: Impaired LVEF has been 
shown to be a strong predictor of SCD and currently forms the basis of primary 
prevention ICD implants in ischaemic cardiomyopathy. However, only 20-30% 
patients in primary prevention ICD trials ever receive appropriate device 
therapy; [80] in contrast to 2/3rd of the victims of SCD in population based studies 
with a normal or mildly impaired LVEF. [89] The vast majority of MI survivors 
have a preserved or mildly reduced LVEF and they still go on to have a large 
number of SCD events despite the presumed low risk. In the Maastricht 
Circulatory Arrest Registry, 51% of victims of sudden circulatory arrest with 
echocardiography during the study period had an LVEF >40%. [90] The 
specificity of LVEF as a marker of SCD is questioned by these observations. 
The sensitivity and specificity of LVEF for major arrhythmic events post-MI was 
found to be 59% and 78% respectively in a meta-analyses of 20 studies. [91] 
 In the high-risk risk group with LVEF ≤ 35%, only a small 
proportion benefit from ICD implant. Primary prevention ICD trials have 
demonstrated that only 20-30% of patients, under current prescription, receive 
an appropriate ICD therapy. [80] The SCD rate in MADIT II was 10% in the 
conventional arm and 3.8% in the ICD arm. Although, this was higher in the 
conventional arm, the vast majority of these “high-risk” patients would not 
benefit from ICD therapy by virtue of not having had a cardiac arrest. [26] 
Similarly, the rate of fatal VAs was only 8% in the CARISMA (Cardiac 
Arrhythmias and Risk Stratification after Myocardial Infarction) and 5% in 
MUSTT trial over a follow-up period of two years. [92,28] Thus the risk associated 
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with a poor LVEF is not uniform across this “high-risk” subgroup. Moreover, a 
reduced LVEF is a marker for both SCD and total mortality. 
 While various guidelines specify LVEF criteria for device implant, the 
technique by which this should be measured is not specified. 
Echocardiography is the most commonly used modality in clinical practice. 
However, the reliability of echocardiography and the associated inter and intra-
observer variability has been questioned. It has been shown that CMR has 
greater reproducibility than echocardiography in assessment of LVEF. Also, 
using CMR as the reference standard, echocardiography was found to 
systematically overestimate EF by an average of 3 percentage points (37.5% 
versus 34.4%). And hence, using strict LVEF criteria, CMR would have resulted 
in almost 21% of patients being reclassified regarding ICD eligibility. [93] The 
prognostic ability of LVEF is heavily influenced by the measurement modality 
being used. Also, a single time point measurement might not suffice as left 
ventricular function is subject to change with evolution of the underlying 
disease process and also with various pharmacological and invasive 
interventions. 
Limitations of Clinical Trial Design: the dominant parameter governing entry 
into most primary prevention ICD trials has been LVEF. However, this entry 
requirement has not been stratified with a different threshold being used across 
clinical trials. The entry threshold varied between a LVEF ≤ 30% to ≤ 40%. The 
LVEF of patients actually enrolled into the trial and those deriving benefit from 
device therapy was not always in line with the entry threshold. [19] The entry 
threshold for SCDHefT was ≤ 35%, while the median LVEF amongst enrolled 
patients was 25% with an interquartile range of 20% - 30%. Moreover, 
subgroup analysis of patients with LVEF ≥ 30% (constituting 17% of all recruits) 
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was indicative of no ICD benefit. [25] Also, to note there is no time specified to 
obtain the LVEF, which determines eligibility for an ICD. This could be 
measured early on (≥4 weeks) post MI or several years after the index event.  
 The clinical implications of LVEF are not limited to manifestation of SCD. 
Rather, both a poor LVEF and SCD are inseparable from heart failure. The 
presence or absence of heart failure has a significant bearing on the benefits 
derived from the ICD and its associated risks. Heart failure has been used as 
an entry criterion in some but not all clinical trials and there is no apparent 
uniformity in its selection. A high prevalence of heart failure was found in study 
patients in clinical trials which used it as an entry criteria (DEFINITE and 
SCDHeFT) [25,29] and in those who did not (MADIT II). [26] Subgroup analysis of 
the MADIT population also suggested that an EF< 25% and/or a history of 
heart failure were better predictors of ICD use and mortality during follow-up 
than EF <26% without heart failure. [19,26] Interactions between LVEF and heart 
failure should be taken into account when risk stratifying patients. 
 The study populations in the vast majority of ICD trials may not be a true 
reflection of the general population. The elderly population (age ≥ 80yrs) was 
largely excluded from most trials. Varying benefit with age has been in 
subgroup analysis of various trials. Patients over 70yrs of age had a similar 
benefit from ICD implant as the younger population in MADIT II. [26] This was 
not true in the SCDHeFT population. [25] Patients with renal dysfunction on 
haemodialysis have been excluded from most trials as well. The high 
prevalence of CAD in these patients increases their risk of fatal arrhythmias. 
However, this might be largely confounded by the likely increased incidence of 
total mortality in this population given their multiple co-morbidities. In addition, 
subgroup analysis from MADIT II showed that patients with advanced renal 
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disease did not demonstrate a mortality benefit from ICD implantation. [26] 
Female population is not very well represented in the ICD trials. This might be 
a reflection of lower incidence of CAD in this gender. However, a clear 
difference in ICD benefit between men and women has been seen in some ICD 
trials. [32] This needs to be explored further. 
Critical analysis of the existing evidence does suggest that ICDs have a 
clear survival benefit in high-risk patients with severely impaired left ventricular 
function post MI. However, the current risk stratification is by no means perfect. 
Improved risk stratification is required so that patients receiving ICDs will derive 
maximum benefit, while those not expected to achieve much benefit are 
excluded from consideration of device therapy. ICDs are fraught with morbidity 
and mortality. The general population needs to be protected from these risks 
while making sure that those at highest risks are not denied of survival benefit. 
While deriving maximum clinical benefit, it is also crucial to make ICD therapy 
cost-effective. 
 The dominant risk stratification marker in primary prevention ICD trials 
has been LVEF. Alongwith other limitations discussed before, one of the 
conceptual flaws appears to be the use of a single time point measurements 
determining ICD prescription. The static nature of these designs does not take 
into account the dynamic pathophysiology of ischaemic heart disease that 
encompasses changes over time and is likely to influence the presence and 
stability of current risk markers. [94] 
 The concept of cardiovascular ageing and CAD being caused by 
premature biological ageing has emerged in recent years. This is in addition to 
and distinct from chronological ageing. On the background of a similar risk 
factor profile, an individual with accelerated biological ageing is more likely to 
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develop CAD and/or manifest its complications at a younger age when 
compared to someone who ages at a normal rate. An ideal risk marker would 
be able to capture this accelerated biological ageing early on and distinctly 
from chronological ageing and help predict the occurrence of cardiovascular 
events and SCD. 
Telomere biology has recently been shown to capture cardiovascular 
ageing especially in the realm of CAD. Recent research has identified 
leukocyte telomere biology as a potentially important marker for a range of 
diseases and disease potential. [95-103] Telomere biology is a potential robust 
biomarker for cardiovascular events in CAD as it changes progressively with 
chronological age, has inherent variation amongst individuals, quantifies 
accelerated biological ageing by reflecting the replicative potential of the cell 
and also by indicating the cumulative lifelong burden of oxidative stress.  
Before moving on to the telomere structure and their role in premature 
biological ageing, it is important to understand the difference between 
chronological and biological ageing. 
1.3. The Biology of Ageing 
1.3.1 Chronological and Biological Ageing 
Ageing is the progressive accumulation of changes with time that are 
associated with or responsible for the ever-increasing susceptibility to disease 
or death. Ageing per se is not a disease, but a natural process that can be 
distinguished from diseases by at least four criteria. [104,105] Unlike any disease, 
age related changes (1) occur in every animal that reaches a fixed size in 
adulthood (2) take place in virtually all species (3) occur in all members of a 
species only after the age of reproductive success (4) occur in animals 
removed from the wild and protected by humans. 
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 An individual’s age, as we commonly see it, is the chronological age, 
which is an extrinsic variable measured in calendar days/months/years. It is 
governed by a fixed, extrinsic timeline that progresses at the same rate in all 
individuals of every species. On the other hand, biological ageing, has a great 
variation amongst individuals (even of the same species), is governed by 
intrinsic variables and cannot be determined solely by fixed calendar times. 
The rate of biological ageing can be the same as the chronological ageing, 
slower or faster than chronological ageing. An individual who has a faster 
biological ageing rate than chronological ageing rate will have “premature 
biological ageing” as a result. This premature biological ageing, even in the 
absence of an additional disease process, will lead to accelerated cellular 
senescence and a shorter finite life span. Of the various stochastic and 
developmental-genetic theories of ageing, cellular senescence provides the 
most definitive mechanism, postulating a link between limited replicative 
capacity at a cellular level and biological ageing. 
1.3.2 Limited Replicative Capacity  
In the early 1920’s, immortality of explanted cells was claimed on the basis of 
experiments carried out on chicken heart fibroblasts. It was suggested, that the 
only reason that these cells are unable to replicate continuously was that 
researchers were unsure as to how to cultivate them. [106] This observation was 
challenged in the 1960’s by Hayflick, who demonstrated that normal human 
fibroblasts in culture had a finite replicative capacity and this was linked to 
cellular ageing and senescence.  
 Hayflick and Moorhead mixed equal number of normal human male 
fibroblasts that had gone through numerous divisions (cells at fortieth 
population doublings) with female fibroblasts that had undergone very few cell 
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divisions (cells at the tenth population doubling). Unmixed cell populations 
served as controls. When the male ‘control’ culture stopped dividing, the mixed 
culture was examined and only female cells were found. This experiment 
showed that the older cells “remembered” that they were old even in a mixed 
culture. And the concept of the Hayflick limit i.e. the number of divisions a given 
cell type is capable of, is now well accepted. [107] 
 Despite the landmark findings in cellular senescence, Hayflick’s 
experiment did not explain what controls the number of divisions a cell is 
capable of or how the “older” cells knew they were older. 
1.3.3 DNA Replication 
DNA synthesis in eukaryotic cells is mediated by the enzyme DNA polymerase. 
Deoxyribonucleotides are added to the 3’ hydroxyl terminus of DNA by the 
polymerase enzyme. The new DNA is synthesised as the parental DNA 
unwinds at the replication fork. Both strands of parental DNA act as a template. 
The overall direction of synthesis is 5’ à 3’ for one strand and 3’ à 5’ for the 
other strand. As DNA polymerase can only synthesise in the 5’ à 3’ direction, 
there is a “leading” and a “lagging” strand. The discontinuous assembly of the 
lagging strand enables 5’ à 3’ polymerisation at the nucleotide level to give 
overall growth in the 3’ à 5’ direction. DNA polymerase uses short primers to 
initiate DNA synthesis. These are removed once the synthesis is complete and 
the resultant gaps filled by ligation mediated by DNA ligase.  
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    Figure 2: The End Replication Problem 
[A. Parental DNA. B. Bottom strand synthesised by leading strand synthesis 
(5’à3’) to the last nucleotide. Top strand synthesised by discontinuous lagging 
strand synthesis primed by RNA primers. C. RNA primers removed and filed in 
leaving a 5’ gap]. 
  
Olovnikov pointed out the shortcoming of this mechanism of DNA 
synthesis. He noted that the DNA ligase can only join two strands together; at 
the every end of a linear DNA molecule there will be only one strand and so the 
newly synthesized DNA will be shorter than the template by the length of the 
primer. This is known as the “end replication problem” and forms the basis of 
the cellular mitotic clock. The relationship between this mitotic clock, cellular 
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senescence and biological ageing is explained by the presence of 
telomeres.[108] 
1.4 Telomeres 
1.4.1 Telomeres – Historical Perspective 
Telomeres are the terminal sequences of linear eukaryotic chromosomes that 
“cap” the chromosomal ends and protect them from erosion. The word 
telomere originates from Greek telos meaning “end” and meros meaning “part”. 
They were first identified in the work carried out by Herman Muller and Barbara 
McClintock in the 1930’s and 1940’s. As Muller noted from his experiments: 
“...the terminal gene must have a special function, that of sealing the end of the 
chromosome, so to speak, and that for some reason a chromosome cannot 
persist indefinitely without having its ends thus sealed.” 
At that time their function was not very clear but there was evidence that 
telomeres prevented the ends of chromosomes from fusing to each 
other.[109,110] Muller noted that terminal deletions and inversions were rare post 
X-irradiation of chromosome ends. This level of chromosomal stability could 
only be possible with the help of special protective terminal ends. McClintock 
studied the broken chromosome ends of Zea Mays (maize/corn) and found that 
broken chromosome ends were reactive and fused with other broken ends. 
This was in contrast to normal, natural chromosome ends, which tend to be 
stable. Also, broken chromosome ends underwent degradation in the cell, 
which was subsequently harmful for the chromosome involved. And hence 
concluded that each chromosome end had a unique structure or sequence that 
identified it as natural and distinguished it from broken DNA. [110] In 1961, 
Hayflick’s experiments on fibroblasts provided evidence that primary cells could 
only undergo a limited number of cell divisions and are not immortal. This 
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phenomenon, commonly known as Hayflick’s limit, [111] confirmed the presence 
of a cellular counting mechanism. This cell cycle arrest described by Hayflick 
was then linked to the terminal ends of chromosomes by Olovnikov. [108]  
 The first telomeric sequence was discovered by Blackburn in 1978 in 
telomeres of ciliated protozoan, Tetrahymena thermophile, consisting of a 
simple sequence of hexameric repeats of the nucleotides TTGGGG. [112] The 
human telomeric sequence was discovered 10 years later by Moyzis and 
consists of a highly conserved hexameric TTAGGG repeats. [113] Once this 
sequence was known, the length of human telomeres could be measured. The 
possibility of telomeric shortening was described in 1986 when it was shown 
that telomere lengths are not same in all tissues. [114] Telomeric shortening was 
demonstrated in dividing fibroblasts in culture. [115] This observation in 
combination with other experiments, provided strong evidence for telomeric 
shortening limiting cell proliferation in culture. [115-117] 
 The next major landmark in telomere biology was discovery of the 
enzyme telomerase by Greider and Blackburn in 1985. [118] This was the 
potential solution to short telomeres limiting the rate of cell growth. The unique 
characteristic of telomeres in somatic cells is their age related attrition and their 
positive association with replicative capacity of cells in cell culture. The enzyme 
telomerase is the compensatory mechanism that overcomes this limitation by 
(by-passing the end-replication problem encountered by DNA polymerase) 
elongating telomeres. The structure of the human telomere and enzyme 
telomerase is described next. 
1.4.2 Human Telomere and Telomerase 
Telomere – structure and function: Telomeres are special functional complexes 
at the ends of eukaryotic chromosomes which protect the dsDNA ends and are 
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involved in maintain genomic stability and in regulation of cellular lifespan. [119] 
They consist of tandem repeats of TTAGGG sequence spanning several 
kilobases. The number of terminal hexameric repeats is variable and is shorter 
in somatic tissues (~ 10kb) than in germ cells (~15kb). The very distal ends of 
telomere comprises of a single stranded G-rich overhang, which is always 
orientated 5’ – 3’ and can be up-to 200 nucleotides long. [120] Adjacent to this is 
a complex region of segmentally duplicated DNA tracts called the subtelomeric 
repeat DNA. Human subtelomeric segmental duplications (subtelomeric 
repeats) comprise approximately 25% of the most distal 500kb and 80% of the 
most distal 100kb in human DNA. The overall size, sequence content, and 
organization of subtelomeric segmental duplications relative to the terminal 
(TTAGGG)n repeat tracts and to subtelomeric 1-copy DNA are different for 
each subtelomere. [121] 
 
 
Figure 3: Human telomere structure 
[Schematic representation of human telomere (upper) showing telomeric 
repeats and sub-telomeric region and the simplified 3D structure (lower)] 
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Telomeres protect the chromosomal ends from degradation and 
unwanted fusion events. It provides a means to replicate the chromosome 
completely by telomerase dependent replication or through recombination. 
Telomeres also serve to position the chromosome within the nucleus and are 
involved in the selective silencing of proximal subtelomeric genes. [105,121] 
Telomeres undergo attrition with each cell division and their length thus reflects 
the replicative history of cells and hence serving as a mitotic clock at least at 
the cellular level. 
Telomeric complex: The 3’ protruding G-rich strand can form complex 
structures of telomeres, the G-quadruplexes. These assume different 
conformations which can come in the way of DNA replication and telomere 
elongation by telomerase. [123] In the non-mitotic phase of the cell cycle this G-
rich strand is shielded by the telomere shelterin complex in which the telomere 
binds internally to form the D and T-loops. The single stranded G-rich overhang 
can invade the pre-ceding double stranded region to form a telomere loop (t-
loop). This can lead to invasion and displacement of upstream 3’ telomeric 
DNA creating a displacement loop (D-loop) via base pairing which would 
contain three strands – two G-rich and one C-rich strand. A section of the 
terminal duplex may also invade resulting in a D-loop consisting of four strands 
– two G-rich and two C-rich. The D-loop is though to be essential for the 
stabilisation of the larger T-loops. [124] The formation of these loops depends on 
telomere binding proteins, especially TRF2. Increased amounts of TRF2 lead 
to more efficient G-rich overhang and hence T-loop formation which then 
protects the shortest telomeres in the cell and delays senescence. [125]  
 The shelterin complex is a group of protective telomere binding proteins 
and determines the protective function or “capping” function of telomeres. 
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These include telomere repeat binding factor 1(TRF1), TRF2, 
repressor/activator protein 1 (RAP1), TRF1-interacting nuclear protein 2 (TIN2), 
TIN2-interacting protein 1 (TPP1) and protection of telomeres 1 (POT1). In 
human cells, the best known telomeric proteins are TRF1 and TRF2 and both 
are negative regulators of telomeric length. Telomeres lacking TRF2 have been 
shown to signal p53 and ATM dependent apoptosis, [126] while overexpression 
of a dominant negative form of TRF2 induced end-to-end chromosome fusions 
and senescence. [127]   
 
 
  
                                       Figure 4: The Shelterin complex 
[Schematic representation of telomeric binding proteins. RAP1: 
Repressor/Activator Protein 1, TRF1: Telomere Repeat binding Factor 1, 
TRF2: Telomere Repeat binding Factor 2, TIN2: TRF 1 Interacting Nuclear 
factor 2, POT1: Protector of Telomeres 1, TPP1: PIP1-POT1-TIN2 organizing 
protein]  
 
                    (Taken from Int J Oncol 2012 Nov;41(5):1561-9) [128] 
 
TRF1 and TRF2 are also involved in the ATM and ATR pathways, which 
are sensors of DNA damage. They can induce cell cycle arrest via kinase 
activation (Chk1 for ATM and Chk2 for ATR) or via DNA damage response 
pathway. These cause DNA damage in telomeres where telomerase is reduced 
or the shelterin complex is impaired. [129] TRF2 can reduce the senescence set 
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point, defined as telomere length at senescence, from 7 to 4 kilobases that can 
cause a cell to initiate the senescence pathway. [130] TRF2 can also protect 
short telomeres and prevent checkpoint activation by more efficient formation 
of t-loop structures. [125] TRF2 also recruits another member of the shelterin 
complex – RAP1. Its in vivo role is not clearly understood but its 
overexpression can cause lengthening of telomeres. [131] It has been shown 
that RAP1 deficiency can be dispensable for telomere capping but leads to 
increased telomere recombination and fragility. [132] Also, RAP1 can bind to 
non-telomeric sites through the TTAGGG consensus motif, suggesting its role 
in transcriptional control. [132] Another shelterin component is POT1 (Protection 
of telomeres), and it can act as a telomerase dependent positive regulator of 
telomere length. POT1 binds to TPP1 at its carboxyl end and this union is 
essential for the localisation of POT1 in telomeres and also for the regulation of 
telomeric length interacting with telomerase. [133,134] TIN2 is an important 
mediator of TRF1 function [135] and has been shown to suppress telomere 
elongation in telomerase positive cells and could potentially control telomere 
length by modulating telomere function. [136] TPP1 is encoded by the ADC gene 
and there is evidence that it is required for telomerase recruitment to telomeres 
thereby preventing early occurrence of degenerative pathologies. [137] Thus it is 
clear that telomere function is not solely dependent on its length. The structure 
and level of expression of telomere binding proteins plays an important role in 
maintain telomere integrity and function. 
Telomere position effect (TPE): refers to transcriptional silencing of genes 
adjacent to telomeres which can be the mechanism underlying telomere 
mediated senescence. [138] TPE has been best characterised in yeast 
Saccharomyces cerevisiae, where reversible silencing of a gene appeared to 
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be related to both to telomere length and distance from the telomere. [139] Also, 
marker genes inserted less than 4kb from telomeric repeats were frequently 
repressed and expressed late in S phase. [140] And hence it was postulated that 
telomere attrition in humans could effect the expression of various genes. 
 Transcriptional silencing near human telomeres was shown when 
luciferase reporters placed adjacent to telomeric repeats had a much lower 
expression than those placed at non-telomeric sites. Moreover, this reduced 
expression could be restored by using a histone deactetylase inhibitor, 
trichostatin A. Further support to these findings was provided by demonstrating 
that over-expression of hTERT in the telomeric clones resulted in telomeric 
extension and a 2 to 10-fold decrease in luciferase compared to control clones. 
Not only was the silencing effect of longer telomeres proven, but the magnitude 
of silencing correlated with the telomere length. [140] 
Telomerase-Basic structure: is a ribonucleoprotein composed of a highly 
conserved reverse transcriptase (TERT) and a RNA primer (TERC) that 
provides the template for the synthesis of telomeric repeats at chromosomal 
ends. [141] The telomerase holoenzyme is believed to assemble in the cajal 
body where TERT and TERC form a ribonucleoprotein enzyme complex. [142] 
Although TERT and TERC can generate enzymatic activity in vitro, additional 
proteins are required for assembly and activity of telomerase in vivo. [142] These 
integral protein components of the heterogenous telomerase complex include 
dyskerin, NHP2, NOP10, pontin/reptin, Gar1 and TCAB1. [143] Dyskerin, pontin 
and reptin form a scaffold that recruits and stabilizes human telomerase RNA 
and assembles the telomerase ribonucleoprotein component. Once this 
complex is formed, pontin and reptin are believed to dissociate from the 
complex and release the catalytically active enzyme. [144] 
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Telomerase activity and telomere elongation by telomerase: telomerase activity 
varies markedly between different cell types. To determine this differential 
expression of telomerase, human foetal tissues of 8-21 weeks gestational age 
were assayed for telomerase activity. [145] All tissues expressed telomerase at 
the earliest ages examined. Lung, liver, spleen and testis maintained 
telomerase activity up till 21 weeks. Brain and kidney telomerase were 
detected till the 16th week and were undetectable thereafter. Cardiac tissue did 
not display any telomerase activity after the 12th week.  Lysates of heart, brain 
and kidney without telomerase activity failed to inhibit the activity of known 
telomerase positive cells suggesting that suppression of telomerase during 
gestational development is due to lack of active telomerase rather than the 
presence of an inhibitor. [145] From being highly expressed during embryonic 
development, telomerase activity is suppressed in somatic cells. Telomerase 
activity has been detected in highly proliferative cells like stem cells, progenitor 
cells, endometrium, lymphocytes, skin keratinocytes and in vast majority of 
cancers. [146]  
 Telomerase is capable of elongating telomeres and hence delaying the 
onset of senescence. In telomerase dependent replication, the RNA template 
of the telomerase complex binds to the 3’ end of the telomeric DNA. This is 
followed by telomerase mediated G-strand elongation with the RNA moiety of 
the enzyme acting as the template and 3’ end of chromosome acting as the 
primer. The complimentary C-rich strand is generated by lagging strand 
synthesis creating a single strand overhang. Telomere elongation by 
telomerase is tightly regulated during the cell cycle with telomeric repeats being 
added in the S phase and M phase. [147] Also, telomerase does not act on every 
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telomere in each cycle but characteristically shows an increased preference for 
telomeres as their lengths decline. [148] 
1.4.3 Mechanisms of Telomere Shortening and Repair 
Telomere shortening is a potential mechanism for a biological clock that 
determines cellular behaviour and is thought to trigger cell senescence and 
premature biological ageing. The two postulated mechanisms of telomere 
shortening are cellular replication and a more stochastic shortening secondary 
to external stimuli. 
Telomere length and replicative senescence: the inability of DNA polymerases 
to replicate a linear DNA molecule to its very end, commonly known as the end 
replication problem, [108] leads to telomere shortening with every cell division. 
However, the rate per cell division probably is constant, but the rate as a 
function of population doubling may vary.  It changes from cell to cell, from one 
division cycle to the next and as a function of external stressors. [149] 
Inflammation heightens the cellular turnover, which further exacerbates the age 
related telomeric shortening. This is a reflection of the replicative history of the 
cell and on this basis it has been suggested that telomere loss might serve as a 
mitotic clock. 
 The resulting telomere hypothesis of senescence states that (1) 
shortening of telomeres to some threshold value triggers senescence (2) 
telomeres shorten at a constant rate and so that telomere length is a faithful 
indicator of replicative history. [149] 
Telomere length and stochastic shortening: The causal link between the 
gradual decrease in mean telomere length and senescence induction has been 
questioned by a number of observations. In their experiment on human 
fibroblasts infected with viral strains, Smith and Whitney (1980) found 
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increasing proportion of cells entering senescence at late passages and hence 
demonstrating bimodal nature of senescence. [150] However, the mean 
telomere length shortens in a linear fashion. [151] Also, in tissue cultures, 
senescence has been found to be induced with a mean telomere length much 
longer than that would be expected to trigger senescence mechanisms. 
In addition to replicative shortening, sudden extensive shortening of 
single telomeres can take place by a more stochastic process that can be 
induced by various stimuli. Different mechanisms for this sudden shortening 
have been suggested. These include oxidative damage inflicting single 
stranded breaks in telomeres, replication slippage and unequal sister chromatid 
exchange and recombination causing circularisation and thus deletion of distal 
repeats. However, the predominant mechanism amongst these is exposure to 
oxidative stress. [152] 
 Oxidative stress can have a much greater and much faster impact on 
telomere shortening than the end replication problem alone. Telomeres are 
more susceptible to damage caused by oxidative stress due to the direct 
erosion of GGG repeats and also a negative impact on telomere length is 
observed due to inhibition of telomerase activity by oxidative stress. [153] 
A combination of increased cell turnover secondary to systemic and 
local inflammation and the effect of oxidative stress and free radicals are 
thought to be the basis of cellular senescence and premature biological ageing 
that marks the process of atherosclerosis. This is represented by the telomere 
length, which registers the turnover rate of cells, a rate that is augmented by 
chronic inflammation and an increase in the cumulative oxidative burden. 
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1.4.4 Telomeres and Cardiovascular Disease 
There is evidence to suggest that some types of heart disease may represent a 
disease of premature biological ageing and that telomere length, independent 
of chronological age, is predictive of increased risk of cardiovascular disease. 
 Telomere biology and coronary artery disease: telomere length in 
circulating leukocytes has been shown to have a strong association with CAD 
in diverse populations. [95-99] Whether telomere shortening is causal for CAD or 
just an epiphenomenon is debatable. However, studies have shown the 
existence of telomere shortening before manifestation of clinical disease and 
hence supporting the hypothesis that telomere shortening can be the primary 
cause leading to clinical expression of a disease process. 
  In cross-sectional studies, shorter mean telomere length in 
circulating leukocytes has been associated with triple vessel CAD [100] and 
premature MI. [96] Age and sex adjusted mean telomere length in cases has 
been shown to be significantly shorter (300bp) in cases with atherosclerosis 
than in healthy controls. [96] A large cross-sectional study compared the 
telomere lengths of 598 male patients with CAD with 653 age-matched controls 
across Europe. In addition, 413 coronary artery bypass graft patients and 2 
groups of 461 patients with familial hypercholesterolemia (FH), of whom 162 
had premature CAD, were recruited. It was reported that telomere length was 
significantly shorter in cases (7.85 kb) compared with control subjects (8.04 kb, 
P < 0.04). This was also true for the coronary artery bypass graft sub-study. In 
the FH patients, leukocyte telomere length was shorter in those with CAD 
compared with the non-CAD subjects. On the other hand, telomere length was 
not associated with any measured CAD risk factors except for age. These data 
confirm that subjects with CAD have shorter telomeres than control subjects, 
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and extends this to those with monogenic and polygenic forms of CHD, such as 
FH. [101] 
 Relationship between telomere biology and risk of CAD in patients with 
acute coronary syndrome has been shown in a large prospective study [102] In 
addition, telomerase activity in leukocytes has been associated with the 
presence of calcified atherosclerotic coronary plaque, and shown to be a 
predictor of plaque progression in the presence of short telomeres. [103] Also, 
shorter telomeres are associated with high-risk plaque morphology on virtual 
histology intravascular ultrasound, but not total 3-vessel plaque burden in 
CAD.[103] Monocytes with disrupted telomeres show increased pro-
inflammatory activity, which is also seen in CAD patients, suggesting that 
telomere shortening promotes or is associated with high-risk plaque subtypes 
by increasing pro-inflammatory activity. [154] 
 These observations were not limited to circulating leukocytes and similar 
results have been replicated in coronary endothelial cells as well. Not only were 
the coronary artery endothelial cell telomeres significantly shorter in cases 
when compared to age matched controls (p< 0.0001) but within the CAD cases 
there was significant difference in the telomere lengths between the 
atherosclerotic and non-atherosclerotic regions of the coronary artery. [100] 
Similar increased rates of telomere attrition in atherosclerotic regions have also 
been shown in the aortic endothelium. [155] 
 The cause-effect relationship of CAD and telomere attrition is not very 
well established but there is increasing evidence that short telomeres precede 
the development of clinical disease and are not just the cause of CAD. In the 
West of Scotland Primary Prevention Study (WOSCOPS), the odds ratio for 
coronary events over the next 4.9 years was almost doubled in placebo treated 
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subjects in the lower two tertiles of baseline telomere length compared with the 
highest, while a study of 143 people over the age of 60 found that having 
shorter than average telomeres was associated with a more than threefold 
higher cardiac mortality over the next 8.9 years. Furthermore, mean telomere 
length has been shown to be shorter in asymptomatic young adults with a two-
generational history of heart disease compared to healthy age-matched 
controls with no such family history. This supports the hypothesis that shorter 
telomere length is a primary abnormality predisposing to cardiovascular 
disease. [98] 
 Because telomeres shorten with age and the average amount of 
telomeres lost per year can be computed, another way of presenting the 
difference in telomere length in those with or without CAD (or those who will 
develop CAD) is the number of years of age to which this equates. [156] A 
difference of 8 to 12 years has been shown across several studies; implying 
that patients with CAD have telomeres equivalent in size to normal subjects 
who are 8 to 12 years older). [95,96,98] This observation is invaluable to the 
concept of premature biological ageing in patients with (or those who are likely 
to develop) CAD. 
Telomere biology and other cardiovascular diseases: shorter telomeres have 
shown to be associated with cardiovascular diseases other than CAD. Shorter 
telomeres have been associated with pathophysiology of CHF and decreased 
renal function in subjects with heart failure. [157,158] In a large cohort of 620 
patients with CHF derived from the MERIT-HF study and 183 age and gender-
balanced controls, telomere length of white blood cells was also about 40% 
reduced in patients with CHF and related to the severity of disease. [159] 
Decreased left ventricular ejection fraction in the elderly, without evidence of 
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previous myocardial infarction, has also been associated with reduced 
telomere length. One standard deviation of shorter telomeres was associated 
with a 5% lower ejection fraction. [160] 
Telomere biology and vascular tissue: Strong co-relation between the telomere 
lengths of circulating leukocytes and vascular endothelium has been shown in 
cohort studies. Shorter telomeres in coronary endothelial cells from patients 
with CAD than in subjects without CAD, [161] exaggerated telomere shortening 
in atherosclerotic plaques and at sites prone to atherosclerosis such as 
bifurcations has been shown. [155] There is also evidence that endomyocardial 
biopsies of subjects with dilated cardiomyopathy have more rapid cellular 
senescence and cell death associated with a telomere length reduction of 39% 
in comparison to normal hearts. [161] 
Telomere biology and cardiovascular risk factors: Various cardiovascular risk 
factors have been associated with shorter telomere length in leukocytes, 
including obesity, smoking and type-two diabetes. [162,165] Gender is a known 
risk factor for coronary artery disease, with prevalence higher in men. In 
women psychological stress, obesity and smoking and low socioeconomic 
status [163-165] have been associated with shorter leukocyte telomeres. Many of 
these associations could reflect the effect of oxidative stress or chronic 
inflammation on telomere attrition. [166] Telomere length has also been 
associated with hypertension. For a given chronological age, men with shorter 
telomeres are more likely to have a higher pulse pressure. [163] However, 
adjustment for these risk factors does not have a significant impact on the 
association between shorter telomere length and CAD suggesting that the 
relationship is not just a reflection of the effect of these risk factors on telomere 
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attrition. Incidence of cardiovascular disease is influenced by ethnicity and 
telomere lengths differ among geographical locations. [97,167] 
Telomere biology and ventricular arrhythmias: There have been no studies to 
date, exploring the association of telomere biology with ventricular arrhythmias. 
VAs post MI can be caused by a number of mechanisms with re-entry being an 
important one in chronic CAD. Re-entry mechanisms are related to significant 
electrical heterogeneity as a result of structural and/or electrical remodeling of 
the left ventricle. Post infarction areas, including regional and intramural fibrotic 
zones and scars, remain electrically unexcitable and may form local conditions 
for re-entry leading to sustained monomorphic VT. [168,169] The manifestations of 
CAD create distinct and time-varying changes in the myocardium that enhance 
the risk of VAs. Scar formation after MI is a major contributor to arrhythmia 
susceptibility. Peri-infarct cardiomyocytes have been shown to exhibit 
progressive shortening of action potential duration post MI, followed by a return 
to near-normal action potential over time. [170] Moreover, peri-infarct cells have 
been shown to have reduced side-to-side coupling. [171] Heterogeneities in 
action potential duration and altered coupling between infarct border zone 
tissue and surrounding myocardium create a region of conduction slowing 
susceptible to local conduction block necessary for re-entrant excitation. 
Alternatively, disordered initiation or propagation of cardiac action potentials 
can also be a result of functional changes in myocardial ion channels. Chronic 
oxidative stress often involves changes in the transcript and protein expression 
of cardiac ion channels/transporters that are required to maintain normal 
electrical functioning and intracellular ionic homeostasis – this is known as 
electrical remodeling. [172,173] This electrophysiological change produces a 
substrate that is vulnerable to malignant VAs. 
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 With the current evidence, it is difficult to be certain of the role of 
telomere biology in arrhythmogenesis. However, if an association is 
established between systemic telomere biology and clinical cardiac 
arrhythmias, then this will require further study of the interaction of telomere 
biology and functional cardiac electrophysiology and cardiac remodeling post 
MI. Telomere shortening is felt to contribute to biological ageing through an 
increased vulnerability to oxidative stress and subsequent fibrosis secondary to 
reduced genomic stability. [174] Ventricular myocardial fibrosis is considered 
central for initiation and maintenance of re-entry VT through its role in 
promoting electrical heterogeneity. Telomeres may be seen to play a central 
role in this by virtue of poor myocardial repair process. Other mechanisms of 
telomere mediated VAs in this cohort could include telomerase mediated 
prolonged lifespan of inflammatory cells promoting ischaemia or prolonged 
lifespan of peri-infarct cardiac cells promoting anisotropy and arrhythmic 
potential. Comprehensive mechanistic studies will be required to investigate 
this further if an initial correlation between telomere biology and VA is 
established in this study.  
1.5 Rationale, Aims and Hypothesis 
This review has demonstrated that ICDs are being increasingly used in current 
practice and are the most effective intervention for the prevention of SCD in 
ischaemic cardiomyopathy patients. However, they are associated with 
morbidity and mortality. The key investigation guiding ICD prescription under 
current guidelines is LVEF. However, this risk stratification process has major 
limitations and needs improvement.  
 Telomere biology offers a promising approach to an improved risk 
stratification process for primary prevention ICD implants. Considering the 
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evidence discussed in the previous sections, demonstrating a relationship 
between telomere biology and cardiovascular disease and taking into account 
the mechanisms of telomere shortening and arrhythmogenesis, we 
hypothesised that: 
 Telomere shortening at the time of the index event (myocardial 
infarction) results in poor myocardial repair process and predisposes patients 
to greater arrhythmic tendency. 
 Hence, the load of short telomeres, mean telomere length and/or 
telomerase activity would be different in ischaemic cardiomyopathy patients 
with and without VA and would co-relate with the incidence of VA. 
In order to test this hypothesis, we carried out a retrospective case-control 
study in patients with ischaemic cardiomyopathy and ICDs. This was to 
facilitate a comprehensive investigation of the characteristics of leukocyte 
telomere biology and their association with development of potentially fatal VA. 
The specific aims of the study were: 
1. To acquire detailed characterisation of the mean leukocyte telomere 
length, load of short telomeres and telomerase activity in patients 
with ischaemic cardiomyopathy with primary prevention ICDs and 
correlate these findings with the incidence of previously documented VA 
requiring ICD therapies (as a surrogate marker of SCD). 
2. To investigate genetic variation in telomere related single nucleotide 
polymorphisms and correlate these variations alone and in 
combination with telomere dynamics with the incidence of previously 
documented VA requiring ICD therapies (as a surrogate marker of 
SCD). 
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3. To investigate any association between mean telomere length, load of 
short telomeres and telomerase activity and other clinical variables 
including eGFR, BNP, NYHA class and LVEF. 
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Chapter 2 – METHODS 
2.1 Introduction to the Methods 
The materials and methods utilised in the research project are described in this 
chapter. All patients were recruited from the device clinic at St Bartholomew’s 
hospital. I screened the clinical notes of 350 patients attending the device clinic 
to identify if they met the inclusion and exclusion criteria of the study. Of these, 
140 patients were eligible to participate in the study and were invited to 
participate. I discussed the study with them via initial telephone contact and 
then at their clinic visit before obtaining informed consent. Following this, a 
detailed clinical phenotypic assessment was done including medical history, 
echocardiograms, ICD interrogation and blood tests as detailed in the next 
section. Blood samples were immediately transferred on ice to the laboratory.    
The vast majority of experiments were performed in the Translational 
Medicine and Therapeutics Laboratory at the William Harvey Heart Centre, 
Charterhouse Square Campus, Queen Mary University of London. A small 
subsection of experiments were carried out at Department of Clinical Genetics, 
Vejle Hospital, Aarhus University, Denmark.  
The experiments described in this thesis were performed on human 
DNA extracted from peripheral blood leukocytes. All DNA samples were stored 
in an anonymous manner at the Translational Medicine and therapeutics 
Laboratory at the William Harvey Heart Centre, Charterhouse Square Campus, 
Queen Mary University of London. Storage of samples and all procedures 
carried out on them were in accordance with the Human Tissue Act 2004. 
I performed all experiments used in this research project. I received 
initial training in telomere experimental methodology from Dr Scott Brouilette, 
post-doctoral fellow, at the William Harvey Heart Centre in Professor Suzuki’s 
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laboratory. I was trained for qPCR analyses for mean telomere length on DNA 
samples obtained from a separate clinical cohort (Genomic Advances in 
Sepsis). I performed qPCR measurements (in duplicate) on a total of 80 
samples of which 30 samples were analysed by both Dr Brouilette and myself 
(to determine the inter-individual variability) to ensure accuracy of the 
technique learnt. The coefficient of variance for these samples was 11%. For 
the 90 samples analysed in this study (results presented in section 3.3.3) 
qPCR measurements were performed in duplicate by myself. The intra-assay 
coefficient of variation was 5.8%. Dr Laila Bendix, Vejle Hospital, Denmark; 
supervised the analysis of load of short telomeres (see section 2.7 and 3.3.5) 
using the Universal Single Telomere Length Analysis protocol.  
2.2 Study Design and Patient Recruitment 
This case-control observational study was carried out at St Bartholomew’s 
hospital and William Harvey Research Centre. Ethical approval was obtained 
from the local research ethics committee. All patients gave written informed 
consent and were recruited from the ICD clinic at St Bartholomew’s Hospital. 
Investigators were blinded to clinical history and all telomere analysis was 
carried out blinded to clinical data. 
To be eligible for recruitment, patients had to meet all of the following 
criteria: 
Inclusion criteria 
• Caucasian ethnicity 
• Previous MI with coronary artery disease demonstrated on angiography 
• No evidence of reversible ischaemia on angiography or functional 
imaging 
• Poor systolic function with Left Ventricular Ejection Fraction ≤ 35%  
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• ICD implanted for primary prevention (risk of sudden cardiac death due 
to ischaemic cardiomyopathy) 
Exclusion criteria 
• Age < 18yrs 
• Carcinoma 
• Chronic inflammatory disorders ascertained by patients medical history, 
white cell count and CRP levels 
• Inability or unwillingness to sign consent form 
• Life expectancy less than 6 months as a result of non-cardiac disease 
2.3 Phenotypic Assessment and Investigations 
I assessed all patients were in the device clinic at recruitment. All patients 
underwent: 
Medical history: a detailed medical history was obtained to include identification 
of hypertension, diabetes mellitus, chronic renal failure, hypercholesterolemia, 
smoking status, family history of ischaemic heart disease, New York Heart 
Association Functional Classification (NYHA) and a full drug history. 
Echocardiogram: a trans-thoracic echocardiogram to calculate left ventricular 
dimensions and LVEF by modified Simpson’s method. 
ICD interrogation: all patients recruited to the study had primary prevention ICD 
implants on the background of ischaemic cardiomyopathy. Details of the ICD 
implant were noted including type of device, pacing thresholds and 
programming criteria. Programmed ventricular arrhythmia zones were based 
on standard departmental criteria for primary prevention devices at the time of 
implant. The vast majority of patients had their devices programmed as a two 
zone device (VT and VF) with a mean lower rate of VT zone at 170 ± 2 bpm 
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(programmed ATP and shock therapies) and the VF zone (shock only) at 205 ± 
2 bpm, reflecting practice at our institution at the time. Based on the above 
device programming criteria, potentially fatal VA was defined as sustained 
ventricular tachycardia at a rate > 170 bpm (and lasting greater than 30 
seconds) or ventricular fibrillation requiring device therapy. Over the course of 
follow-up since device implant, a small proportion of patients had some device 
programming changes done based on their clinical need. Although these 
changes could potentially have an impact on the study results, this was 
accepted as a recognised limitation of this retrospective case-control study 
design and heterogeneity of the patients recruited. 
 ICDs were interrogated to identify recent arrhythmias and therapies  
delivered since the last clinic visit. ICD therapies served as a surrogate for 
potentially fatal VA (and hence SCD) and included both ATP and shock. All 
previous ICD clinic notes and device traces (since implant) were individually 
looked at to identify both appropriate and inappropriate therapies (ATP and 
shocks). Inappropriate and aborted shocks were recorded but did not constitute 
a surrogate marker for SCD and were not included in the study analyses. 
Blood analyses: peripheral blood samples were taken for assessment of total 
serum cholesterol, lipid profile, white cell count, creatinine and estimated GFR 
(by the MDRD equation). Additional samples were taken for measurement of 
leukocyte telomere length & telomerase activity (in duplicate), load of short 
telomeres and plasma BNP. 
2.4 Leukocyte Collection and Preparation 
2.4.1 Reagents and Solutions 
The following reagents were used, solutions prepared and utilized for this 
experiment: 
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1. Reagents 
a. RPMI 1640 media (Sigma R0883) 
b. Penicillin/Streptomycin, 100 x (Sigma P0781) 
c. L-Glutamine, 200mM (Sigma F2442) 
d. Dimethylsulphoxide, DMSO (Sigma D2650) 
e. Histopaque 1077 (Sigma H8889) 
2. Solutions preparation 
a. Wash Mix: this solution was used to wash the cells (leukocytes) and 
also served as a base for preparation of the Freeze mix. It was 
prepared by adding 5ml of Penicillin/Streptomycin and 5ml of 200mM 
Glutamine to 500 ml of RPMI 1640 media. 
b. Freeze Mix: this solution was used for cryopreservation of the cells 
(leukocytes). It was prepared by adding 5ml of DMSO and 15 ml of 
Foetal Bovine Serum (FBS) to 30 ml of Wash Mix.  
2.4.2 Isolation of Leukocytes 
 Whole blood was drawn into 4 x 6 ml of EDTA vacutainer tubes and 
processed within half an hour of venepuncture. 3ml of histopaque was added to 
each accuspin tube, which was then centrifuged in a bench centrifuge (Hettich 
EBA 20, UK) at 800 g RCF for 30 seconds. This resulted in the histopaque 
moving below the fret within the accuspin tube. The blood is mixed well by 
inverting the EDTA vacutainer tube a few times. 5ml of blood was then added 
to the accuspin tube in a laminar flow hood. The tube was then centrifuged at 
2500 rpm for 20 min. This enabled the lymphocyte layer to be completely 
separated from the remaining blood. 
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2.4.3 Collection of Leukocytes 
Using a 3ml Pasteur pipette, the uppermost layer of fluid (plasma) was carefully 
removed from the accuspin tube and discarded into a waste bottle containing 
disinfectant (Virkon, Sigma, UK). The lymphocyte layer was then transferred to 
a 15ml centrifuge falcon. 
2.4.4 Cryopreservation of Leukocytes 
14ml of pre-warmed Wash mix was then added to the 15ml falcon containing 
leukocytes. This was then centrifuged at 1000 rpm (210g RCF) for 10 min at 
room temperature. The supernatant was discarded into a waste bottle 
containing disinfectant (Virkon, Sigma, UK) after centrifugation. The cells were 
then re-suspended in 2ml of Freeze mix and aliquoted into cryovials. These 
were stored at -80°C for future use for DNA isolation.  
 
  
   Figure 5: Buffy coat and DNA extraction 
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2.5 DNA extraction 
2.5.1 Reagents and Solutions 
The following reagents from the QIAgen Flexi Gene – QIAgen 51206 kit were 
utilized for this experiment: 
1. Reagents 
a. Buffer FG1 
b. Buffer FG2/QIAgen Protease 
c. 100% Isopropanol 
d. 70% Ethanol 
e. Buffer FG3 
2. Solutions prepared 
The BufferFG2/QIAgen Protease for different batch volumes of buffy 
coat (leukocyte volumes) are: 
	  	  Table 2: volumes of Buffer FG2 (in ml) and QIAgen Protease (in µL) required 
to prepare different batch volumes (ml) of Buffy Coat reagent. 
 
2.5.2 Cell Lysis 
The frozen buffy coats were thawed in a 37°C bath with mild agitation for 30 
min. 2 ml of buffy coat was added to a 15 ml falcon containing 5 ml of lysis 
buffer FG1. The solution was mixed by inverting and then centrifugation was 
carried out in a bench centrifuge (Hettich EBA 20, UK) for 5 min at 2000G RCF 
at room temperature. The supernatant was discarded in a waste bottle 
containing disinfectant (Virkon, Sigma, UK) and the falcon left inverted on an 
absorbent paper to get rid of any residual fluid, leaving a visible white pellet.   
Total volume of Buffy Coat in batch 
(ml) 
1 3 5 10 30 50 60 
Volume of Buffer FG2 (ml) 1 3 5 10 30 50 60 
Volume of QIAgen Protease (ul) 10 30 50 100 300 500 600 
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2.5.3 Protein Digestion 
Denaturation buffer FG2 and QIagen protease (3ml/30µl) was added to the 
pellet and the falcon vortexed immediately (3-4 pulses for 5sec) till the pellet 
was completely homogenised. The falcon was inspected carefully to ensure 
complete homogenisation. If traces of pellet remained, then 300µl of 
denaturation buffer was added and the solution vortexed again. Further mixing 
was done by inverting the falcon thrice, following which it was incubated for 10 
min at 65°C in a water bath. Protein digestion was indicated by change of 
solution colour from red to olive green.   
2.5.4 DNA Precipitation 
2ml of 100% isopropanol was then added and the solution mixed by inversion 
till precipitated DNA was visible as a white thread. Centrifugation was carried 
out in a bench centrifuge at 2000G RCF at room temperature for 3 min. The 
supernatant was poured off, taking care not to loose the pellet. The falcon was 
then inverted on absorbent paper to drain the residual fluid, taking care not to 
loose the pellet. The pellet was then washed by inversion in 2ml of 70% 
ethanol and vortexed for 5 sec. Centrifugation was carried out in a bench 
centrifuge at 2000G RCF for 3min at room temperature. The supernatant was 
discarded and the falcon inverted on absorbent paper for 10-15 min to drain the 
residual fluid. The DNA pellet was air dried for 5 min till all residual fluid had 
evaporated.	  
2.5.5 DNA Hydration 
Up to 600µl of DNA hydration buffer FG3 was added to the pellet and the 
falcon vortexed for 5s at low speed. This was then placed in a water bath at 
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65°C for 1 hour to dissolve the DNA. The sample was then cooled at room 
temperature and stored at 4°C until DNA determination was carried out. 
2.5.6 DNA Quantification 
DNA was quantified in duplicate by spectrophotometry. Calibration of 
spectrophotometer was done by using hydration buffer FG3.  
Nucleic acids have a peak absorbance in the ultraviolet range, at 
approximately 260 nm. Sample purity was assessed by using the 260/280 ratio 
– pure DNA has an absorbance 260/280 ratio of 1.8 – 1.9. Lower ratios are 
caused by substantial protein contamination whereas higher ratios indicate 
RNA contamination. Samples that were found to be too dilute were precipitated 
with ethanol and re-suspended in a smaller volume. [175] 
2.6. Quantitative real time PCR analysis of mean telomere 
length  
2.6.1 Quantitative Real time PCR Assay Principles 
Real time PCR analysis 
Polymerase chain reaction relies on the self-replicating nature of DNA, using 
short primers to initiate synthesis of a target sequence by a DNA polymerase. 
Parent strands are separated by heating the DNA, short primers are annealed 
and extended by DNA polymerase. The repetition of this process over 
numerous cycles (20-40), results in amplification of the original target 
sequence. In theory, doubling of the target sequence should occur after every 
replication. However, in practice, this only occurs till the reaction components 
are in excess, functional polymerase is present and the PCR products are 
being formed at a fixed rate (i.e. no primer-dimer or non-specific products are 
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accumulating). The point at which the amplification reaches a plateau (called 
‘end point determination’) is used for quantification of PCR products.	  
Telomere PCR  
When compared to conventional amplification, telomere PCR is challenging 
due to the repetitive nature of the telomeric repeats. The principle underlying 
telomere PCR was described by Cawthon in 2002 [176] in his novel method for 
estimating telomere length using real-time PCR and relative quantification. He 
determined the relative telomere lengths by measuring (for each DNA sample), 
the factor by which the sample differed from a reference DNA sample in its 
ratio of telomere repeat copy number to single gene copy number. 
It is postulated that longer telomeres will have more potential primer 
annealing sites and hence there will be an increase in fluorescence and 
decrease in number of cycles needed to reach a given threshold compared to a 
shorter telomere.   
Method of analysis 
Analysis of the telomere PCR products can be done by a number of methods. 
Methods for relative quantification include 2-standard curves method, 
comparative CT method, Pfaffl and comparative quantification.  
Comparative quantification (Corbett Research, Cambridge, UK) was 
employed for analysis of mean telomere length in this assay. It is one of the 
more recently developed methods that increases the accuracy of the assay and 
is widely used and published. Comparative quantification compares the relative 
expression of samples to a control sample in a run when a standard curve is 
not available.  
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The basic principle of comparative quantification is shown in Figure 6.
 
 
Figure 6: Graph showing comparative quantification analysis for telomere 
length measurement 
 
[The take off point is determined for each sample by extrapolating back 80% 
from the peak reaction velocity]  
 
(Adapted from Rotorgene version 6, Corbett Research) 
 
It depicts the second derivative of an amplification plot, showing the 
relative positions of the second derivative peak and the take off point. The take 
off point is defined as the cycle at which the second derivative is at 20% of the 
maximum level and indicates the end of the noise and transition to the 
exponential phase. The second derivative of the amplification plot produces 
peaks corresponding to the maximum rate of fluorescence increase in the 
reaction. The amplification is an indication of the efficiency of the sample 
reaction. The amplification value of all samples is averaged to produce a mean 
amplification value. The relative concentration of each sample compared with 
the calibrator sample is calculated based on the take off point and reaction 
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efficiency. It calculates efficiency of every sample within a run rather than 
taking values from a set of standard curves. This increases the accuracy of the 
analysis compared to other methods.  
An example of relative concentration analysis as per the software is as follows: 
1. The take off point of each sample is calculated by looking at the second 
derivative peaks. 
2. The average increase in raw data 4 cycles after the takeoff is calculated. 
This is the amplification value for the sample. 
3. Outlier amplifications are removed to account for noise in background 
fluorescence. 
4. The remaining amplifications are averaged. This is the average 
amplification. 
5. The average takeoff point is calculated for each calibrator replicate. 
6. The relative concentration for a sample is calculated according to this 
formula: Amplification⌃(Calibrator takeoff – Sample takeoff) 
2.6.2 Reagents and Solution 
The following reagents and solutions were utilized in this assay: 
1. Reagents 
a. Primers: telomere (forward and reverse primers), 36b4 (forward and 
reverse primers), 100x conc (Sigma, UK) 
b. Quantifast SYBR Green PCR Mix: 2 x conc. Contains HotStar Taq 
Plus DNA Polymerase, SYBR Green PCR buffer, dNTP mix (dATP, 
dCTP, dGTP,dTTP) and ROX passive reference dye  
c. DEPC (diethylpyrocarbonate) treated water 
d. k562 cell line 
2. Solutions 
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a. Primer working stock: dilute the master stock of primers with double 
distilled water to a working stock concentration of x 10.  
2.6.3 Real Time Telomere PCR Assay 
Leukocyte telomere length was measured with a quantitative real time PCR 
based technique that compares telomere repeat sequence copy number to 
single-copy gene (36b4) copy number in a given sample. This was done using 
the QuantiFast SYBR Green PCR mix (Qiagen, UK).  
 The DNA extraction and quantification was done as described before 
(see section 2.5). The QuantiFast SYBR green PCR master mix, primers and 
DNA were thawed on ice. Working stock of the primers was prepared as 
described above. Next, the reaction mix was prepared with 6uL of 
2xQuantiFast SYBR Green PCR mastermix, 1.2uL each of forward and reverse 
telomere primers and 1.6uL of RNase-free DEPC water per reaction. The 
reaction mix was mixed thoroughly and aliquoted into PCR strip tubes. 2uL of 
template DNA at a concentration of 10ng/uL was added to each tube. All 
reactions were carried out in 12uL volumes. All DNA samples were run in 
duplicate. Non-template control (NTC) and calibrator sample k562 were also 
run in duplicate alongside the samples.  
 The samples were run in a 72 well rotor (Rotor Gene-Q, Qiagen). 
Cycling conditions were 95°C incubation for 10 min (activates DNA 
polymerase), followed by 20 cycles (for telomere) and 30 cycles (36b4) of 95°C 
for 15s (denaturation) and 58°C for 1 min (combined annealing/extension). This 
was followed by a melt ramp from 50°C to 99°C with the rise of temperature 
being 1°C with each step. 90s of pre-melt conditioning was carried out prior to 
first step, thereafter it was 5s for each step. The specificity of all amplifications 
was determined by melting curve analysis. 34 study samples, a calibrator 
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sample and one no-template control sample (all in duplicate) were processed 
per run.  
 The PCR reaction described above was carried out using both telomere 
and 36b4 specific primers in two separate runs. The telomere specific primers 
used were forward primer - 
5’CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT3’, reverse 
primer - 5’GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT3; the 
36b4 primers used were forward primer - 
5’CAGCAAGTGGGAAGGTGTAATCC3’, reverse primer - 
5’CCCATTCTATCATCAACGGGTACAA3’.  
 Analysis of PCR output was performed using Comparative Quantitation 
(Corbett Life Science Rotorgene analysis software version 1.7, Corbett Life 
Science, UK). The takeoff value of each sample was calculated based on the 
second derivative peak of the amplification plot, which represents the start of 
the exponential phase. The amplification efficiency was calculated for all the 
samples across the run and the mean amplification efficiency determined. The 
relative concentration of the sample was then calculated relative to the 
calibrator sample using the takeoff value and amplification efficiency. The same 
calibrator sample was used in all the runs to allow comparison of results across 
the runs. This process was performed for both the telomere (T) and 36b4 (S) 
assays and the telomere length expressed as the ratio of these (T/S), using 
mean data from duplicate runs.  
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2.7. Quantification of critically short telomeres by Universal 
STELA 
2.7.1 Universal STELA Assay Principles 
The Universal Single Telomere Length Analysis (U-STELA) assay enables the 
measurement of the load and distribution of the shortest telomere within an 
entire cell population. This is a modification of the original STELA assay, which 
measures the shortest telomeres on single chromosomes within a cell. As 
opposed to the original STELA, this assay can measure the load of short 
telomeres in a biological sample regardless of the specific chromosomal 
location of the shortest telomere. U-STELA assay principles are outlined in the 
figure below. [152]  
The extracted DNA is digested with the help of restriction enzymes, 
which leave the same sticky overhang. The choice of these restriction enzymes 
is crucial as they determine the size of subtelomeric fragment, which is 
eventually included in the estimated telomere length. The combination of 
restriction enzymes used was MseI/NdeI as this mixture digests the DNA very 
proximal in the telomeric block, leaving at worst only a very short, although 
unknown, part of non-telomeric DNA in the final PCR product. However, there 
is a very small chance of the telomere being cut in the most centromeric part of 
the telomeric repeat block (1). The digestion step generates pieces of genomic 
DNA varying between 10-3000 bp, the vast majority of which have the same 
sticky overhang 5’-AT-3’ at both ends (2). However, for every chromosome 
end, a fragment of DNA with the telomeric region including the 3’-overhang at 
one end and a smaller part of the sub-telomeric region with a 5’-AT-3’ overhang 
at the other end, is also formed (3).  
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Figure 7: Image showing U-STELA assay principles 
 [Extracted DNA is digested by restriction enzymes MseI ⁄ NdeI (1). The 
digestion mainly generates pieces of genomic DNA of 10–3000 bp, the great 
majority of which has the same sticky overhang 5’-AT-3‘ at both ends (2). 
However, for every chromosome end a fragment of DNA with the telomeric 
region including the 3’-overhang at one end and a smaller part of the 
subtelomeric region with a 5’-AT-3’ overhang at the other end, is also formed 
(3). The next step is a ligation-based step, in which two specially designed 
oligos (42-mer and 11 + 2-mer panhandle oligo) are annealed and ligated to 
the proximal overhang and to both ends of non-telomeric fragments (for oligo 
sequences see Table 1). These two oligos are designed so that they 
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spontaneously anneal, forming a two-base sticky overhang complementary to 
the overhang formed by the digestion. The other end of the paired oligos is a 
long, single-stranded and GC-rich overhang (4 and 5). The third step is another 
ligation step. An oligo (telorette) is annealed to the G-rich 3’-overhang of the 
telomeric repeat (5). This oligo consists of seven bases complementary to the 
telomere repeat sequence and a tail of 20 non-complementary nucleotides. 
After annealing the telorette is ligated to the 5’- end of the C-rich strand of the 
telomere. Finally a fill-in step is required (6) so that the GC-rich proximal 
overhang becomes double stranded, hereby serving as template for the 
upstream PCR primer (the adapter primer). In the first step of the PCR all DNA 
pieces are denatured. When the temperature is lowered for the annealing step, 
two things can happen. For the intra-genomic fragments where the upstream 
sequence is ligated to both ends, the complementary ends will anneal to each 
other, forming a panhandle, which will be relatively stable due to a high melting 
temperature of the panhandle sequence. A PCR, based on intragenomic 
fragments as template, will therefore be suppressed (7). For the telomeric 
fragments (8), the adapter will anneal to the filled-in part of the upstream 
sequence, thereby initiating PCR. In the following PCR cycles the teltail primer 
will be able to anneal to the PCR product obtained by the adapter primer (9), 
thereby producing telomeric products of different lengths reflecting the lengths 
of the individual telomeres (10).] 
 
 
(Adapted from Bendix et al, 2010) [152] 
The next step is a ligation-based step, in which two specially designed 
oligos (42-mer and 11 + 2-mer panhandle oligo) are annealed and ligated to 
the proximal overhang and to both ends of non-telomeric fragments. These two 
oligos are designed so that they spontaneously anneal, forming a two-base 
sticky overhang complementary to the overhang formed by the digestion. The 
other end of the paired oligos is a long, single-stranded and GC-rich overhang 
(4 and 5).  
Following this, another ligation step is carried out. An oligo (telorette) is 
annealed to the G-rich 3’-overhang of the telomeric repeat (5). This oligo 
consists of seven bases complementary to the telomere repeat sequence and 
a tail of 20 non-complementary nucleotides. After annealing the telorette is 
ligated to the 5’- end of the C-rich strand of the telomere.  
Finally a fill-in step is required (6) so that the GC-rich proximal overhang 
becomes double stranded, hereby serving as template for the upstream PCR 
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primer (the adapter primer). In the first step of the PCR all DNA pieces are 
denatured. When the temperature is lowered for the annealing step, two things 
can happen. For the intra-genomic fragments where the upstream sequence is 
ligated to both ends, the complementary ends will anneal to each other, 
forming a panhandle, which will be relatively stable due to a high melting 
temperature of the panhandle sequence. A PCR, based on intragenomic 
fragments as template, will therefore be suppressed (7).  
For the telomeric fragments (8), the adapter will anneal to the filled-in 
part of the upstream sequence, thereby initiating PCR. In the following PCR 
cycles the teltail primer will be able to anneal to the PCR product obtained by 
the adapter primer (9), thereby producing telomeric products of different 
lengths reflecting the lengths of the individual telomeres (10). 
2.7.2 Reagents and Solutions 
The following reagents and solutions were utilised in this assay: 
1. Reagents 
a. Restriction enzymes MseI and NdeI; HinfI and RsaI, 40U/uL (Roche 
Applied Sciences) 
b. TE Buffer, 20x conc (10mM TRis-Hcl, 1mM EDTA, pH 7.5) 
(Invitrogen) 
c. Quanti-iT Picogreen dsDNA reagent (Invitrogen) 
d. Dimethylsulphoxide, DMSO 
e. Lambda DNA standard, concentration 100ug/ml (Quanti-iT Picogreen 
dsDNA kit) 
f. Oligonucleotides (50uM) 
- 11+2 mer panhandle (5’TACCCGCGTCCGC3’) 
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- 42 mer panhandle (5’TGT AGC GTG AAG ACG ACA GAA AGG 
GCG TGG TGC GGA CGC GGG3’) 
- Telorette 3 (5’TGC TCC GTG CAT CTG GCA TCC CTA ACC3’) 
g. NE Buffer 2 (New England Biolabs) 
h. ATP (New England Biolabs) 
i. T4 DNA Ligase, 20U (New England Biolabs) 
j. Diethylpyrocarbonate treated water (DEPC) 
k. Primers 
- Adapter primer, 0.1uM (5’TGT AGC GTG AAG ACG ACA GAA3’) 
- Teltail primer, 0.1uM (5’TGC TCC GTG CAT CTG GCA TC3’DIG) 
l. Bovine Serum Albumin (BSA, New England Biolabs) 
m. Failsafe Buffer H (Epicentre, VWR, Denmark) 
n. Failsafe Enzyme (Epicentre, VWR, Denmark) 
o. Failsafe PCR Premix H (Epicentre, VWR, Denmark) 
p. Digestion Buffer 10x conc (Roche Applied Science) 
q. Control DNA, low and high, 50uL (Roche Applied Science) 
r. DIG Molecular weight marker (Roche Applied Science) 
s. Loading buffer, 5x conc (Roche Applied Science) 
t. DIG Easy Hybridisation granules (Roche Applied Science) 
u. Telomere hybridization probe (Roche Applied Science) 
v. Washing buffer, Maleic acid buffer, Blocking buffer 10xconc (Roche 
Applied Science) 
w. Anti-DIG-AP antibody, 0.75 U/uL (Roche Applied Science) 
x. Detection Buffer, 10x conc (Roche Applied Science) 
y. Substrate, Denaturation and SSC solutions (Roche Applied Science) 
2. Solutions Prepared 
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a. TE Buffer working solution: prepare1 x TE buffer working solution by 
diluting the concentrated buffer 20 fold with sterile, distilled, DNAse 
free water 
b. Picogreen dsDNA reagent: add 200 fold dilution of concentrated 
DMSO solution in TE Buffer. Add 100uL of Quanti-iT Picogreen 
dsDNA reagent to 19.9ml TE.  
c. Lambda DNA standard, working solution: dilute original lambda DNA 
standard (100ug/ml) by 50 fold in TE buffer to achieve a 
concentration of 2ug/ml 
d. Dig Easy Hyb working solution: re-constitute Dig Easy Hyb granules 
with 64 ml autoclaved, redistilled water and incubate at 37°C until 
complete re-constitution. Solution should be prepared several hours 
before use 
e. SSC working solution: dilute the 20 x SSC, 1:10 with double distilled 
autoclaved water to attain a concentration of 2 x SSC 
f. Blocking solution: dilute the 10 x blocking buffer, 1:10 with maleic 
acid buffer 
g. Anti-DIG-AP working solution: spin the Anti-DIG-AP vial for 5 min at 
13000 rpm before use. Dilute with blocking solution to a final 
concentration of 75mU/ml (1:10,000) 
h. Detection Buffer: dilute the 10 x detection buffer, 1:10 with 
autoclaved, double distilled water  
2.7.3 DNA Digestion with Restriction Enzymes 
DNA was extracted from buffy coats as described before. 50 patient samples 
were used per run with a DNA concentration of 10ng/uL. 2 positive controls and 
2 negative controls were also run in the same plate. DNA digestion was carried 
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out with 1:1 mixture of restriction enzymes MseI and NdeI (Roche Applies 
Sciences) and incubated at 37°C for 2 hours which was followed by inactivation 
at 65°C for 20 min.  
 The quality of DNA digestion and integrity of the initial DNA template 
were tested using agarose gel electrophoresis. 10uL of the digested DNA 
template was run alongside 10uL of the corresponding non-digested template 
and then visualised with a nucleic acid stain.  
 The digestion was confirmed to be adequate if the digested DNA 
appeared as a smear below 600bp. The original intact DNA template should be 
seen as a single compact band migrating at 23kb.  
2.7.4 DNA Template Quantification  
The samples were quantified again with Quant-iT Picogreen dsDNA assay 
(Invitrogen). The picogreen reagent mix was prepared with TE buffer.  
The DNA standard curve was generated using lambda DNA standard 
provided in the kit.  A range of standards was obtained with different 
concentrations. These were obtained by diluting the original lambda standard 
with double distilled water. The samples were analysed in triplicate, the DNA 
lambda standard in duplicate and BLANK sample (TE buffer) in duplicate.  
100uL of working solution picogreen mix to each well. The reagents 
were mixed well and incubated at room temperature for 2-5 min away from 
light. Following this, the sample fluorescence was measured using a 
fluorescence microplate reader at standard fluorescein wavelengths (excitation 
480nm, emission 520 nm). The fluorescence value of BLANK was then 
subtracted from that of each of the samples. The DNA concentration of the 
samples was determined based on the standards used and the samples were 
normalized to 2ng/uL.   
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2.7.5 Ligation with Linker Oligomers and Primers 
8ng of digested DNA was used as template. The oligonucleotides mix 
containing 50umol of 42-mer and 50umol of 11+2-mer was added to the DNA 
template in a total volume of 10uL. The mixture was then ramped down from 
65°C to 16°C over 1 hour. This was followed by a ligation step with 20U T4 
DNA ligase (New England Biolabs) in a mixture containing 1 x NE Buffer2 and 
1x ATP. This mixture was left to ligate overnight at 16°C.  
 The samples were heated to 35°C and a second ligation step was 
carried out with 20U of T4 DNA ligase (New England Biolabs), 10-3 uM 
telorette-3, 1 x NE Buffer2 and 1x ATP. After another 12 hours of ligation and 
20 min of inactivation at 65°C, the ligated products were diluted with sterile 
autoclaved water to a final concentration of 40pg/uL. 
2.7.6 Polymerase Chain Reaction 
Polymerase chain reaction was then performed using the two ligated 
oligonucleotides as targets for PCR. The concentration mix comprised of 80pg 
of ligated DNA, 1X Failsafe PCR PreMix H (Epicentre, VWR, Denmark), 0.1µM 
primers (teltail and adapter) and 1.25 U Failsafe enzyme (Epicentre, VWR, 
Denmark), made up to a volume of 12uL. The reactions were carried out in a 
Hybaid Thermocycler (Thermo Electron) with the first cycle at 68°C for 5 min 
constituting the fill-in step. The second cycle was at 95°C for 2 min. This was 
followed by 26 cycles at 95°C for 15 sec, 58°C for 30 sec and 72°C for 12 min. 
The last cycle was at 72°C for 15 min, following which the samples were held 
at 4°C. 
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2.7.7 Southern Blotting and Detection 
STELA products were detected by Southern Blotting using TeloTAGGG 
telomere length assay (Roche Applied Sciences, Denmark) according to the 
manufacturer’s manual.  
Separation of the DNA products was done by agarose gel 
electrophoresis. A 0.8% agarose gel was prepared in 1 x TAE buffer using 
highly pure, nucleic acid grade agarose – Agarose MP.  4uL of DIG molecular 
weight marker was mixed with 12uL of nuclease free water and 4uL of 5x 
loading buffer. The samples were then loaded on to the gel along with the DIG 
molecular weight marker. The gel was then run at 5V/cm in 1 x TAE buffer.  
For blotting, the gel was immersed in HCl and then rinsed with water 
twice. The gel was then submerged in denaturation solution. This was rinsed 
with water again and then submerged in neutralization solution. Following this, 
the STELA products were transferred onto a positively charged nylon 
membrane by southern blot vacuum transfer using VacuGeneTM XL Vacuum 
Blotting System (GE Healthcare). The transferred DNA was fixed with UV 
crosslinking and the membrane washed with 2 x SSC solution. 
The blotted STELA products were then hybridized overnight to a DIG-
labeled probe specific for the telomeric sequence. These were subsequently 
incubated with a DIG-specific antibody coupled to alkaline phosphate (Roche 
Applied Sciences).  
Finally, after the addition of detection buffer and substrate solution, the 
telomere probe was visualized using the chemiluminescent substrate CDP-Star 
(Roche Applied Sciences), and the chemiluminescence signal was detected 
using BioSpectrum Imaging System (UVP, AH Diagnostics). 
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2.7.8 Calculation of Load of Short Telomeres 
The size of the PCR products was calculated relative to a DIG-labeled 
molecular weight marker (Roche Applied Sciences) using VisionWorks LS 
Acquisition and Analysis Software (Ultra-Violet Products Ltd, AH Diagnostics).  
The number of PCR products with a length less than 1500 base pairs 
(bp) were counted and calibrated based on the PCR template concentration. 
The load of short telomeres was presented as the number of telomeres below a 
length of 1500 bp per genome equivalent of template DNA.  
2.8. Quantification of Telomerase Activity by Telomere Repeat 
Amplification Protocol 
2.8.1 TRAP Assay Principles 
Quantification of telomerase activity was done by the Telomere Repeat 
Amplification (TRAP) protocol, which allows highly specific amplification of 
telomerase mediated elongation products combined with non-radioactive 
photometric detection following an Enzyme Linked Immunosorbent Assay 
(ELISA) protocol. 
 The TRAP assay consists of two steps (1) Elongation/amplification (2) 
Detection of products by ELISA. 
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Figure 8: Image showing principle underlying Telomerase ELISA assay 
 [In step 1 (elongation), telomerase adds telomeric repeats to the 3’ end of the 
biotin labelled synthetic P1-TS primer.In the second step (amplification),the 
elongated products are amplified by PCR using the P1-TS and P2 
primersgenertaing PCR products with the telomerase specific 6 nucleotide 
increments. Step 3 and 4 include detection if these products by ELISA ] 
(Taken from TeloTAGGG telomerase PCR ELISA manual) [177] 
In the first step, telomerase adds telomeric repeats (TTAGGG) to the 3’ 
end of the biotin labeled synthetic P1-TS primer based on the telomerase 
content of the sample (number of telomeric repeats α telomerase activity). 
These elongation products are then amplified by PCR using the primers P1-TS 
and P2, generating PCR products with the telomerase specific 6 nucleotide 
increments.  
In the second step, an aliquot of the PCR product is denatured and 
hybridised to a digoxigenin (DIG) labeled, telomeric repeat-specific detection 
probe. The resulting product is immobilized via the biotin labeled primer to a 
streptavidin coated microplate. The immobilized PCR product is then detected 
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with an antibody against digoxigenin (anti-DIG-POD) that is conjugated to 
peroxidase. The probe is then visualised by virtue of peroxidise metabolising 
TMB to form a coloured reaction product. [177] 
2.8.2 Reagents and Solutions 
The following reagents from the Quanti-Fast Picogreen (QiaGen, UK) and Telo 
TAGGG Telomerase PCR ELISA (Roche,UK), were used in this assay: 
1. Reagents 
a. Trypsin 
b. Phosphate buffered saline (PBS) 
c. Lysis reagent  
Is used for preparation of cell extracts from cell cultures.  
d. Reaction mixture 
Is a tris-buffer which contains telomerase substrate, primers, 
nucleotides and Taq polymerase. It also contains biotin labeled P1-
TS primer and P2 primer. This is used for the telomerase mediated 
primer elongation and PCR amplification. 
e. Denaturation reagent 
Is a sodium hydroxide (0.5%) solution 
f. Hybridization buffer 
Contains a DIG-labeled detection probe complementary to the 
telomeric repeat sequence. 
g. Washing buffer 
h. Anti-DIG-POD (Anti-digoxigenin-peroxidase) 
It is a lyophilized stabilized polyclonal antibody from sheep. 
i. Conjugate dilution buffer 
j. TMB substrate solution 
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Contains the POD substrate 3,3’,5,5’-tetramethyl benzidine 
k. STOP reagent 
Contains sulfuric acid (<5%) 
l. Positive control extract  
Is a cell extract prepared from lyophilized immortalized telomerase-
expressing human kidney cells (293) 
m. Microplate (MTP) 
Is a strip frame with 12x8 well modules pre-coated with streptavidin 
and post-coated with blocking reagent with a desiccant capsule. 
2. Solutions Preparation 
a. Washing buffer x1 
An appropriate volume of washing buffer (10x conc) was diluted with 
autoclaved double distilled water (1:10) and mixed thoroughly. The 
diluted solution is stable for 1 month at temperatures of 2-8°C. 
b. Anti-DIG-POD stock solution 
The Anti-DIG-POD lyophilisate was re-constituted in 240uL of 
autoclaved double distilled water. The resultant solution had an 
antibody concentration of 0.5U/ml. This solution is stable for 6 
months at a temperature of 2-8°C. 
c. Anti-DIG-POD Working Solution 
This was prepared by diluting an appropriate amount of the re-
constituted anti-DIG-POD stock solution with conjugate dilution buffer 
to a final concentration of 10mU/ml. This solution cannot be stored 
and should be prepared immediately before use. 
d. Positive Control Cell Extract 
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The lyophilized cell extract was re-constituted on ice with 20uL 
autoclaved double distilled water and mix thoroughly. The re-
constituted solution had a concentration of 1x103 cell equivalents per 
microliter. The solution was then dispensed in into 1-3uL aliquots. 
This solution cannot be stored and needs to be prepared 
immediately before use.  
2.8.3 Cell Counting with Automated Cell Counter 
The frozen buffy coats were thawed at 37°C for 5 min. These were vortexed at 
a slow speed and kept on ice. 20uL of cells from buffy coat were suspended in 
20uL of trypsin in an ependorff. This was vortexed at a slow speed for a couple 
of seconds. These cells were then analysed using a Countess Automated Cell 
Counter (Invitrogen, UK). 10uL of the above suspension was added to a glass 
slide specific to the cell counter machine (Countess Cell Counting Chamber 
Slides / Invitrogen, UK, C10228). On some occasions, the suspension was 
found to be too concentrated for cell count. This was then diluted with PBS 1:5 
or 1:10, following which the cells were trypsinised for a repeat cell count. An 
automated cell count was obtained and the number of live cells and viability 
recorded. 
2.8.4 Generation of Negative Controls 
Heat inactivated negative controls were generated for this assay. Cell solution 
equivalent to 2 x 105 cells per single reaction were transferred to a new 
ependorff. Centrifugation was carried out at 3000G RCF at a temperature of 
4°C for 10 min. The supernatant was aspirated in the laminar flow hood with a 
vacuum tip. The resulting pellet was then re-suspended in 500uL of PBS (pre-
chilled on ice).  
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Again, centrifugation was carried out at 3000G RCF at a temperature of 
4°c FOR 10 min.  The supernatant was discarded and the pelleted cells were 
re-suspended in 200uL of lysis solution (pre-chilled on ice). Homogenous 
suspension was ensured by pipetting the solution a few times, followed by slow 
vortex for a few seconds. These were then left to incubate on ice for 30 min. 
Following this centrifugation was carried out at 16000G RCF at a temperature 
of 4°C for 20 min. 175 uL of the resultant supernatant was transferred to a 
fresh ependorff.   
10uL of each sample was transferred to a 96 well plate. These samples 
were then incubated at 85°C for 10 min. Negative controls were thus generated 
by heat inactivation of the proteins.  
2.8.5 Telomere Repeat Amplification Protocol (TRAP reaction) 
The 96 well plate with the negative controls was then cooled on ice. 10uL of 
samples were then transferred on to the same plate as depicted in the plate 
layout below. 
NC NC NC NC  S S S S    
            
            
            
            
            
            
            
 
        Table 3: 96-well plate layout for negative controls (NC) and samples (S) 
The reaction mix is thawed on ice and the positive controls re-constituted with 
20uL of diethylpyrocardbonate (DEPC) treated water (Invitrogen, UK). The 
amount of reaction mix and DEPC treated water required for one reaction plate 
was calculated based on number of samples, keeping the DNA amount fixed at 
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3uL. These proportions were calculated for 28 samples, 28 negative controls 
and 2 positive controls for one reaction plate as shown in table 4. 
 x 1 (µg) x 60 
Reaction Mix 25 1500 
DNA 3  
dH2O 22 1320 
Total 50  
 
Table 4: Table showing quantities of reaction mix, DNA and distilled water (all 
in µL) required for setting up PCR reaction for 1 and 60 samples 
 
 
Hot start PCR was then carried out using PCR system and a combined primer 
elongation and amplification reaction performed in a thermal cycler. For the first 
cycle the samples are kept at 25°C for 10 min to enable primer elongation. The 
second cycle was designed for telomerase inactivation wherein samples were 
kept at 94°C for 5 min. Amplification of the samples was then carried out over 
the next 30 cycles with programmed temperature variation cycling through 
94°C for 30s, 50°C for 30s and 72°C for 90s to facilitate denaturation, 
annealing and polymerization respectively.  The final cycle holds the samples 
at 72°C for 10 min. This is summarised in table 5. 
         TIME TEMPERATURE CYCLES 
Primer elongation 10 min 25°C 1 
Telomerase 
inactivation 
5 min 94°C 1 
Amplification: 
Denaturation 
Annealing 
Polymerisation 
 
30s 
30s 
90s 
 
94°C 
50°C 
72°C 
 
 
1-30 
 10 min 72°C 1 
  4°C  
 
Table 5: Table showing various steps of TRAP reaction elongation/amplification 
protocol 
 
[Primer elongation and PCR cycling steps with optimal conditions – 
temperature and number of cycles] 
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The 96 well plate was transferred on to ice after holding it at 4°C in the PCR 
machine. 
2.8.6 Hybridisation and Detection by Enzyme Linked 
Immunosorbent Assay 
Following PCR, 5µl of amplification product (samples in duplicate) and 20µl 
denaturation solution was added in each well of a fresh 96-well plate. These 
were then incubated at room temperature for 10 min. 225uL of hybridization 
buffer was added to each well. Following this, 100uL of each sample was 
transferred to a pre-coated MP module. The plate layout is shown below.  
 
S SD NC S SD NC S SD NC S SD NC 
            
            
            
            
            
           PC 
           PC 
 
S: sample 
 SD: sample duplicate (technical replicate) 
 NC: negative control  
 PC: positive control 
 
               Table 6: MP Module layout 
 
The next step involved shaking the MP module at 300RPM at 37°C for 2 hours. 
The hybridization solution was then removed completely by washing with wash 
buffer. This was done over three washes with 200uL of wash buffer per well for 
30s per wash.  100µl of Anti-DIGPOD was added to each well. The MP module 
was covered with foil and then incubated at room temperature for 30 min while 
shaking at 300RPM. Further five washes were carried out with 200uL of wash 
buffer per well for 30s per wash. 100µl of substrate solution (pre-warmed to 
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room temperature) was added to each well. The MP module was then covered 
with foil and incubated at room temperature for 20 min while shaking at 
300RPM. A colour change to blue, relative to positive controls, in the samples 
was observed. At this point, 100uL of STOP solution was added to each well 
and a colour change to yellow was observed in each well. The telomerase 
activity was measured on the ELISA plate reader at an absorbance of 450nm 
and a reference filter of 690nm within 30 min of addition of the STOP solution. 
2.9. SNP Genotype analysis by Taqman assay 
2.9.1 Taqman SNP Genotyping Assay Principles 
Taqman genotyping probes are used for detection of single nucleotide 
polymorphisms by increasing the specificity of PCR reactions. Its basic 
principle relies on the 5’-3’ nuclease activity of the enzyme Taq-polymerase 
and fluorophobe based detection.  
 The genotyping assay contains two primers for amplifying the 
polymorphic sequence of interest and two fluorescent probes with a minor 
grove binder (MGB) at the 3’ end of each probe. The two primers target the 
region that flanks the SNP of interest. The MGB probe contains a reporter dye 
at the 5’ end – VIC dye linked to allele 1 probe and FAM dye linked to allele 2 
probe. A non-fluorescent quencher (NFQ) is also present at the 3’ end of each 
probe. The NFQ prevents liberation of the reporter fluorescence if the probe is 
not degraded. The MGB stabilises the double stranded matrix formed between 
the probe and the target.  
 During the PCR reaction, each taqman probe anneals specifically to its 
complementary sequence between the forward and reverse primer sites as 
shown in the figure below. While the oligonucleotide probe is intact, the 
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proximity of the reporter dye to the quencher dye results in quenching of the 
reporter fluorescence primarily by Forster type energy transfer (FRET).  
 
 
Figure 9: Image depicting the 5’ Nuclease assay process 
[Various steps of the 5’nuclease assay as described in the text are shown here] 
(Taken from QiAGEN SNP Probe manual) [178] 
 
 The primers bound to the template DNA are extended by the DNA 
polymerase. The DNA polymerase cleaves only those probes that are 
hybridized to the target. This cleavage separates the reporter dye from the 
quencher dye, which results in increased fluorescence by the reporter. This 
increase in fluorescence signal only occurs when probes that have hybridized 
to the complementary sequences have cleaved. And hence, the fluorescence 
signal generated by PCR amplification indicated which alleles are present in 
the sample.  
	  	  
105	  
 A substantial increase in VIC-dye fluorescence only indicates 
homozygosity for allele 1. FAM-dye fluorescence increase indicates 
homozygosity for allele 2. Whereas, both VIC- and FAM-dye fluorescence 
indicates allele 1 and allele 2 heterozygosity. [178] 
2.9.2 Reagents and Solutions 
The following reagents and solutions (Taqman SNP genotyping assays, 
Applied Biosystems) were used in this assay: 
1. Reagents 
a. Taqman genotyping assay: two MGB probes (one probe labeled with 
VIC dye detects allele 1 sequence, the other probe labeled with FAM 
dye detects the allele 2 sequence) and two primers for amplifying 
polymorphic sequence of interest. 
b. Taqman genotyping master mix 
c. TE buffer (10mM Tris-HCl , 1mM EDTA, pH 8, made using DNase-
free, autoclaved, double distilled water) 
d. DEPC (diethylpyrocarbonate) treated water  
2. Solutions 
a. SNP genotyping assay working solution: dilute the 80 x SNP 
genotyping assay with TE buffer to 20 x working stock. Multiple aliquots 
of the diluted SNP genotyping assay can be stored at -25°C 
2.9.3 Quantifying Genomic DNA 
The DNA was quantified as described before (see section) 
 
2.9.4 Reaction Mix and Wet DNA Platform Preparation 
The reaction mix was prepared using 0.5 uL of 20 x SNP Genotyping probe 
and 5uL of 2 x PCR Mastermix. The genotyping probe was vortexed slowly for 
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a minute before addition to the mastermix to ensure homogenous mixing. The 
DNA samples were diluted with DEPC water to deliver a final concentration of 
20 ng. The mastermix was aliquoted into 0.1 ml strip tubes (72-well Rotor 
Gene-Q, QiAgen), following which genomic DNA was added to strip tubes. Two 
no template controls (NTC) were also included. All reactions were carried out in 
a final volume of 10uL. All pipetting was carried out in a laminar flow hood to 
avoid any cross contamination. Once the DNA platform is ready it was 
centrifuged briefly to spin down the contents and eliminate any air bubbles. 
2.9.5 PCR Amplification 
PCR was carried out in a real time PCR thermal cycler (Rotorgene, QiAgen, 
UK). The samples were initially incubated with temperature increased to 95°C 
and held at that temperature for 10 min. The polymerase is activated by this 
heating step. This was followed by 40 cycles of PCR at 92°C for 15s 
(denaturation) and 60°C for 90s (anneal/extend). 
2.9.6 Allelic Discrimination and Scatter Plot Analysis 
After PCR amplification, allelic discrimination read and analysis was performed 
using the Rotor Gene Q software (Qiagen). Allelic discrimination uses real-time 
kinetic from two or more channels to genotype samples. Within the SNP 
genotyping tool, the allelic discrimination software was used. Both Cycling A 
Green and Cycling A Yellow channels were selected and genotypes assigned 
to each channel. Automatic allele calls were made by the software, which were 
subsequently verified. Allelic discrimination analysis was performed based on 
set thresholds.  
Scatter graph analysis was also performed. This enables genotyping 
based on relative expression of amplification plots across two channels. The 
display is normalized to account for different fold increases in each channel 
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and log transformed to accentuate the differences in expression between 
samples. Unlike allelic discrimination, genotype here was determined based on 
regions defined by a scatter graph rather than from a single threshold.  
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Chapter 3 – ASSOCIATION OF TELOMERE DYNAMICS WITH 
VENTRICULAR ARRHYTHMIAS 
3.1 Introduction and Aims 
As discussed in Chapter 1, ICDs have a clear survival benefit in high-risk 
patients with severely impaired left ventricular function post MI. [1,19,20] 
However, ICDs are associated with morbidity and mortality. Importantly, 67% of 
the patients never receive an appropriate shock after ICD implantation under 
the current guidelines, suggesting a need for better risk stratification. [80,81] 
 Telomere length and telomerase activity in leukocytes have recently 
been shown to correlate with biological ageing, health status and 
pathogenesis/prognosis of several types of cardiovascular diseases. Telomere 
biology has the potential of identifying accelerated biological ageing distinct 
from chronological ageing and help predict the occurrence of cardiovascular 
events. It has been associated with CAD in diverse populations, triple vessel 
CAD, premature myocardial infarction and acute coronary syndromes. [94-97] 
Telomere shortening has also shown to correlate strongly with the presence of 
cardiovascular risk factors (including obesity, smoking and type two diabetes), 
decreased renal function in subjects with heart failure and presence of 
atherosclerotic plaques in vascular tissues. [99,101,157,158,165] 
 Telomeres are a promising option to improve risk stratification of SCD in 
CAD patients given their ability to quantify accelerated biological ageing (which 
reflects the replicative potential of the cell and/or the cumulative lifelong burden 
of oxidative stress) distinct from an individual’s chronological age. Keeping in 
mind the evidence demonstrating a relationship between telomere biology and 
cardiovascular disease and taking into account the mechanisms of telomere 
shortening described before; it was hypothesised that telomere shortening due 
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at the time of myocardial infarction results in poor myocardial repair process 
and predisposes patients to greater arrhythmic tendency.  
 To test this hypothesis, a retrospective case-control study was designed 
wherein the association between leukocyte telomere dynamics (mean telomere 
length, telomerase activity and load-of-short telomeres) and ventricular 
arrhythmias in ischaemic cardiomyopathy patients was examined. 
3.2 Methods 
This case-control observational study was carried out at St Bartholomew’s 
hospital, William Harvey Research Institute and Vejle hospital, Denmark. 
Ethical approval was obtained from the local research ethics committee. All 
patients gave written informed consent and were recruited from the ICD clinic 
at St Bartholomew’s Hospital. Investigators were blinded to clinical history and 
all telomere analysis was carried out blinded to clinical data. 
3.2.1 Subjects 
A total of 350 patients attending the ICD clinic at St Bartholomew’s hospital 
were screened over one year (February 2011 – February 2012). Of these 140 
met the inclusion criteria and 90 agreed to participate in the study.  
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Figure 10: Number of patients recruited (Boxes show number of patients 
included) 
 
Inclusion and exclusion criteria governing recruitment are described in detail in 
chapter 2. The major reasons for exclusion were non-ischaemic 
cardiomyopathy, secondary prevention ICDs and gout. 
 Of the 90 patients enrolled in the study, the cases comprised 35 patients 
who had primary prevention ICDs on a background of ischaemic 
cardiomyopathy and had received appropriate therapy from the ICD for 
potentially-fatal VA. The control cohort comprised of 55 patients with ischaemic 
cardiomyopathy who had primary prevention ICDs and had never received any 
therapy from their device. Diagnosis was verified by inspection of hospital 
records. 
Mean telomere length and telomerase activity were measured on all of 
the cases and controls recruited. A randomly selected subset of male patients 
form the above cohort were recruited for the analysis of critically short 
350 assessed for eligibility 210 did not meet inclusion 
criteria. 50 declined. 
90 patients enrolled  
90 patients 
Baseline assessment and 
investigations performed 
Telomere length and 
Telomerase; n=90 
Load-of-short telomeres; 
n=30 
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telomeres. A total of 30 patients were included, 15 in the cases and 15 in the 
control arm. 
3.2.2 Measurements 
Clinical 
A standard questionnaire was filled in for all enrolled patients. Clinical details 
were obtained at recruitment by interviewing the patient and by examining their 
hospital records. The questionnaire recorded their medical history (to identify 
hypertension, diabetes, chronic renal failure, hypercholesterolemia, smoking 
status, family history of ischaemic heart disease and any other significant 
medical conditions), drug history, NYHA class, details of ICD implant, 
programming and previous arrhythmia history. 
 At recruitment, the patients also underwent a trans-thoracic 
echocardiogram to assess left ventricular function (LVEF measured by 
modified simpsons method) and detailed ICD interrogation to identify therapies 
delivered. A peripheral venous blood sample for general labs (including renal 
function, inflammatory markers - WCC and CRP, lipid profile), brain natriuretic 
peptide (BNP) and telomere biology in duplicate. 
 Phenotypic assessment is detailed in Chapter 2, section 2.3 
Telomere biology analysis 
Leukocytes were extracted and buffy coat aliquots prepared from whole blood 
within 30 min of venepuncture and genomic DNA extracted from them as 
described in chapter 2. Quantitative real time PCR analysis was used for 
analyses of mean telomere length, universal single telomere length analysis for 
quantifying critically short telomeres and telomere repeat amplification protocol 
assay for analysis of telomerase activity as detailed in the methods section in 
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chapter 2. All samples were analysed in duplicate and blinded to the clinical 
data. 
3.2.3 Study End Points 
The primary end point of the study was the difference in telomere dynamics 
(mean telomere length, telomerase activity, load-of-short telomeres) between 
patients subsequently experiencing appropriate ICD therapies for potentially 
fatal VA compared to those without any appropriate ICD therapies. ICD 
therapies were used as a surrogate for SCD and promoted differentiation 
between cases and controls. Potentially fatal VA was defined as sustained 
ventricular tachycardia at a rate > 170 bpm (and lasting at least 30 seconds) or 
ventricular fibrillation requiring device therapy. This was based on the 
programming criteria for primary prevention implants at our institution as 
explained in section 2.3. 
 Secondary end points included correlation between telomere dynamics 
and LVEF, eGFR and serum BNP. 
3.2.4 Statistical Analyses 
Sample size was determined by designing the study to have 90% power to 
detect a significant difference in telomere dynamics between the potentially 
fatal and no potentially fatal VA groups at a type 1 error of 5%. A significant 
difference in the primary outcome measure was defined as 300bp mean 
telomere length difference between the cases and controls. This was based on 
published literature and a strong correlation observed between telomere length 
assessment by TRF analyses and qPCR in previous experiments performed by 
our group. For telomerase activity, the sample size was based on pilot data 
derived from initial analyses on 20 patients. Telomerase studies, to date, have 
used an average sample size of 20 patients. Not enough evidence was 
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available from published cardiovascular literature to substantiate power 
calculations for this study. Hence, the average sample size (n = 20) used in 
published telomerase studies was used to obtain initial data, the results of 
which formed the basis of power calculations for the telomerase cohort. It was 
necessary to transform the telomerase activity to Log (Telomere + 0.0001). The 
calculations assume a difference of 0.8 in the two means with a pooled 
standard deviation of 1.3658. 15 patients in the cases cohort and 15 in the 
controls were required for the load-of-short telomeres based on the expected 
difference between groups of 0.2 with a standard deviation of 0.2. 
Continuous variables are reported as mean ± standard deviation, or 
median (range) if not normally distributed. Characteristics of cases and controls 
were compared using chi-squared test for categorical variables and unpaired t-
test for continuous variables if normally distributed or Mann-Whitney U test if 
not normally distributed. The effects of age, gender, WCC, genotype and other 
individual cardiovascular risk factors on mean telomere length, telomerase 
activity and load-of-short telomeres were assessed using regression models. 
The above telomere dynamics, as a risk factor for appropriate ICD therapy for 
potential fatal VA (surrogate for SCD), were assessed using logistic regression. 
All analyses was carried out using SAS VERSION 9.3 stats software. 
 
3.3 Results 
3.3.1 Demographics 
The baseline demographic characteristics of cases and controls are shown in 
Table 7. 
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Mean	  Telomere	  Length	  &	  
Telomerase	  	   Cases	  	  	  	   Controls	   p-­‐value	  
Number	  of	  patients	   35	   55	   	  
Age(yrs),	  mean±SD	   69.3±7.6	  	   71.6±8.8	   0.19	  
White	  cell	  count	  (109/L),	  mean±SD	   7.7±1.7	  	   	  7.46±1.7	  	   0.43	  
Male	  gender,n(%)	   32(91.4)	  	   48(87.3)	   0.78	  
Diabetes,n(%)	   7	  (20)	   18	  (32.7)	   0.28	  
Hypertension,n(%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   14	  (40)	  	   25	  (45.4)	   0.77	  
Time	  from	  MI	  to	  ICD	  implant,	  
months;mean±SE	  	  	  	  	  	  	   106.8±14.5	   89.5±12.0	   0.36	  
Time	  from	  MI	  to	  recruitment,	  
months;mean±SE	  	  	  	  	  	  	  	   138.51±12.98	   99.27±22.41	   0.19	  
Time	  from	  ICD	  implant	  to	  
recruitment,	  months;mean±SE	  	  	  	  	  	  	  	   46.5±4.55	   38.1±4.11	   0.18	  
LVEF,%;mean±SD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   26.73±7.2	   27.24±7.6	   0.75	  
eGFR,	  mean±SD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   63.94±21.8	   60.59±20.22	   0.49	  
NYHA	  GradeIII,	  n(%)	   33	  (94.28)	   50	  (90.91)	   0.62	  
Load-­‐of-­‐short	  telomeres	  	   	   	   	  
Number	  of	  patients	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   15	   15	   	  
Age,	  mean±SD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   72.2±7.4	   71.2±9.6	   0.76	  
White	  cell	  count	  (109/L),	  mean±SD	   8.03±1.4	   7.75±1.6	   0.64	  
Male	  gender,n(%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   15	  (100)	   15	  (100)	   1	  
Diabetes,n(%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   3	  (20)	   3	  (20)	   1	  
Hypertension,n(%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   3	  (20)	   	  4	  (26.6)	   0.67	  
Time	  from	  MI	  to	  ICD	  implant,	  
months;mean±SD	  	  	  	  	  	  	  	   130.87±22.28	   133.64±21.78	   0.93	  
Time	  from	  MI	  to	  recruitment,	  
months;mean±SD	  	  	  	  	  	  	  	   168.9±17.54	   141±20.67	   0.31	  
Time	  from	  ICD	  implant	  to	  
recruitment,	  months;mean±SE	  	  	  	  	  	  	  	   	  48.3±7.64	   	  38.3±8.03	   0.4	  
LVEF,%;mean±	  SD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   25.3±6.4	   26.9±7.9	   0.55	  
eGFR,	  mean±SD	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   56.7±17.9	   54.1±17.3	   0.69	  
NYHA	  GradeIII,	  n(%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   12	  (80)	   13(86.6)	   0.81	  
 
 
Table 7: Baseline demographics of cases and controls included in the study 
 
[Results shown as mean±standard deviation or number of patients and % of 
total group. LVEF: Left Ventricular Ejection Fraction, eGFR: Glomerular 
Filteration Rate, NYHA: New York Heart Association classification] 
 
All recruited subjects were Caucasians. The cases and controls were well 
matched for age and gender. The mean age at recruitment was 69.3 ± 7.6 
years for cases and 71.6 ± 8.8 years for controls. There was no significant 
difference in cardiovascular risk factors between the two groups. The vast 
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majority of patients had NYHA grade III amongst cases and controls and the 
LVEF was less than 35% across the entire cohort in keeping with the inclusion 
criteria. The mean WCC in cases was 7.7±1.7 and controls 7.46±1.7, indicating 
no significant difference in their inflammatory status. At recruitment, the time 
since ICD implant and time from MI to ICD implant was similar in cases and 
controls (46.5±4.55, 38.1±4.11, p = 0.18 and 106.8±14.5, 89.5±12.0, p = 0.36 
months in cases and controls respectively). 
 The subset of patients for the analysis of critically short telomeres 
exhibited a similar demographic profile. All subjects were men and cases and 
controls were well matched for age. There were no significant differences in 
cardiovascular risk factors, renal function, WCC, LVEF, NYHA class and time 
since ICD implant between cases and controls as shown in table 7. 
3.3.2 Correlation of Clinical Parameters with ICD Therapy  
A univariate analysis was performed to assess the correlation of clinical 
parameters with ICD therapy. There was no significant correlation between ICD 
therapy and gender (OR 0.63, CI 0.151 – 2.618, p-value 0.524), diabetes (OR 
0.50, CI 0.184 – 1.380, p-value 0.18), hypertension (OR 0.93, CI 0.39 – 2.232, 
p-value 0.87), WCC (OR 1.11, CI 0.865 – 1.425, p-value 0.41), LDL (OR 1.822, 
CI 0.913 – 3.634, p-value 0.09), eGFR (OR 1.01, CI 0.989 – 1.033, p-value 
0.34) and LVEF (OR 1, CI 0.945 – 1.059, p-value 0.98). Although correlation 
with gender was computed, this was probably skewed by the fact that the 
number of females in both groups was very small. The absence of a significant 
correlation with LVEF can be explained by the narrow range of LVEF in our 
patient cohort based on inclusion criteria. The only significant correlation seen 
was with age of the patient (OR 0.93, CI 0.184 – 0.986, p-value 0.01). The 
correlation analysis of ICD therapy with clinical parameters is shown in Table 8. 
	  	  
116	  
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Gender 
 
 
0.63 
 
0.151 – 2.618 
 
0.524 
 
Age 
 
0.93 
 
 
0.887 – 0.986 
 
0.01 
 
Diabetes 
 
 
0.50 
 
0.184 – 1.380 
 
0.18 
 
Hypertension 
 
 
0.93 
 
0.39 – 2.232 
 
0.87 
 
WCC 
 
 
1.11 
 
0.865 – 1.425 
 
0.41 
 
LDL 
 
 
1.822 
 
0.913 – 3.634 
 
0.09 
 
BNP 
 
 
0.99 
 
0.985 – 1.012 
 
0.82 
 
eGFR 
 
 
1.01 
 
0.989 – 1.033 
 
0.34 
 
LVEF 
 
 
1.00 
 
0.945 – 1.059 
 
0.98 
 
Table 8: Univariate correlation analysis of ICD therapy with clinical parameters  
 
[WCC: White Cell Count, LDL: Low Density Lipoprotein, BNP: Brain Natriuretic 
Peptide, GFR: Glomerular Filteration Rate, LVEF: Left Ventricular Ejection 
Fraction] 
 
 
3.3.3 Mean Telomere Length 
The mean white cell telomere length as a function of age is shown in Figure 11 
for both cases and controls. As expected, the mean telomere length ratio 
decreased steadily with age at a mean yearly rate of 0.0063 ± 0.0032, with  
evidence of inter-individual variation in telomere length at any given 
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chronological age- Figure11. This rate of decline in telomere length with age 
was similar to that noted in other studies. [98,158] 
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            Figure 11: Correlation of mean telomere length with age 
This correlation between mean telomere length and age nearly reached 
significance  (p=0.06). The very narrow interquartile age range (62 – 75 yrs) in 
our cohort may account for the weak correlation (despite having a similar rate 
of decline) observed when compared to other telomere studies. 
 A univariate analysis did not show any significant correlation between 
mean telomere length and ICD therapy as shown in the table 9 (OR 1.48, CI 
0.253 – 8.762, p-value 0.66). 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Mean telomere length 
 
1.488 
 
 
0.253 – 8.762 
 
0.66 
 
Table 9: Univariate correlation analysis of ICD therapy and mean telomere 
length 
            
           
n=90,  
Slope = 0.0063 ± 0.0032,  
p=0.06  
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 This correlation was further weakened when telomere length was 
adjusted for age, WCC and gender in a multivariate analysis as shown in table 
10. 
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Mean telomere length 
 
 
0.858 
 
0.108 – 6.833 
 
0.88 
 
Age 
 
 
0.95 
 
0.896 – 1.007 
 
0.06 
 
Gender 
 
 
0.496 
 
0.048 – 5.107 
 
0.55 
 
WCC 
 
1.056 
 
 
0.804 – 1.386 
 
0.69 
 
Table 10: Multivariate correlation analysis of ICD therapy and mean telomere 
length  
 
There was no significant difference in the mean telomere length between cases 
(fatal VA) and controls (no-fatal VA), p=0.66, as shown in figure 12 below.  
Also, age, gender and WCC adjusted mean telomere length did not have a 
significant correlation with incidence of ICD therapy (OR 0.858, CI 0.108 – 
6.833, p-value 0.88). 
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Figure 12: Mean telomere length (with 95% confidence interval) in cases and 
controls 
 
3.3.4 Telomerase Activity 
The leukocyte telomerase activity (n = 90) as a function of age is shown in the 
figure 13 for both cases and controls. 
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    Figure 13: Correlation of telomerase activity with age 
 
n=90, 
Slope = 0.003 ± 0.006 
p=0.03 
 
 
p=0.03  
SD=0.28 
Cases: Mean ± SD = 1.159 ± 0.2 
Controls: Mean ± SD = 1.134 ± 0.29 
p=0.66 	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Leukocyte telomerase activity was seen to decrease significantly with 
increasing chronological age (n = 90, p = 0.03) – Figure 13. This has not been 
consistently reported in the small number of clinical telomerase studies 
conducted so far. 
 A univariate analysis showed a highly significant correlation between 
telomerase activity and ICD therapy as shown in table 11 (OR 4.8, CI 1.46 – 
15.78, p-value 0.009). 
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Telomerase activity 
 
4.8 
 
 
1.46 – 15.78 
 
0.009 
 
Table 11: Univariate correlation analysis of ICD therapy and telomerase activity 
 
This correlation still remained significant when telomerase activity was 
adjusted for age, gender and WCC as shown in table 12.   
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Telomerase activity 
 
 
5.302 
 
1.293 – 21.742 
 
0.02 
 
Age 
 
 
0.938 
 
0.885 – 0.993 
 
0.03 
 
Gender 
 
 
0.845 
 
0.138 – 5.158 
 
0.85 
 
WCC 
 
0.996 
 
 
0.751 – 1.322 
 
0.98 
 
Table 12: Multivariate correlation analysis of ICD therapy and telomerase 
activity  
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There was a significant difference in the telomerase activity between cases 
(fatal VA) and controls (no fatal VA) with the telomerase activity being much 
higher in cases (0.50 versus 0.18, p = 0.009) as shown in the figure 14 below. 
Also, the age, gender and WCC adjusted telomerase activity had a significant 
correlation with incidence of ICD therapy (OR 5.302, CI 1.293 – 21.742, p-
value 0.02). 
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Figure 14: Telomerase activity (with 95% confidence interval) in cases and 
controls 
 
 
3.3.5 Critically Short Telomeres 
The load-of-short telomeres was calculated based on the number of bands 
below 1500 bp. The threshold of 1500 bp was chosen as the cut-off for critically 
short telomeres largely based on previously published literature [152,179] and also 
similar findings replicated in this study. The exact threshold at which telomeres 
become critically short is difficult to ascertain and may perhaps even vary 
between cell types. In all studies carried out with U-STELA to date, almost 
identical results were obtained with thresholds set at 1000bp, 1500 bp and 
Cases: Mean ± SD = 0.50 ± 0.69 
Controls: Mean ± SD = 0.18 ± 0.26 
p = 0.009 	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2000 bp. However, bands below 1000 bp were infrequent and hence a single 
potential questionable band could impact the results. At 2000 bp, a consistent 
increase in the clustering of bands was seen which might be a consequence of 
gradual replicative shortening. Bands below 1500 bp were hence thought to 
best represent telomeres derived from stochastic shortening and have been 
used as a threshold in published studies to date. This, however, is based on a 
limited number of published studies and a larger evidence base is awaited. 
 The U-STELA gels from which the load-of-short telomeres were derived 
are shown in Appendix A, alongwith the resultant bands quantified using Vision 
Works LS Acquisition and Analysis software. An example of the U-STELA gel 
with markers is shown in Figure 15 and the resultant quantified bands in Table 
13. 
	  	  
123	  
 
Figure 15: U-STELA gel with markers  
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Band 
Gel1_1 
A(M) B C D E F G H I J(M) 
1 21226 2335.619 2640.817 2540.360 2573.414 2475.521 2763.049 2246.772 2606.898 21226 
2 8576 2039.161 2217.914 2232.297 2133.545 2133.545 2556.834 1760.335 2396.794 8576 
3 7427 1936.900 1540.748 1961.898 1694.401 1694.401 2350.765 1559.893 2000 7427 
4 6106 1630.937  1760.335 695.723 1164 1875.976 1341.609 1540.748 6106 
5 5000 1451.207  1477.508   957.914  849.003 5000 
6 4268 1138.895  1416.865      4268 
7 3630 1059.057  1122.459      3630 
8 2799 849.002  387.603      2799 
9 2000 654.593        2000 
10 1900 280.425        1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
Table 13:  Telomere bands quantified from U-STELA gel 
 
The number of bands below 1500 bp were counted and calibrated based on 
the initial PCR template concentration. These were then presented as the 
number of telomeres below 1500 bp per genome equivalent of template DNA 
used and comparison made between cases and controls. All analysed gels with 
quantified telomere bands are shown in Appendix A. 
The load-of-short telomeres as a function of age are shown in the figure below 
(Figure16) for both cases and controls. There was no correlation between the 
load-of-short telomeres and age (p = 0.57). 
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     Figure 16: Correlation of load-of-short telomeres with age 
 
A univariate analysis showed a significant correlation between load-of-short 
telomeres and ICD therapy in ischaemic cardiomyopathy patients (OR 3.478, 
CI 1.202 – 10.064, p-value 0.02) – table 14.  
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Load-of-short telomeres 
 
3.478 
 
 
1.202 – 10.064 
 
0.02 
 
Table 14: Univariate correlation analysis of ICD therapy and load-of-short 
telomeres 
 
This correlation remained significant despite adjustment for other parameters 
including age and WCC in multivariate analysis as shown in table 15 below. 
 
 
 
 
 
n= 30,  
Slope = 0.00064 ± 0.0034,  
p =  0.57 
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Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Load-of-short telomeres 
 
4.560 
 
 
1.185 – 17.541 
 
0.02 
 
Age 
 
 
0.963 
 
0.846 – 1.097 
 
0.57 
 
WCC 
 
 
0.986 
 
0.458 – 2.123 
 
0.97 
 
Table 15: Multivariate correlation analysis of ICD therapy and load-of-short 
telomeres  
 
 
 
There was a significant difference in the load-of-short telomeres between cases 
(fatal VA) and controls (no fatal VA) with the load-of-short telomeres being 
much higher in cases (n = 30, p = 0.02) as shown in the figure below. Also, the 
age and WCC adjusted load-of-short telomeres had a significant correlation 
with incidence of ICD therapy (OR 4.560, CI 1.185 – 17.541, p-value 0.02) – 
Figure 17.         
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Figure 17: Load of short telomeres (with 95% confidence interval) in cases and 
controls 
Cases: Mean ± SD = 0.393 ± 0.15 
Controls: Mean ± SD = 0.241 ± 0.09 
p= 0.02 	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We also looked at mean telomere lengths (in cases and controls) in this subset 
of 30 patients who had critically short telomeres analysed. In keeping with the 
earlier analyses of mean telomere length (n = 90), there was no significant 
difference between cases and controls – Figure 18. 
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Figure 18: Mean telomere length (with 95% confidence intervals) in cases and 
controls in the cohort analysed for load analyses (n = 30) 
 
 
3.3.6 Correlation of Telomere Dynamics with Time to Therapy from 
ICD implant 
A multivariate analysis was performed to assess the correlation between age 
and gender adjusted mean telomere length and telomerase activity with time to 
ICD therapy from the date of ICD implant. This is shown in table 16. 
 
 
 
Cases: Mean ± SD = 1.065 ± 0.13 
Controls: Mean ± SD = 1.098 ± 0.12 
p= 0.48 	  
	  	  
128	  
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Telomerase activity 
 
 
1.372 
 
0.762 – 2.471 
 
0.292 
 
Mean telomere length 
 
1.430 
 
 
0.100 – 20.441 
 
0.79 
 
Age 
 
 
0.954 
 
0.890 – 1.023 
 
0.19 
 
Gender 
 
 
0.626 
 
0.075 – 5.215 
 
0.66 
 
Table 16: Multivariate correlation analysis of telomere dynamics with time to 
therapy from ICD implant 
 
There was no significant correlation between time to ICD therapy with mean 
telomere length (OR 1.43, CI 0.10 – 20.44, p-value 0.79) and telomerase 
activity (OR 1.372, CI 0.762 – 2.471, p-value 0.292) from the time since ICD 
implant. 
 
3.3.7 Sensitivity and specificity of telomere dynamics in predicting 
VA 
ROC analysis was performed to determine the sensitivity and specificity of 
telomere dynamics to determine the incidence of VA in this patient cohort. The 
area under the curves (AUC) data indicated that the load of short telomeres 
and telomerase activity were better at determining the incidence of cardiac 
arrhythmia in ischaemic cardiomyopathy patients than LVEF (AUC 0.82, 0.66 
and 0.47 for load, telomerase and LVEF respectively) – Figure19.  
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   Figure 19: ROC analysis of telomere dynamics and LVEF with ICD therapy 
 
3.3.8 Correlation of Telomere Dynamics with LVEF, eGFR and BNP 
Investigating the secondary end points of the study, it was noted that there was 
no significant correlation between telomerase activity and eGFR (p value 0.11), 
BNP (p value 0.29) and LVEF (p value 0.55). Also, the load of short telomeres 
did not correlate significantly with eGFR (p value 0.76), BNP (p value 0.18) and 
LVEF (p value 0.42).  
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Similarly, there was no significant correlation between mean telomere 
length and eGFR (p value 0.64) and BNP (p value 0.45). However, a significant 
correlation was noted between the mean telomere length and LVEF (p-value 
0.04) in this group of ischaemic cardiomyopathy patients. This was despite the 
very narrow range of LVEF 10% - 35% present in the study cohort. The 
correlation plot between mean telomere length and LVEF for both cases and 
controls is shown in figure 20 below. 
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Figure 20: Correlation of telomere length and LVEF in cases and controls 
 
 
 
 
 
 
 
n=, 90 
Slope = 0.008 ± 0.004,  
p= 0.04 
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3.4. Discussion 
3.4.1 Overview of study results 
The principal finding of this study is that the load of critically short telomeres is 
greater and telomerase activity higher in white blood cells obtained from 
peripheral blood of patients with ischaemic cardiomyopathy who have received 
ICD therapy for potentially fatal cardiac arrhythmia compared to patients with 
no VAs. A similar observation was not found in the mean telomere length 
measurement.  
 The entire cohort comprised of individuals with severely impaired left 
ventricular function post MI and had an ICD fitted for prevention of sudden 
death from cardiac arrhythmia. All recruited patients were Caucasians as ethnic 
variation can confound telomere biology results. [97,101] Both cases and controls 
had a similar burden of CAD, cardiovascular risk factors, time since ICD 
implant, inflammatory status and were of a similar age group and hence 
negating the effect of potential confounding factors on telomere biology 
assessment. 
 Despite LVEF being the defining criteria for ICD implants post MI, we did 
not find a significant association between LVEF and ICD therapy. This is 
understandable in this patient cohort due to a very narrow range of LVEF 
present and also due to the exclusion of any patients with normal left 
ventricular function. Of the various clinical parameters studied it was only the 
age of the patient that had a significant association with ICD therapy. This was 
adjusted for in all further analysis.  
 The leukocyte telomerase activity increased as a function of increasing 
chronological age. This correlation was significant despite a narrow age range 
present in this study cohort. This could reflect a protective response to the 
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decreasing telomere length with increasing age. Moreover, the telomerase 
activity was higher in the cases when compared to controls and exhibited a 
significant correlation with ICD therapy, even after adjustment for age, WCC 
and gender.  This finding becomes more important prognostically, as there was 
no significant association between telomerase activity and time to ICD therapy 
(from implant) or the number of therapies received. This implies that 
telomerase activity may have a causal role in determining ICD therapy in 
ischaemic cardiomyopathy patients. 
 Likewise, the load of critically short telomeres was greater in the cases 
when compared to the controls and correlated significantly with ICD therapy in 
a multivariate regression analysis. Importantly this correlation became more 
significant with decreasing telomere threshold from 2000bp to 1000bp and 
hence strengthening the validity of the observed association.  
 As seen in previous studies, we found that mean telomere length 
decreased with increasing chronological age. However, this correlation was not 
as significant as that seen in some other studies, [96,97,158] which is largely down 
to the very narrow interquartile age range (62 - 75 yrs) and absence of 
significant numbers of younger age group in our patient population. Moreover, 
in a heterogenous human population, demonstration of a significant age-
dependent attrition in mean telomere length is only possible when the age 
distribution is sufficiently wide. This is due to the wide scatter of mean telomere 
length among individuals of the same age and also the slow age dependent 
attrition of telomere length. Contrary to the other telomere markers studied, the 
mean telomere length did not vary much between cases and controls and did 
not have any significant correlation with ICD therapy. This suggests that the 
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incidence of cardiac arrhythmia necessitating ICD therapy was closely 
associated with the shortest telomere rather than the mean telomere length. 
There was no significant association between the telomere biology 
markers studied and several other demographic characteristics, cardiovascular 
risk factors and markers of inflammation in this study. These factors did not 
confound or explain the association (or lack of) seen between telomere biology 
markers and ICD therapy. There was no independent effect of gender on 
telomere biology markers. This is contrary to what has been found in other 
studies that have shown females to have shorter telomeres than men.[163,180,181] 
The lack of association with gender might be due to the small number of 
females present in the study. The absence of association between telomere 
biology and inflammatory markers studied, does not exclude the possibility that 
the chronic inflammation and oxidative stress is an important factor contributing 
to the observed difference in telomere biology markers between cases and 
controls. Even if these markers provided a reliable assessment of inflammation, 
it is unlikely that a single point measurement of these variables would 
accurately reflect the cumulative burden of inflammation and oxidative stress 
that is likely to have an impact on telomere biology. Another possibility is that 
these markers may be more relevant in the pre-clinical phase of the disease as 
inflammation and oxidative stress promote atherogenesis. However, once CAD 
is established other factors (genetic and environmental) may have a greater 
role in determining biological ageing and hence telomere attrition. [182] 
ROC analysis indicated that telomere markers (load of short telomeres 
and telomerase activity) were better at determining the incidence of VA than 
LVEF alone in ischaemic cardiomyopathy patients. However, it has to be 
considered that all patients had a LVEF ≤ 35% and these results may vary if a 
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wider range (including normal) of LVEF is used. This was not possible within 
the realms of this study. 
Amongst the secondary end points studied, there was a significant 
correlation between mean telomere length and LVEF. The mean telomere 
length decreased with a worsening left ventricular function. This was despite 
the narrow range of LVEF (10 – 35%) present in this patient cohort. This 
significant association between a biological marker of ageing and a clinically 
relevant marker of cardiac function, indicates that the cumulative biological 
stress effects myocardial function in patients with CAD. Whether this 
association is independent of the presence of CAD, is difficult to establish, 
given the current design of the study. 
3.4.2 Possible reasons for the observed differences in telomere 
dynamics between cases and controls and the mechanisms 
involved 
In this study the load of short telomeres was greater and telomerase activity 
higher in cases than controls whereas the mean telomere length was similar 
across the two groups. This difference (or lack of) in the telomere biology 
markers between cases and controls could be due to a number of different 
reasons.  
The observed difference could be an artefact. 
It is highly unlikely that the observed difference is an artefact as the strength of 
correlation between telomere biology markers and ICD therapy is very strong. 
Univariate correlation analysis of ICD therapy with telomerase activity was 
significant at a p-value of 0.009, and with load of short telomeres at a p-value 
of 0.02. This correlation remained significant in multivariate regression analysis 
both for telomerase activity (p-value 0.02) and load of short telomeres (p value 
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0.02). Moreover, for the load of short telomeres, it became more significant as 
lower thresholds of telomere length were used (at 1500 bp, p-value 0.02; at 
1000 bp, p-value 0.001). 
 Also, it is worthwhile to note that the observed difference was not 
present in all markers of telomere biology. The mean telomere length was not 
significantly different between cases and controls.  
All recruited patients inherited a similar profile of telomere biology markers. 
Different rates of attrition due to environmental factors resulted in the observed 
difference. 
If we are to assume that all subjects were born with the same telomere length 
and the same level of telomerase activity, then the observed difference would 
be a result of different rates of telomere attrition in cases and controls 
secondary to acquired external factors. In this study cohort, all patients had a 
prior MI and we hypothesised that telomere attrition at the time of MI results in 
poor myocardial repair process and predisposes patients to greater arrhythmic 
tendency. Hence, leukocyte telomere biology markers will be different in 
ischaemic cardiomyopathy patients with and without potentially fatal VA and 
these would correlate with the incidence of VA (ICD therapy). 
 Atherosclerosis and CAD were present in both cases and controls, 
whereby they were exposed to both inflammatory burden and oxidative stress, 
which form an integral part of this disease process. Both inflammation and 
oxidative stress (reactive oxygen species) are central to the pathobiology of 
age related cardiovascular disorders and biological ageing. Inflammation is 
associated with increased cell proliferation, accelerating the attrition rate due to 
end replication problem (mean telomere length). Oxidative stress results in the 
formation of single strand breaks, preferentially at the telomeres, resulting in 
	  	  
136	  
stochastic telomeric shortening (load of short telomeres) and causing an 
accelerated telomeric shortening at the next cell division (mean telomere 
length).  
 Inflammation has a central role in all stages of the atherosclerotic 
process from initiation and evolution of atheroma to decisively contributing to 
the precipitation of acute thrombotic complications of atheroma including MI. 
[183] This may have a direct effect on telomere attrition due to increased cell 
turnover secondary to inflammation and hence contributing to the replicative 
senescence of telomeres. Moreover, cellular senescence has been shown to 
be a major feature of atherosclerotic plaques, [184,185] and the finding that 
interference with telomere function in coronary endothelial cells in vitro causes 
expression of molecules implicated in atherogenesis, [186] suggests that shorter 
telomeres could contribute directly to the pathophysiology of atherosclerosis. 
 Oxidative stress, wherein production of free radicals – reactive oxygen 
species (ROS) – exceeds the cellular antioxidant capacity, has also been 
shown to play a major role in atherosclerosis and cellular senescence. This is 
by virtue of its role in regulating cellular proliferation, differentiation and cellular 
death [187,188] and also its role in activation of the apoptosis and the resultant 
impact on the ageing process. [189] This is exemplified in the widely accepted 
“free radical theory of ageing” proposed by Harman. [190] There is an 
exponential increase in oxidative damage and reduction in antioxidant 
defenses with increasing chronological age and hence the resultant cellular 
senescence and premature biological ageing secondary to increased oxidative 
stress. [190,191] A major factor mediating this process is thought to be stochastic 
shortening of telomeres and compromised telomeric integrity. [130,192] 
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 Testing the hypothesis in this study, no striking association was seen 
between the mean telomere length and cardiac arrhythmia occurrence in 
ischaemic cardiomyopathy patients. This represents an important contrast to 
the studies that have shown a relationship between shorter mean telomere 
length and cardiovascular disease. [95-98,193] However, the present study 
compares cases and controls with established CAD and left ventricular 
impairment, in contrast to the widely distinct phenotypes evaluated in 
previously published studies. Hence, it might not be possible to detect a subtle 
difference in mean telomere length between cases and controls due the 
inability of a single time point measurement to reflect a gradual linear decline in 
mean telomere length in two closely related groups. However, this “small” 
difference in telomere attrition was clearly reflected in the load of short 
telomeres as the number of telomeres below 1500bp was significantly lower in 
cases compared to controls. 
 Traditionally, the vast majority of studies evaluating telomere biology in 
cardiovascular disease have looked at mean telomere length in leukocytes. 
This represents impact of replicative senescence on telomere attrition and was 
described by Olovnikov as the “end replication problem”. [194] The enzyme 
telomerase is capable of extending telomeres but is generally suppressed in 
somatic cells. In many cells senescence and cell death occurs when mean 
telomere length reaches a critical value. Thus, mean telomere length provides 
a marker for biological age, with shorter telomeres indicating an increased 
biological age. However, this mechanism of telomere attrition and biological 
ageing was not well depicted in our study population, as mean telomere length 
did not have a significant association with cardiac arrhythmia. Other 
mechanisms of telomere attrition may be more relevant here, as reflected in the 
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load of short telomeres, and the widely studied replicative senescence in 
cardiovascular ageing might not be enough to explain the disease process. 
 The causal link between the gradual decrease in mean telomere length 
and cellular senescence has been questioned by a number of observations.[152] 
Firstly, senescence induction has been shown to be bimodal with an increasing 
proportion of cells entering senescence at late passages, [195] while mean 
telomere length seems to shorten in an almost linear fashion. [196-199] Secondly, 
in tissue cultures senescence was found to be induced with mean telomere 
length much longer than what would be expected to trigger the senescence 
mechanisms. As a result of these findings, it has been suggested that telomere 
associated senescence may not depend solely on a global decrease in mean 
telomere length and instead be triggered by a single, or a group of few, 
critically short telomeres within the cell. [200-202] 
 The formation of these critically short telomeres cannot be fully 
explained by replication-driven telomere shortening alone. These are likely to 
have been formed by a sudden loss of a large telomere fraction from a 
particular telomere. The proposed mechanisms for this stochastic shortening 
include oxidative damage inflicting single strand breaks in telomeres, [203-205] 
replication slippage and unequal sister chromatid exchange [206,207] and 
recombination causing circularization and thus deletion of distal repeats. [208-211] 
Vast majority of evidence so far suggests that oxidative stress is the most 
clinically relevant parameter leading to formation of critically short telomeres. 
Various observations have shown free oxygen radicals to be a major cause of 
telomere shortening in human fibroblasts in vitro: (1) telomeres in non-
proliferating cells accumulate single strand breaks because of a specific 
deficiency in base excision repair [212,213] (2) these breaks result in telomere 
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shortening during DNA replication, probably by transiently stalling the 
replication fork [196,198] (3) oxidative stress increases the telomere shortening 
rate by up to one order of magnitude [205,212,214] (4) diminution of oxidative stress 
slows down the rate of telomere shortening and decelerates replicative 
senescence [215] (5) the telomere shortening rate correlates with the cell strain-
specific anti-oxidative capacity. [216] 
 Based on the above observations, it is largely believed that telomere 
attrition is a combination of gradual linear shortening due to the end replication 
problem reflecting the number of cell divisions; superimposed by a more 
stochastic mechanism causing a sudden shortening of a single telomere which 
has the potential to trigger an early senescence response as cell proliferation 
proceeds. Oxidative stress augments telomere attrition per replication and the 
inflammation increases cellular turnover, which would further increase telomere 
shortening. 
 In the present study, critically short telomeres (likely to have been 
generated due to oxidative stress during index MI) appear to be the 
predominant mechanism resulting in premature senescence and arrhythmia 
prediction. This is suggested by our findings, which show that the load of short 
telomeres had a significant association with ICD therapy despite a similar mean 
telomere length across cases and controls. This postulate is further supported 
by a recent study performed by our group (Dr Bendix, Vejle hospital, Denmark), 
wherein a strong correlation was established between senescence and 
oxidative damage by treating human mesenchymal stem cells - hMSCs 
(primary and hTERT immortalized) with sub-lethal doses of hydrogen-peroxide 
which induces stochastic telomeric shortening. After exposure to acute 
oxidative stress a positive correlation was found between load of short 
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telomeres and the percentage of senescent cells (primary hMSCs, p-value = 
0.0009; hMSC-telo 1, p-value = 0.0021), whereas a correlation between mean 
telomere length and percentage of senescent cells was absent (primary 
hMSCs, p-value = 0.29; hMSC-telo 1, p-value = 0.13). By treating with sub 
lethal doses and continuing cell growth post exposure, we increased the 
likelihood that senescence observed in the following population doublings was 
telomere dependent rather than a result of immediate DNA damage. [179] 
Telomeres, by virtue of their high guanine triplet content, are more sensitive to 
oxidative damage and repair less efficiently than genomic DNA. Also, oxidative 
stress can interfere with telomere maintenance via a suppressive effect on 
telomerase. [217,218]  
 Oxidative stress induced telomere shortening occurs in a stochastic 
manner and can occur to any single telomere in a cell without effecting the 
mean telomere length considerably, but nonetheless be detrimental to the cell 
since one critically short telomere alone can trigger cell senescence. Thus 
oxidative stress can cause immediate (single and double stranded breaks) 
damage to telomeres resulting in the production of single shortened telomeres. 
These damaged, excessively shortened telomeres may still be long enough to 
protect chromosome ends and may therefore not immediately affect cell 
growth. However, with cell proliferation these telomeres at an earlier time will 
reach a critically short length, causing premature senescence. Thus, these 
provide a very early and sensitive marker of oxidative stress induced DNA 
damage, which is distinct from the gradual decrease in mean telomere length. 
These critically short telomeres within the cell population were measured by 
using our novel method U-STELA and were significantly different between 
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cases and controls indicating the likelihood of a higher level of oxidative stress 
in subjects who developed cardiac arrhythmia post MI. 
 Another major finding of this study was the significant increase in 
telomerase activity in cases when compared to controls and a significant 
association between telomerase activity and incidence of cardiac arrhythmia. 
This could represent a protective response to counteract the greater load of 
short telomeres in the cases, wherein telomerase binds to the shortest 
telomeres to provide stability. There was no significant association between 
telomerase activity and the number ICD therapies, excluding the possibility of 
telomerase increase as a direct consequence of the ICD therapy. 
 Alternatively, compromised telomeric integrity may play an important 
role in the context of cardiac arrhythmia in cases and hence the increased 
telomerase may reflect a telomere independent role as a transcription factor 
driving expression of key mitochondrial genes and thus protecting the 
mitochondrial genome from oxidative stress. [217] 
 
All recruited patients did not have a similar profile of telomere biology at birth. 
The observed difference is due to the effect of genetics and heredity. 
Another intriguing possibility is that cases and controls inherited telomeres (and 
telomerase activity) of different lengths. And hence, the observed difference in 
telomere biology markers is a result of hereditary differences supplemented by 
additional attrition secondary to environmental factors. This would also suggest 
that shorter telomeres are causally related to cardiac arrhythmia in CAD, rather 
then just being a marker of the disease process. 
 Genetic determination of telomere length has been suggested in 
twin and family studies with estimated heritability of approximately 78%. [181,219] 
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Slagboom et al examined the correlation between monozygotic and dizygotic 
twins and found a higher correlation in monozygotic twins (0.78) than dizygotic 
twins (0.39). Given that monozygotic twins are identical, they are intuitively 
expected to inherit telomeres of the same length regardless of the precise 
mode of inheritance. Any measured differences in telomere length between the 
twins at a later date likely reflect differing rates of attrition throughout life. [219] 
 If there is a primary genetic basis/association determining 
telomere length, then individuals born with shorter telomeres would be at a 
greater risk of premature biological ageing, more prone to stochastic and 
replicative shortening during MI and hence more likely to develop cardiac 
arrhythmias post MI. And hence telomere biology might just not be a marker of 
disease process but have a greater bearing in the functional basis and 
causality of the disease process. The genetic variation in telomere biology 
markers has been further investigated in chapter 4. 
3.4.3 Strengths of the study 
The current study is novel in characterising the telomere dynamics of patients 
at high risk of sudden death. It investigates the association between telomere 
dynamics in peripheral leukocytes and incidence of cardiac arrhythmia. 
Moreover, as opposed to studying a single telomere parameter, it 
simultaneously measures mean telomere length and telomerase activity in all 
patients (n = 90) and load of short telomeres in a subset (n=30), at the same 
time point. Not only does this provide an opportunity to potentially examine the 
clinical utility of this novel marker, but from a basic science perspective, it gives 
a holistic view of the mechanisms underlying cellular senescence and 
biological ageing and its role in cardiovascular disease. 
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 The experimental methodology used in this study examines various 
facets of telomere biology and has several advantages. Telomere length 
analysis was done using the real time qPCR in contrast to the previously 
established gold standard telomere restriction fragment (TRF) analysis by 
southern blot. This had several advantages including (1) greater speed of 
analysis needing up to 10 hrs to run multiple samples at the same time. 
Whereas, setting up and running a standard southern blot can take several 
hours to days.  (2) qPCR requires minimal amount of starting material (ng 
levels) when compared to TRF analysis (µg levels) and hence can be applied 
to cohorts where DNA may not be readily available, to study specific cell types 
and facilitates multiple experiments on the same sample amount available. (3) 
qPCR is specific to true telomeric repeats and hence variation in estimated 
length due to subtelomeric repeats is significantly less. The coefficient of 
variation of qPCR can be reduced to less than 4% when using different DNA 
standard dilutions on each plate. [220] TRF analysis tells little about any 
particular telomere, and is indicative of the mean telomere length of that 
particular sample. Different telomeres within the same cell and the same 
telomere within different cells may have different lengths and this results in the 
characteristic telomere “smear”. In addition, the smear can also include a 
variable region of subtelomeric DNA that contributes to the estimate of the 
mean telomere length. The coefficient of variation can be as high as 5% 
depending on the restriction enzymes used, which suggests the presence of 
subtelomeric length polymorphisms and/or subtelomeric restriction site 
polymorphisms that can confound the TRF length results. [176] 
 However, the qPCR itself is subject to similar criticism in that it estimates 
the mean rather than the specific telomere length. Although, the mean telomere 
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length provides useful information on cellular ageing, the study of specific 
telomere length is crucial. This is because there is a high degree of inter- and 
intracellular alongwith inter- and intra chromosomal variation in telomere length 
as indicated by the wide melt-curves obtained in PCR analysis and the smear 
seen in TRF analysis. Moreover, the hypothesis that the presence of a single 
critically short telomere induces senescence, requires a more detailed analysis 
than just mean telomere length. This was carried out in this study by using the 
Universal Single Telomere Length Analysis (Universal STELA).  This technique 
enables the measurement of the load and distribution of the shortest telomeres 
in the entire cell sample. [152,220] Hence, a combination of methods used to 
assess telomere length enabled quick and accurate analyses of effect of 
replicative senescence and stochastic shortening on telomere length and 
hence biological ageing in cardiovascular disease. 
 The study has clearly established a strong correlation between critically 
short telomeres and telomerase activity with incidence of VA in ischaemic 
cardiomyopathy patients. These results are now being used as the basis of 
prospective, multicentre trials to examine longitudinal changes in telomere 
biology and their association with cardiac arrhythmia, to confirm or refute the 
clinical worth of this novel marker in ICD prescription. To the basic scientist, 
this would provide further support to the building evidence that telomere length 
is a primary abnormality predisposing to more advanced cardiovascular 
disease. 
3.4.4 Limitations of the study 
A number of limitations of this study require consideration. This is a case 
control study, which gives a cross-sectional analysis of telomere changes at a 
single time point. Longitudinal changes could not be determined due to the 
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study design. Hence it is difficult to speculate whether telomere attrition is a 
primary abnormality predisposing to increased susceptibility to cardiac 
arrhythmia in this group of patients or if it is just an epiphenomenon. Also, by 
virtue of this being a cross-sectional study, the effects of certain longitudinal 
factors might have been deemed non-significant due to large inter-individual 
variation. 
 Also, there is a potential for introducing bias due to the study design. 
The cases included in the study are those who survived a MI and subsequently 
developed a poor left ventricular function. However, a significant proportion of 
subjects who have an MI, do not survive the primary event. Not including this 
group of patients may introduce a survival bias and it becomes challenging to 
exclude the small chance of longer telomeres conferring a poor survival 
prognosis post MI. 
 The ICD is one of the primary data collection tools in this study and also 
the defining criteria for division between cases and controls. All patients had a 
primary prevention ICD implant on the background of ischaemic 
cardiomyopathy and devices were programmed in a similar fashion at implant 
based on institutional practice. The device programming, to a large extent, 
determined the incidence of ICD therapy and hence classification of cases and 
controls in the study. Over a period of follow-up since implant, some patients 
underwent device programming changes based on their clinical need. This 
made the group more heterogenous and could have had an impact on study 
results. However, this was accepted as a potential shortcoming of the 
retrospective nature of the study design and also the need to prioritise patient 
safety in a clinical setting. 
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 The mean telomere length was computed by qPCR method. The 
coefficient of variance for qPCR has been shown to range between 6.4% to 
28% in various studies. [220] This is because qPCR is more susceptible to minor 
variances in sample conditions and DNA integrity. Small variations in sample 
quality as well as individual donor differences may be amplified by qPCR which 
could decrease the accuracy of the results. This is a well recognised limitation 
of qPCR and a smaller sample size in this study could have potentially 
amplified this problem. 
Despite its novelty and advantages, U-STELA method (used for 
analysing critically short telomeres) is a very laborious method and is not as 
high throughput as the real time PCR. This limits its utility for large-scale 
epidemiological studies. Development of a more user-friendly technology is 
warrantied. 
 Mean telomere length, critically short telomeres and telomerase activity 
have been analysed in the whole white blood cell population. A difference in 
mean telomere length between different subsets of white cells and their 
variation with gender has been shown in some studies. [221-223] The potential 
impact of not analysing white cell subsets, can be appreciated by considering 
the example of atherosclerosis, which was a common factor in both cases and 
controls in this study. Atherosclerosis is characterised by systemic oxidative 
stress and low-grade chronic inflammation, mediated by monocytes, 
macrophages and T-lymphocytes. [224-226] Recruitment of these inflammatory 
cells varies during the course of the disease. Leukocyte subsets play a crucial 
role in the age dependent development of atherosclerosis and hence telomere 
length in leukocytes provides substantial information about cardiovascular 
ageing in this group of patients. However, this information can vary if whole 
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white blood cell population is used depending on the stage of the disease 
process. Moreover, the composition of leukocytes can vary significantly 
amongst individuals and due to acute infection or comorbidity and even in the 
same individual from one day to another. Hence telomere length of monocytes, 
granulocytes or specific T-cell populations may provide more stable results. 
Better evidence is required to substantiate this. 
 All telomere analysis has been performed on leukocytes derived from 
peripheral blood samples. This has not been directly correlated with the 
primary tissue of interest i.e. cardiomyocyte. Other studies have shown a 
correlation between leukocyte telomere length and vascular tissue including 
carotid and aortic endothelium and venous grafts. [155,161] However, the number 
of these studies are limited and leukocyte telomere biology has not been 
correlated with other tissues. This correlation is largely presumed on the basis 
of the limited amount of evidence present and also keeping in mind the primary 
hypothesis that telomere length is largely inherited and hence individuals with 
shorter telomeres in peripheral blood samples should also possess shorter 
telomeres in all other cell types. 
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Chapter 4 – ASSOCIATION OF GENETIC VARIATION IN 
TELOMERE RELATED SNP WITH VENTRICULAR 
ARRHYTHMIAS 
4.1. Introduction and Aims 
It has already been demonstrated in the previous chapter that leukocyte 
telomere biology has a significant association with incidence of potentially fatal 
cardiac arrhythmia in patients with ischaemic cardiomyopathy. Telomere 
attrition has a significant association with cardiovascular ageing and disease 
process and is a result of heredity and genetic variation at birth, compounded 
by environmental factors including oxidative stress and chronic inflammation 
associated with atherosclerosis. The effect of replicative senescence and 
stochastic shortening on telomere length was investigated in the previous study 
(chapter 3).  
Telomere length has a strong genetic determination, with heritability 
estimates ranging from 44% to 80%. [119,227] The telomere hypothesis 
postulates that shorter telomeres are causally implicated in the pathogenesis of 
coronary artery disease. Consequently, shorter inherited telomeres could 
represent a primary abnormality predisposing to an increased risk of 
cardiovascular ageing. Since a substantial proportion of the marked inter-
individual variation in telomere length is genetically determined, [119,219,228] this 
should be taken into consideration when analysing inter-individual variability. 
The concept of genetics and heredity of telomere biology has emerged given 
the high inter-individual variation in telomere length across newborns [229-232] 
and in individuals of the same age group, telomere length in poorly proliferating 
cells reflecting the telomere length found during early development, [233] 
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telomere length comparisons across monozygotic and dizygotic twins and the 
association of paternal age at conception and telomere length heritability. [233]  
A number of genetic loci have been associated with telomere length. As 
telomerase (reverse transcriptase TERT and ribonucleoprotein TERC) is 
responsible for maintaining telomere length, factors that influence telomerase 
activity are clearly important when considering an association between 
telomere length and clinical phenotype. There is increasing evidence that 
genetic variation in key genes impact on telomere length and telomerase 
activity. A growing number of single nucleotide polymorphisms (SNPs) have 
been associated with telomere length and/or telomerase activity. Some of 
these include rs12696304, rs16847897, rs10511887, rs610160 (Codd et al); 
[234] rs2630778, rs11551026, rs2125173, rs10506083, rs10844149 (Mangino et 
al); [235] rs 2735940 (Matsuabara et al).[236] Other SNPs reported to have an 
association with mean telomere length in the British Heart Foundation Family 
Heart Study (BHF – FHS), [237] United Kingdom and Blood Service donors 
(UKBS) [238] have been shown in Appendix C. 
Notably, a genome wide association analysis of mean telomere length 
(in 2917 individuals with follow up replication in 9492 individuals) identified an 
association between telomere length on 3q26 (rs 12696304, combined p = 3.72 
x 10-14) at a locus that includes TERC, which encodes the telomerase RNA 
component. Each copy of the minor allele of rs12696304 was associated with a 
~ 75 bp reduction in mean telomere length, equivalent to ~ 3.6 years of age 
related telomere length attrition. This association was thought to be mediated 
by an effect on TERC expression. However, telomerase levels were not 
available to substantiate this. [234,237] 
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Thus genetically determined telomerase expression influences telomere 
length but its functional impact on somatic cells (where telomerase is largely 
suppressed) is unknown. Despite several reported associations (SNPs and 
telomere length), we elected to investigate correlations of SNP12696304 with 
telomere biology in our study because it has a very strong association with 
mean telomere length (p = 3.72 x 10-14), is located at a locus including 
telomerase RNA component TERC and shown to have a significant impact on 
mean telomere length measurements (each copy of minor allele associated 
with a ~ 75bp reduction in mean telomere length). [234]  Financial constraints 
were an additional factor limiting the number of SNPs that could be 
investigated. 
Following on from results of the previous study (chapter 3) and the 
evidence suggesting genetic determination of telomere biology, it was 
hypothesised that (1) telomerase activity will be different across different 
genotypes of the SNP 12696304 on chromosome 3q26 (that encodes TERC) 
(2) differential telomerase expression across genotypes would have an impact 
on cardiovascular ageing and hence the incidence of VA in this cohort.  
To test this hypothesis, the current case-control study was designed to 
test the association between genetic variation in SNP 12696304 and leukocyte 
telomere biology (telomerase activity and mean telomere length) with incidence 
of cardiac arrhythmia in ischaemic cardiomyopathy patients.   
4.2. Methods 
This case-control observational study was carried out at St Bartholomew’s 
hospital and William Harvey Research Centre. Ethical approval was obtained 
from the local research ethics committee. All patients gave written informed 
consent and were recruited from the ICD clinic at St Bartholomew’s Hospital. 
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Investigators were blinded to clinical history and all genotyping was carried out 
blinded to clinical data. 
4.2.1 Subjects 
The patients enrolled in this study were the same cohort as described in the 
previous chapter. The recruitment process, inclusion and exclusion criteria 
have been described before. SNP genotyping analysis was performed on all 
the 90 patients recruited to the study (35 cases and 55 controls).  
4.2.2 Measurements 
Clinical 
A standard questionnaire was filled in for all enrolled patients. Clinical details 
were obtained at recruitment by interviewing the patient and by examining their 
hospital records. The questionnaire recorded their medical history (to identify 
hypertension, diabetes, chronic renal failure, hypercholesterolemia, smoking 
status, family history of ischaemic heart disease and any other significant 
medical conditions), drug history, NYHA class, details of ICD implant, 
programming and previous arrhythmia history. These have been detailed in 
Chapter 2. 
 At recruitment, the patients also underwent a trans-thoracic 
echocardiogram to assess left ventricular function (LVEF measured by 
modified simpsons method), peripheral venous blood sample for general labs 
(including renal function, inflammatory markers - WCC and CRP, lipid profile), 
brain natriuretic peptide (BNP) and telomere genotyping. 
Genotyping analysis 
Genomic DNA was extracted from whole blood as described in chapter 2. 
Taqman SNP genotyping and allelic discrimination was used to genotype 
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patients to assess the association of genetic variation in telomere related SNP 
and ventricular arrhythmias. All samples were analysed blinded to clinical data. 
4.2.3 Statistical Analyses 
Statistical analyses were carried out using SAS VERSION 9.3 software. 
Continuous variables are reported as mean ± standard deviation, or median 
(range) if not normally distributed. Characteristics of cases and controls were 
compared using chi-squared test for categorical variables and unpaired t-test 
for continuous variables if normally distributed or Mann-Whitney U test if not 
normally distributed. The effects of age, gender, WCC, genotype and other 
individual cardiovascular risk factors on telomerase expression in individual 
genotypes were assessed using a logistic regression model. The individual 
genotype (telomere SNP rs 12636904), as a risk factor for appropriate ICD 
therapy for potential fatal VA (surrogate for SCD), alone and in combination 
with telomere dynamics telomerase activity with were assessed using logistic 
regression. 
4.3. Results 
4.3.1 Demographics 
90 patients were enrolled in this study. Of these 35 were in the case arm and 
55 in the control arm. This was the same cohort as described in the previous 
chapter. Their baseline demographic characteristics have been described in 
chapter 3. 
 
4.3.2 Correlation of ICD Therapy with Genotype 
A univariate analysis to examine the association of ICD therapy and the 
genotype is shown in the table below – table 17. 
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Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
SNP C/C 
 
 
1 
 
- 
 
- 
 
SNP C/G  
 
 
0.54 
 
0.21 – 1.417 
 
0.343 
 
SNP G/G  
 
0.80 
 
 
0.198 – 3.236 
 
0.907 
 
Table 17: Univariate correlation analysis of ICD therapy and genotype 
No significant correlation between the genotype and ICD therapy was identified 
(C/C OR 1; C/G OR 0.54, CI 0.21 – 1.417, p-value 0.343; G/G OR 0.80, CI 
0.198 – 3.236, p-value 0.907). 
An adjusted model again showed no significant correlation between 
genotype and ICD therapy (C/C OR 1; C/G OR 0.632, CI 0.211 – 1.891, p-
value 0.48; G/G OR 0.921, CI 0.194 – 4.374, p-value 0.84) – Table 18. 
 
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
SNP C/C 
 
 
1 
 
- 
 
- 
 
SNP C/G  
 
 
0.632 
 
0.211 – 1.891 
 
0.48 
 
SNP G/G  
 
0.921 
 
 
0.194 – 4.374 
 
0.84 
 
Gender 
 
 
0.845 
 
 
0.138 – 5.158 
 
0.85 
 
Age 
 
 
0.938 
 
0.885 – 0.993 
 
0.03 
 
    Table 18: Multivariate correlation analysis of ICD therapy and genotype 
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4.3.3 Correlation of ICD Therapy and Telomere Length in Different 
Genotypes 
There was no significant correlation between mean telomere length and ICD 
therapy and VA in the present study as shown in chapter 3. The distribution of 
mean telomere length across different genotypes and its association with ICD 
therapy in the individual genotypes was investigated.  
 The mean telomere length was shorter in individuals homozygous for G 
allele when compared to the heterozygotes and those homozygous for C allele 
(1.28,1.10,1.18) in cases. These findings are similar to those reported in other 
studies, although in a different clinical context. [234] The mean telomere length 
for the entire cohort (cases and controls) was not significantly different between 
the two homozygous allele groups. This difference only emerged significant in 
patients who had ICD therapy for potentially fatal VA. However, within 
individual genotypes, there was no significant difference in telomere length 
between cases and controls (C/C, C/G, G/G; p-value 0.41, 0.64, 0.71). The 
association of mean telomere length with ICD therapy in the individual 
genotypes is shown below. 
 
Correlation of ICD therapy and mean telomere length in genotype C/C 
There was no significant correlation between ICD therapy and mean telomere 
length in the C/C genotype (OR 1.06, CI 0.86 – 1.32, p-value 0.58) as shown in 
the table below – table19.  
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Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Mean telomere length in 
C/C genotype 
 
 
1.06 
 
0.86 – 1.32 
 
0.58 
 
Table 19: Correlation of ICD therapy and mean telomere length in C/C 
genotype 
 
The mean telomere length was not different between cases and controls in 
genotype C/C (20.58 versus 17.65; p-value 0.41). 
 
Correlation of ICD therapy and mean telomere length in genotype C/G 
The mean telomere length did not correlate with the incidence of ICD therapy in 
the heterozygous cohort (OR 0.91, CI 0.57 – 1.44, p-value 0.68) – table 20. 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Mean telomere length in 
C/G genotype 
 
 
0.91 
 
0.57 – 1.44 
 
0.68 
 
Table 20: Correlation of ICD therapy and mean telomere length in C/G 
genotype 
 
The mean telomere length was not different between cases and controls in 
genotype C/G (15.35 versus 17.02, p-value 0.68). 
Correlation of ICD therapy and mean telomere length in genotype G/G 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Mean telomere length in 
G/G genotype 
 
 
0.92 
 
0.55 – 1.52 
 
0.73 
 
Table 21: Correlation of ICD therapy and mean telomere length in G/G 
genotype 
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Similarly, in individuals homozygous for G-allele, the mean telomere length did 
not correlate with ICD therapy (OR 0.92, CI 0.55 – 1.52, p-value 0.73). The 
mean telomere length was not significantly different between cases and 
controls in genotype G/G (5.4 versus 4.7, p-value 0.71) 
The interaction plot for mean telomere length and ICD therapy (cases and 
controls) across different genotypes is shown in figure 21. 
 
 Figure 21: Interaction plot for mean telomere length across different genotypes 
 
4.3.4 Correlation of ICD Therapy and Telomerase Activity in 
Different Genotypes 
A significant correlation between ICD therapy and telomerase activity has 
already been shown in this study. It was then investigated whether telomerase 
expression was different amongst genotypes an if there was a correlation 
between telomerase activity and genotype with VA.  
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 Overall, with cases and controls combined, the telomerase activity was 
highest in individuals homozygous for C-allele and was similar across the 
heterozygous allele and individuals homozygous for G allele (C/C 0.35, C/G 
0.26, G/G 0.24). 
 
Correlation of ICD therapy and telomerase activity in genotype C/C 
 The odds of receiving ICD therapy in individuals homozygous for C-
allele with increase in telomerase activity were 7.507. There was a strong 
association between telomerase activity and ICD therapy in the C/C genotype 
(OR 7.507, CI 1.00-56.61, p-value 0.04) – table 22. 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Telomerase activity in 
C/C genotype 
 
 
7.507 
 
1.00 – 56.61 
 
0.04 
 
 Table 22: Correlation of ICD therapy and telomerase activity in C/C genotype 
 
Correlation of ICD therapy and telomerase activity in genotype C/G 
No significant correlation between ICD therapy and telomerase activity 
was found in the C/G genotype (OR 2.759, CI 0.352 – 21.60, p-value 0.33) – 
table 23.  
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Telomerase activity in 
C/G genotype 
 
 
2.759 
 
0.352 – 21.60 
 
0.33 
 
 Table 23: Correlation of ICD therapy and telomerase activity in C/G genotype 
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Correlation of ICD therapy and telomerase activity in genotype G/G 
The correlation between telomerase activity and ICD therapy was not 
significant in individuals homozygous for the G-allele (OR 4.137, CI 0.117 – 
145.91, p-value 0.43) – table 24. 
 
Parameter Odds ratio 95% Wald 
Confidence Limits 
p-value 
 
Telomerase activity in 
G/G genotype 
 
 
4.137 
 
0.117 – 145.91 
 
0.43 
 
Table 24: Correlation of ICD therapy and telomerase activity in G/G genotype 
 
The interaction plot for telomerase activity with ICD therapy (cases and 
controls) in different genotypes is shown in figure 22. 
 
Figure 22: Interaction plot for telomerase across different genotypes 
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4.4. Discussion 
The main finding of this study is that the telomerase expression was 
significantly higher in individuals homozygous for C allele of a TERC encoding 
SNP. There is a significant correlation between telomerase activity and cardiac 
arrhythmia in ischaemic cardiomyopathy patients as shown in the previous 
chapter. This association remained significant only in the C/C allele of SNP 
12696304 whereas individuals who were homozygous for the G allele or 
heterozygous had similar levels of telomerase across cases and controls. Thus 
increased telomerase activity could predispose individuals with C/C genotype 
to a higher incidence of VA post MI. Also, the genotype (independent of the 
telomerase expression) did not correlate with incidence of cardiac arrhythmia. 
 Telomere length variability has been attributed to genetic influences. 
Heritability estimates of 78% have been derived from twin studies and account 
for inter-individual differences to a large extent. [219] Large-scale genotyping 
studies have identified various genetic variants which affect telomere length as 
they harbor genes that encode proteins with known function in telomere 
biology. These include TERC locus on 3q26, [234] TERT on 5p15.33, NAF1 
(nuclear assembly factor 1) on 4q32.2, OBFC1 
(oligonucleotide/oligosaccharide-binding fold containing 1) [239] and RTEL 1 
(regulator of telomere elongation helicase 1) on 20q13.3. [240-243] TERC and 
TERT are components of the telomerase ribonucleoprotein moiety, whereas 
NAF1 is required for H/ACA box snoRNA assembly, the RNA family to which 
TERC belongs. [240] Therefore, the three most significantly-associated loci 
(3q26, 5p15.33 and 4q32.2) harbor genes involved in the formation and activity 
of telomerase. And hence, the genetic basis for this variation in telomere length 
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is largely due to the presence of telomerase gene variants with variable activity 
in germ-line and/or stem cell pools. 
 Of all the genetic loci associated with telomere length we studied the 
one with the most significant association – rs12696304, which is located 1.5kb 
downstream of TERC. It has been previously shown that each minor (G) allele 
of rs1296304 is associated with a shorter mean telomere length equivalent to ~ 
3.6 years (75bp reduction) of average age-related telomere attrition. [234] Our 
study showed similar results with the mean telomere length being shorter in 
individuals homozygous for the minor allele G. However, this was only true for 
the individuals who experienced ICD therapy for potentially fatal VA (cases) 
and not for the entire cohort. Also the magnitude of difference was much 
smaller, likely due to a much smaller sample size. 
 The most significant associations of various gene loci with telomere 
length encode TERC or TERT and their functional basis is believed to be 
mediated through telomerase expression. However, significant associations 
between telomerase activity and SNP variants have not been shown in 
previous studies and all inferences have been derived from quantitative 
assessment of mean telomere length. The present study shows that the 
telomerase activity was significantly higher in individuals homozygous for C-
allele (compared to homozygous G or heterozygous status) of SNP 12696304, 
which encodes TERC. Also, there was a significant correlation between risk of 
VA and increase in telomerase activity in the C/C genotype. This correlation 
was not significant in the C/G or G/G genotype. Hence homozygosity for C-
allele significantly effects telomerase expression in ischaemic cardiomyopathy 
patients.  
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 As telomerase is responsible for maintaining telomere length, factors 
that influence telomerase activity are clearly important when considering the 
association between telomere length and clinical phenotype. There is 
increasing evidence that genetic variation in key genes has an impact on 
telomere length, which is largely due to the effects exerted by the enzyme 
telomerase. The present study shows (1) a significant correlation between a 
telomere related SNP 12696304 and telomerase activity and (2) a significant 
correlation between telomerase activity and VA in individuals homozygous for 
the major allele (C) of the same SNP 12696304 post myocardial infarction. 
Thus, here is a genetic variant that effects telomerase expression (and hence 
telomere length) and is significantly associated with the incidence of cardiac 
arrhythmia in individuals with ischaemic cardiomyopathy.  
 Given the above findings, it would now be intuitive to try and establish if 
this association is causal in nature. There is no doubt that homozygosity for C 
allele significantly effects telomerase expression, which in turn is significantly 
associated with ICD therapy (VA). However, the important question is: Does a 
high telomerase activity predispose C homozygous individuals to develop VA 
or is the increase in telomerase activity in C homozygous individuals secondary 
to development of VA? When answered, not only will this establish the role of 
telomere biology and its genetic variation as a primary mechanism in causality 
of cardiovascular ageing; but also help develop these markers as potential 
predictors of cardiac arrhythmia in ischaemic cardiomyopathy.  
 It is difficult to answer this question conclusively within the realms of the 
current study. This is largely due to the absence of data depicting longitudinal 
changes in telomere biology in this group of patients, given the study design. 
However, we can hypothesise the cause behind this association and its 
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potential implications can be speculated with reasonable accuracy. Potential 
hypotheses include: 
Increase in telomerase is a result of ICD therapy 
The rise in telomerase activity can be the result of ICD therapy itself. Patients 
received ICD therapy for potentially fatal VA. Both the cardiac arrhythmia or 
ICD therapy itself could potentially have an impact on cellular function and 
stability leading to an enzyme rise, which is independent of telomeric function. 
 However, if this were the case, then one would expect the telomerase 
levels to be proportionate to the number of ICD therapies received. There was 
no significant correlation between telomerase activity and number of ICD 
therapies in this cohort. Also, if the telomerase rise was solely the result of ICD 
therapy, then it would be difficult to explain why this association was seen 
predominantly in one genotype (homozygous C) despite it not including the 
patient with the maximum number of shocks. Nonetheless, conclusions can 
only be drawn with the availability of longitudinal changes in telomerase, before 
and after ICD therapy, from large-scale prospective studies. 
Increase in telomerase is a protective response to critically short telomeres 
Myocardial infarction, a major complication of atherosclerosis/CAD, is 
associated with very high degrees of oxidative stress. As per our primary 
hypothesis (Chapter 1), telomere shortening at the time of MI, results in poor 
myocardial repair process and predisposes patients to greater arrhythmic 
tendency. This is mediated by the formation of critically short telomeres (shown 
to be higher in cases in this study) as a result of stochastic shortening. A single 
critically short telomere can lead to cellular senescence by virtue of genomic 
instability.  
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 The observed increase in telomerase may be a protective response to 
stochastic telomeric shortening to maintain genomic stability and prevent 
cellular senescence. This is further supported by the fact that both telomerase 
activity and load of short telomeres followed a similar trend – higher in cases 
versus controls and highest in individuals homozygous for C-allele of SNP 
12696304. However, it is difficult to be certain at what time point after MI do 
telomeres become critically short and precipitate a rise in telomerase activity. 
Whether this happens before or after the development of left ventricular 
dysfunction, could have important implications in clinical risk stratification of 
SCD in ischaemic cardiomyopathy. 
Genetic variation predisposes some individuals to express telomerase at the 
time of index event in anticipation of later instability (critically short telomeres) 
A very interesting possibility would be individuals being born with a certain 
predilection (mediated by telomere biology) to develop cardiac arrhythmias, 
should they suffer from a MI. This would account for genetic variation in 
telomere dynamics in these individuals. So, the increase in telomerase activity 
in C homozygous alleles of the SNP encoding TERC would be present prior to 
the development of VA. The increased telomerase expression in these 
individuals might be secondary to an inherited variation in TERC, which only 
becomes functional (increased telomerase activity) on exposure to extreme 
oxidative stress (MI). And it is this genetic variation that predisposes them to a 
greater arrhythmic tendency post MI. 
 Poor left ventricular function and MI are categorical traits, which might 
change with age or during the course of a disease process (CAD). However, 
genetic variation in TERC/Telomerase expression would be present at the time 
of genotyping - before (or after) the development of left ventricular dysfunction 
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or cardiac arrhythmias. These can thus be accurately quantified early on in the 
disease process. Thus, if increased telomerase expression is present in C 
homozygous alleles of the studied SNP, before development of left ventricular 
dysfunction post MI, then this can be used as an intermediate phenotype to 
identify individuals prone to VA relatively early on post MI. Again, this needs 
prospective studies to confirm the observed associations and develop telomere 
biology markers for clinical use. 
This study provides novel insights into genetic determination of telomere 
biology and its association with cardiac arrhythmia in ischaemic 
cardiomyopathy patients. The main findings suggest that variants in genes 
encoding proteins with known function in telomere biology have a functional 
effect and can modify clinical phenotype. Telomere biology markers can be 
developed as an intermediate phenotype, as a quantitative marker, to assess 
risk of cardiac arrhythmia post myocardial infarction, early on in the disease 
process. 
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Chapter 5 – GENERAL DISCUSSION AND FUTURE 
DIRECTIONS 
5.1 Overview of the Project  
The primary aim of this study was to characterise telomere biology in patients 
with ischaemic cardiomyopathy and at a high risk of sudden death. This was to 
investigate associations between telomere biology and cardiac arrhythmia and 
to explore their potential for translation into clinical use for risk stratification of 
sudden death. The main findings of the study indicate that load of short 
telomeres is greater and telomerase activity higher in individuals who 
experience potentially fatal VA than in those who do not. Also, these telomere 
markers have a significant correlation with incidence of VA. Thus proving the 
primary hypothesis of the study, stipulating an association between telomere 
biology and VA occurrence post myocardial infarction. Also, genetic variation in 
telomerase expression was found on genotyping a TERC encoding SNP and 
this differential expression across genotypes correlated significantly with 
incidence of VA in the major homozygous allele. 
 Two novel methods were used to assess telomere attrition. The widely 
used real time PCR method assesses the mean telomere length. Although this 
is a very quick method with a high throughput and requires minimal amount of 
starting genetic material, it does have its shortcomings. This is a somewhat 
crude analysis of telomere length, and doesn’t give much information on cell or 
chromosome specific telomere length. The analysis of specific telomere length 
is important because: (1) there is a high degree of inter- and intra-
chromosomal, in addition to inter- and intra-cellular differences in telomere 
length as depicted in the wide melt curves obtained during real time PCR 
analysis. (2) increasing evidence suggests that cellular senescence is not 
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solely a result of gradual decline in telomere length. A single critically short 
telomere (4-7kb) can induce senescence. [244] Moreover, chromosome specific 
patterns of telomere length have been shown, [245] suggesting that there might 
be a chromosome specific telomere length profile that is associated with 
cardiac arrhythmia in ischaemic cardiomyopathy. Or there might be a specific 
telomere that is consistently short in our patient group – similar to the short 
telomere on chromosome 17p (harbouring p53 and tumour suppressor genes) 
that is lost in human cancers. (3) Telomere shortening can result in altered 
gene expression as a result of telomere position effect and hence necessitating 
the study of specific telomeres. Our novel method U-STELA offered a solution 
to the shortcoming of the gold standard real time PCR. It enabled to determine 
the difference in telomere length between cases and controls by analysing the 
critically short telomeres regardless of their chromosomal location. Other 
methods of telomere analysis are unable to detect these short telomeres as 
they use mean telomere length or telomere lengths of dividing cells and 
therefore non-senescent cells. With U-STELA it was possible to quantify the 
critically short telomeres and directly investigate their relationship with cellular 
senescence in this clinical phenotype. The method of quantification of the short 
telomeres is novel in that the number of short bands below a certain threshold 
were counted and expressed as a number relative to DNA concentration of 
each cell. Such a threshold parameter serves as a surrogate measure for the 
frequency within individual cells of telomeres that are no longer able to protect 
the chromosome ends. 
 Telomere length at any given point in time is a function of initial length 
and the rate of attrition. Different mechanisms of telomere shortening and 
factors effecting telomere length were investigated in this study. Genetic 
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variation in a SNP lying 1.5kb downstream of TERC was shown to have an 
impact on telomerase activity. Telomere shortening as a result of replicative 
senescence was reflected in the mean telomere length whereas stochastic 
telomere shortening was determined by quantifying the load of short telomeres. 
These mechanisms of telomere attrition in this clinical cohort represented the 
cumulative inflammatory and oxidative burden at the cellular level. 
 
      Figure 23: Mechanisms of telomere shortening 
 
 Genetic variation in telomerase and its association with cardiac 
arrhythmia has been well demonstrated in the present study. Whether the 
observed difference in telomerase expression was present at birth or the 
genetic variant was only manifested as a functional change after myocardial 
infarction, is difficult to established within the realms of this study. Previous 
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studies have shown that telomerase might account, in part, for the high 
estimate of heritability. A burst in telomerase activity during embryogenesis 
(morula t blastocyst stage) leading to resetting of telomere length to a defined 
set point has been shown. [246] Similarly, it has been shown that the telomere 
length is the same across different foetal tissues at birth. This synchrony 
amongst foetal tissues implies that from blastocyst stage onwards all cells 
would turnover at the same rate until birth. [247] If the telomerase activity is the 
same in all individuals, the telomere length after the “burst” will be a function of 
length before it. However, if two individuals possess variants of telomerase 
gene (with different rates of functional activity) then the length set during this 
“burst” may differ. 
 In this study an association between systemic telomere biology and 
clinical disease severity has been established. Critically-short telomeres are the 
prevailing products of stochastic shortening (likely due to oxidative stress) and 
whether the increased load-of-short telomeres in patients suffering VA are the 
result of ICD shock itself or on-going ischaemic insult, which then increases 
susceptibility to VA is not clear. Nevertheless these findings have major 
implications for studies examining the pathways from exposure of cells to 
oxidative stress to the induction of cellular senescence, because a telomeric 
role can potentially be missed if a method insensitive to changes in single 
telomeres is applied. Mean telomere length is a crude measure of telomere 
dynamics and the load-of-short telomeres may be a superior discriminatory 
marker in patients with ischaemic cardiomyopathy and poor LV function. It is 
also important to consider, the very interesting possibility, of genetic variation in 
telomerase expression and its functional impact on clinical phenotype as 
shown in this study. 
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 Cardiac arrhythmia post MI is a categorical trait and can change during 
the lifetime of an individual. But can a quantitative trait like telomere length 
(mean telomere length or load of short telomeres) and telomerase activity be 
measured with relative accuracy to predict cardiovascular ageing? Could we 
use telomere biology as an intermediate phenotype to identify individuals at a 
high risk of cardiac arrhythmias early on in the disease process? Could further 
research develop telomere biology as a potential biomarker for cardiac 
arrhythmias? 
5.2 Telomere Dynamics as Potential Biomarkers  
Leukocyte telomere biology is generally considered as a marker of cellular 
senescence and biological ageing. It has been shown to have a significant 
association with cardiovascular ageing especially in the context of 
atherosclerosis and myocardial infarction. The present study establishes a 
significant association between telomere dynamics (critically short telomeres 
and telomerase activity) and incidence of potentially fatal cardiac arrhythmias 
(sudden death) in ischaemic cardiomyopathy. Intuitively, if this association is 
validated in a longitudinal study, telomeres could potentially be developed as 
biomarkers for risk stratification of sudden death in this group of patients. 
Telomere biology changes progressively with chronological age, has inherent 
variation amongst individuals, quantifies accelerated biological ageing resulting 
from replicative senescence and oxidative stress. So does telomere biology 
have the potential of a robust biomarker of cardiovascular ageing?  
In an attempt to answer this pivotal question, the current evidence was 
examined against a set of standardised well-defined biomarker of ageing 
criteria developed by the American Federation of Ageing Research: [248,249] 
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Criterion 1: It must predict the rate of ageing. In other words, it would tell 
exactly where a person is in their total life span. It must be a better predictor of 
lifespan than chronological age. 
To fulfill this criterion, telomere attrition should shorten an individual’s life span 
and should be a better predictor of the same than chronological age. Several 
studies have reported shortened telomeres and an increased risk of 
cardiovascular mortality. [180,250,251] This has also been shown in prospective 
twin studies wherein it was found that the twin with the shorter telomeres had a 
threefold higher mortality risk than the co-twin over an average follow up period 
of seven years, regardless of zygosity. [252] 
 These mortality studies provide good evidence to develop telomere 
biology as a marker of cellular senescence and cardiovascular ageing. Survival 
bias in older cohorts might be a potential confounding factor. Whether telomere 
attrition predicts mortality awaits results of further research from longitudinal 
studies. 
Criterion 2: It must monitor a basic process that underlies the aging process, 
not the effects of disease. 
Increasing evidence suggests that telomere biology correlates with biological 
ageing and the pathogenesis and prognosis of cardiovascular diseases. Heart 
disease is believed to represent a disease of premature biological ageing and 
telomere length, independent of chronological ageing, is predictive of an 
increased of cardiovascular risk. The accelerated biological ageing results from 
a combination of replicative senescence and a more stochastic telomere loss 
mainly due to oxidative stress. 
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 In the present study we demonstrated a significant association between 
an increased load of critically short telomeres and increased telomerase activity 
with a higher incidence of potentially fatal VA in patients post myocardial 
infarction with poor left ventricular function. Previous studies have shown a 
significant association between telomere biology and CAD, [95-103] premature 
myocardial infarction, [96] decreased renal function in patients with heart failure, 
[157,158] poor left ventricular function in the elderly and various cardiovascular 
risk factors including hypertension, [163] diabetes, smoking and obesity. [162] 
 The cause-effect relationship of cardiovascular diseases and telomere 
attrition is not very well established. However, there are studies that have 
distinctly shown that short telomeres distinctly precede the development of 
clinical disease and hence short telomeres are not just an epiphenomenon. [98] 
Despite the strong correlation between telomere biology and cardiac 
arrhythmias in our study, we could not prove the causality due the lack of 
longitudinal data. This is true for the vast majority of telomere studies as they 
are cross-sectional in design. 
 The evidence presented above favours telomere biology as a promising 
biomarker of cardiovascular ageing. However, this evidence is not absolute and 
needs further validation in large-scale prospective studies. Given the wide 
inter-individual variation in telomere dynamics, rates of change will be more 
informative and relevant to clinical practice than single time-point absolute 
estimates.  
Criterion 3: It must be able to be tested repeatedly without harming the person. 
For example, a blood test or an imaging test. 
Currently, the vast majority of telomere analysis is done on peripheral blood 
samples. This is easy to obtain and has no potential harm to the patient. It is 
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generally believed that telomere length measured from peripheral blood 
correlates strongly and is a surrogate for telomere analysis in the tissue of 
interest. This belief generally stems from the primary hypothesis that telomere 
length is largely inherited and hence individuals with shorter telomeres in 
peripheral blood should also have shorter telomeres in other cell types. There 
is some evidence that this is true and leukocyte telomere length has been 
shown to be associated with tissue specific telomere length. [253] However, 
other studies suggest that this might not be the case for all tissue types, 
especially those with limited cellular turnover. [254] 
 Given the current evidence, telomere biology currently fulfills this 
criterion of a biological marker. However, it is likely that this will be challenged 
as more studies are carried out using different tissue samples. 
 
Criterion 4: It must be something that works in humans and in laboratory 
animals, such as mice. This is so that it can be tested in lab animals before 
being validated in humans. 
The role of telomeres in ageing has been investigated in animal models, mainly 
mice. Telomere and telomerase has been shown to have a role in the 
pathophysiology of ageing and ageing related diseases in mice. Telomeres 
shorten in the mouse with increasing chronological age. [255,256] Moreover, 
telomeres of telomerase knockout mice show progressive shortening over 
generations, with later generations demonstrating evidence of cardiac 
dysfunction, [257] hypertension, [258] premature ageing and a shortened life 
span. [259] Overexpression of telomerase in mice may contribute to extended 
lifespan. [260] 
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 However, the available evidence is limited and fundamental differences 
in telomere biology between mice and humans cannot be ignored. Inbred mice 
strains have extremely long telomeres when compared to humans (20-150kb 
vs 15kb); [261] telomerase is easily detected in somatic cells in mice, whereas it 
is mostly active in germ cells in humans and certain species of mice are known 
to have a very short life span despite very long telomeres and hence 
suggesting a different mechanism of ageing. [262,263] 
 Sufficient evidence is lacking to accept or refute the mouse model for 
investigating telomere biology prior to validation in humans. Further animal 
studies on the mouse and use of additional animal models are required to get a 
clearer picture. 
Overall, it is apparent that the evidence supporting the hypothesis that 
telomere biology is a biomarker for cardiovascular ageing is equivocal. Further 
evidence is required from longitudinal study designs, which can provide very 
useful information on intra-individual telomere biology over a life span. These 
would be far more useful than cross-sectional analyses, which are a reflection 
of inter-individual variation. In addition to the above considerations, various 
factors that effect telomere biology comparability across individuals have to be 
taken into account: [220] 
Telomere length inheritance and telomere hypothesis: in the present group of 
ischaemic cardiomyopathy patients, two main hypotheses govern telomere 
attrition by virtue of their correlation with coronary artery disease. The first 
hypothesis eludes to accelerated leukocyte telomere shortening secondary to 
stochastic shortening (likely due to oxidative stress) and increased replicative 
senescence (due to increased inflammation) post myocardial infarction and/or 
in stable coronary artery disease. [224,264] The alternative hypothesis, commonly 
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known as “telomere hypothesis” postulates that shorter telomeres may be 
causally implicated in the pathogenesis of coronary artery disease. [98] 
Consequently, shorter inherited telomeres could represent a primary 
abnormality predisposing to an increased risk of cardiovascular ageing. And 
hence, when interpreting inter-individual telomere variability, it might be 
important to consider the initial telomere length at birth. 
Genetic variation in telomerase expression: telomerase dependent telomere 
variability has been shown in large-scale genome wide association studies. A 
significant association of leukocyte telomere length with single nucleotide 
polymorphisms at a locus that includes telomerase RNA component TERC. 
[219,234,265] Hence, not only are there inherited differences in telomere length, but 
genetically determined telomerase activity has an impact on telomere length 
variability. This is then further compounded by the effect of environmental 
factors like inflammation and oxidative stress. 
Population based comparability: A substantial difference in telomere lengths 
across different populations and ethnicities has been shown. [220] In fact, 
ethnicity is a significant confounding factor in telomere studies. The European 
Atherosclerosis Research Study II, showed a significant variation in telomere 
lengths across eleven European countries. The telomere length varied between 
5.1 kb to 18.6 kb. [266] This vast variation across populations and different 
ethnicities poses a challenge for telomere comparisons across populations and 
generalisability for its use as a biomarker. 
Longitudinal measurements of telomere biology: the growing evidence that 
signifies the association of telomere biology with cardiovascular ageing 
(biological ageing) is derived from cross-sectional studies. These allude to 
telomere measurements at a single time point. However, given the dynamic 
	  	  
175	  
nature of coronary artery disease and its varied time course, longitudinal 
changes in telomere dynamics associated with disease process would 
intuitively be more useful.  
 A few studies have investigated changes in telomere dynamics in 
coronary artery disease prospectively. The Heart and Soul study measured 
leukocyte telomere length at baseline and after 5 years in patients with 
coronary artery disease. As expected, telomere attrition was noted over a time 
period of 5 years (5.5 kb at baseline to 5.3 kb at 5 years) with an average 
annual loss of 40 bp. However, it was also noted that telomere shortening was 
only evident in 50% of the patients. The remaining had either no change in their 
telomere length or demonstrated an increase in the same. [267] Another study 
measured leukocyte telomere length over three different time points over 12 
years and concluded that the average annual rate of telomere attrition is 31 bp 
and telomere length elongation is a methodological artefact rather than a real 
phenomenon. [268] 
 Individual telomere length fluctuations might be a natural component of 
age related telomere attrition. These changes in telomere biology over time and 
their association with the disease process need to be established to allow 
comparison across different cohorts and to translate it into clinically useful 
information. These would of course, be further influenced by other factors 
including methodology of telomere measurement, composition of leukocytes at 
any point in time and the short half life of myeloid cells. 
Composition of leukocytes: The vast majority of telomere studies have been 
done on whole blood cell leukocyte. However, the composition of leukocytes 
has been shown to vary during the course of atherosclerosis with varied 
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number of monocytes, granulocytes and lymphocytes being recruited during 
the course of this inflammatory process.  
Role of infection: recent evidence suggests accelerated CD8-Tcell telomere 
shortening in CMV seropositive patients with coronary artery disease. CMV 
infection induces a strong reduction of telomere length in the circulating T-cell 
pool, which is largely attributed to the changes in composition of T-cells. [269,270] 
CMV seropositivity is evident in 70% of the adult population, making this 
observation even more significant for analysis and comparability of telomere 
length.  
Methodological errors in measuring telomere biology: leukocyte telomere 
length has been measured by a number of different techniques including TRF 
southern blot analysis, qPCR, Flow-FISH etc. The co-efficient of variation for 
telomere length measurements by different methods varies between 2 to 28%. 
Even a small measurement error resulting in a co-efficient of variation of 2.5% 
can result in significant misclassification of individual telomere length. [268] The 
advantages and disadvantages of various techniques need to be considered to 
allow uniformity in telomere measurements and to ensure reliability in telomere 
comparisons across different cohorts. 
 
There is enough evidence that telomere biology can be established as a 
biomarker for cardiovascular ageing. To achieve this, the following conditions 
for this marker should be met: [220] 
- Telomere biology should be measured in one or more leukocyte subsets 
to avoid short-term changes in leukocyte composition and its impact on 
longitudinal variability. 
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- The average annual telomere loss in the studied cell subset should be 
greater than in other cell types to reduce methodological measurement 
errors in telomere length analysis. For instance, populations which lose 
40bp/yr are more likely to distinguish an ageing effect than those that 
shorten at 20bp/yr. 
- Longitudinal changes in telomere biology should be characterised in 
prospective studies with the aim to confirm its association with 
cardiovascular ageing. This should be done across different population 
and ethnic cohorts. 
- In addition to chronological and biological ageing, effects of oxidative 
stressors and systemic inflammation on stochastic telomere shortening 
need to be investigated further. These processes are hallmarks of 
cardiovascular ageing and their effect on telomere biology needs to be 
established. 
-  An internal standard (control) should be used to account for genetic and 
population based variability. This reference cell population should age 
slower than the marker population. 
- An age limit might exist where telomere length can distinguish between 
healthy and “prematurely” aged cells, given that telomeres have reached 
a critically short length or the experimental method used can not 
separate between two very short telomeres. This possibility needs to be 
considered and appropriate methods used simultaneously. 
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5.3 Future Directions 
Telomere biology in cardiac arrhythmia and cardiovascular ageing requires 
further understanding if it is to enter widespread clinical practice. The findings 
of the present study provide several new avenues for future research. 
 Having shown a significant association between systemic telomere 
biology and cardiovascular disease severity, it is vital to determine if this 
relationship is causal or not. This could be done by characterising longitudinal 
changes in telomere attrition and telomerase activity in large-scale, multicenter, 
prospective studies and correlating them to the development of cardiac 
arrhythmia in ischaemic cardiomyopathy. Whether telomere attrition/telomerase 
activity are simply biomarkers or whether the observed association has a 
functional basis remains to be determined. This requires further study of the 
interaction between telomere biology and functional cardiac electrophysiology 
and cardiac remodeling after MI. Possible explanations for the underlying 
mechanism include telomerase mediated prolonged lifespan of inflammatory 
cells promoting ischaemia or prolonged lifespan of peri-infarct cardiac cells 
promoting anisotropy and arrhythmic potential. Comprehensive mechanistic 
studies are needed to investigate this further.  
 All telomere analysis in this study has been done on genomic DNA 
derived from peripheral blood leukocytes. This is also true for the vast majority 
of telomere studies published so far. It is well known that atherosclerosis is 
characterised by low-grade chronic inflammation and systemic oxidative stress. 
These are mediated by different leukocyte subsets and recruitment of these 
inflammatory cells varies during the course of the disease. Leukocyte 
populations have a crucial role in age dependent development of 
atherosclerosis, wherein the disease process is mediated by monocytes, 
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macrophages and T lymphocytes. [271] Telomere shortening is believed to occur 
at a faster rate in lymphocytes (than in granulocytes) [221,231] and the persistent 
inflammatory state in atherosclerosis can lead to increased proliferation of 
lymphocytes leading to a shift towards a more mature populations and hence 
shorter telomere lengths. [221] This is also seen with the normal ageing process. 
Concentrations of monocytes and granulocytes in peripheral blood are 
predominantly elevated in acute MI, but could be high in stable CAD as well. 
[272] Granulocytes have a relatively short lifespan, lack proliferation and are not 
known to express telomerase (with the exception of coronary plaque 
neutrophils). [273] Given the characteristics of our clinical cohort, time lapsed 
post MI and the associations observed, lymphocyte subset might be a more 
relevant marker of telomere biology. Total leukocyte telomere length might be 
unattractive given that leukocyte composition changes in individuals with age 
and also over the time course of the underlying disease pathophysiology in this 
cohort.  
 Telomere biology shows considerable variation across different 
ethnicities. Race and ethnicity have shown to be significant confounding factors 
while assessing telomere length. Also, there is considerable genetic variation 
and heritability involved in telomere assessment. If this were to be established 
as a biomarker, it would be essential to standardise this for individual 
ethnicities or across groups of ethnicities. Moreover, the genetic variation in 
telomerase expression shown in this study is likely to be effected significantly 
by the race and ethnicity of the population being studied. This needs further 
thought. 
 Another important question that requires investigation is the correlation 
between telomere analysis in peripheral blood and cardiomyocytes. Although 
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leukocytes provide an easily accessible source for genomic DNA analysis, the 
relevance of measurement of telomere biology in peripheral blood to various 
processes that occur in cardiomyocytes at the time of an infarct have not been 
established so far. There is limited data that suggests that a correlation exists 
between telomere lengths in different tissues of an individual that indicate the 
genetic determination of telomere length. [274] Some studies have shown the 
correlation of leucocyte telomere biology in circulating cells and vascular 
tissues. However, the number of these studies is small and evidence 
inconclusive. This is an exciting area for further research. 
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APPENDIX 
A. U-STELA GELS 
Load of short telomere analysis on 30 patients is shown below. Figures 
include annotated gel images and corresponding raw data. Telomere count 
was done using Vision Works LS Acquisition and Analysis Software (Ultra-
Violet Products Ltd, AH Diagnostics). The number of PCR products with a 
length less than 1500 base pairs (bp) were counted and calibrated based on 
the PCR template concentration. The load of short telomeres was presented as 
the number of telomeres below a length of 1500 bp per genome equivalent of 
template DNA.  
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GEL 1 
 
 
 
 
Figure 24: U-STELA Gel 1  
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 1_1 
 
Figure 24(a): U-STELA Gel 1_1 with markers 
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GEL 1_2  
 
 
Figure 24(b): U-STELA Gel 1_2 with markers 
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GEL 1_3 
 
 
Figure 24(c): U-STELA Gel 1_3 with markers 
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GEL 1_4 
 
Figure 24(d): U-STELA Gel 1_4 with markers 
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GEL 1_5 
 
     Figure 24(e): U-STELA Gel 1_5 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
 
Band 
Gel1_1 
A(M) B C D E F G H I J(M) 
1 21226 2335.619 2640.817 2540.360 2573.414 2475.521 2763.049 2246.772 2606.898 21226 
2 8576 2039.161 2217.914 2232.297 2133.545 2133.545 2556.834 1760.335 2396.794 8576 
3 7427 1936.900 1540.748 1961.898 1694.401 1694.401 2350.765 1559.893 2000 7427 
4 6106 1630.937  1760.335 695.723 1164 1875.976 1341.609 1540.748 6106 
5 5000 1451.207  1477.508   957.914  849.003 5000 
6 4268 1138.895  1416.865      4268 
7 3630 1059.057  1122.459      3630 
8 2799 849.002  387.603      2799 
9 2000 654.593        2000 
10 1900 280.425        1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
  Table 25 (a): Telomere bands corresponding to Gel 1_1 
 
Table 25 (b): Telomere bands corresponding to Gel 1_2 
 
Band 
Gel1_2 
A(M) B C D E F G H I J(M) 
1 21226 2291.080 2374.485 2179.213 2568.817 2514.293 2496.376 2443.389 2258.545 21226 
2 8576 1987.218 1887.562 1862.930 1924.521 2163.684 1974.517 2194.853 1875.206 8576 
3 7427 1779.223 1814.627 1677.102 1756.005 1987.218 1756.005 1974.517 1633.617 7427 
4 6106 1677.102 1245.519 1490.494 1502.209 1779.223 1688.153 1382.875 1292.366 6106 
5 5000 1260.943 770.7533 889.191  1467.336 1525.918 1200.371 1185.688 5000 
6 4268 1140.966    1032.457 1349.252  964.637 4268 
7 3630 242.7649    854.769 1005.306  786.737 3630 
8 2799      285.747   2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
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Table 25 (c): Telomere bands corresponding to Gel 1_3 
 
 
                    Table 25 (d): Telomere bands corresponding to Gel 1_4 
 
 
Band 
Gel 1_3 
A(M) B C D E F G H I J(M) 
1 21226 2540.360 2709.986 2844.850 2590.102 2623.803 2938.816 2821.832 2540.360 21226 
2 8576 2290.765 2217.914 2459.572 2276.006 2305.620 2475.521 2459.572 2119.798 8576 
3 7427 1900 2012.969 2246.772 1550 2133.545 2335.619 2246.772 1932.765 7427 
4 6106 1334.572 1757.702 1877.381  1966.095 2147.379 1757.702 1747.208 6106 
5 5000 1110.962 788.533 1171.986  1811.125 794.465 1514.0174 1635.827 5000 
6 4268   584.656  862.761  998.631 1422.095 4268 
7 3630   553.103  699.858  862.761 1103.585 3630 
8 2799     606.069   1005.306 2799 
9 2000        886.187 2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
Band 
Gel 1_4 
A(M) B C D E F G H I J(M) 
1 21226 2519.918 2591.497 2416.238 2555.457 2702.697 2865.939 2467.534 2555.457 21226 
2 8576 2014.054 2399.378 2042.459 2433.217 2349.499 2702.697 2300.658 2252.832 8576 
3 7427 1855.030 1232.033 1520.699 1877.381 2115.236 2467.534 1855.030 1789.564 7427 
4 6106 1454.469 1180.648 1473.092 1463.751 1757.702 1974.517 1747.208  6106 
5 5000 1223.316  1189.060 619.457 1540.171 1800.312 916.032  5000 
6 4268 714.671  957.914  809.488 1665.480   4268 
7 3630   814.813   1597.110   3630 
8 2799      1172.294   2799 
9 2000      738.489   2000 
10 1900      635.507   1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
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Table 25 (e): Telomere bands corresponding to Gel 1_5 
 
 
 
 
 
 
 
 
 
 
 
Band 
Gel 1_5 
A(M) B C D E F(M) 
1 21226 2388.624 2561.203 2799 2885.929 21226 
2 8576 2284.906 2077.568 2388.624 2419.113 8576 
3 7427 2051.383 1813.606 2241.846 2241.846 7427 
4 6106 1867.130 1577.287 1711.116 1751.398 6106 
5 5000 1559.042 1509.034 1568.138 1461.302 5000 
6 4268 1369.020 1338.726 1017.363 1294.537 4268 
7 3630 1244.823 1217.277   3630 
8 2799     2799 
9 2000     2000 
10 1900     1900 
11 1550     1550 
12 1400     1400 
13 1164     1164 
14 992     992 
15 925     925 
16 831     831 
17 710     710 
18 564     564 
19 492     492 
20 359     359 
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GEL 2 
 
 
 
 
 
 
     Figure 25: U-STELA Gel 2  
 
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 2_1 
 
Figure 25 (a): U-STELA Gel 2_1 with markers 
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GEL 2_2 
 
Figure 25 (b): U-STELA Gel 2_2 with markers 
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GEL 2_3 
 
Figure 25 (c): U-STELA Gel 2_3 with markers 
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GEL 2_4 
 
Figure 25 (d): U-STELA Gel 2_4 with markers 
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GEL 2_5 
 
Figure 25 (e): U-STELA Gel 2_5 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
Band 
Gel 2_1 
A(M) B C D E F(M) 
1 21226 1866.172 1877.381 1959.383 1789.564 21226 
2 8576 1242.802 1705.855 1757.702 1655.537 8576 
3 7427 1084.152 1504.287 1213.548 1400 7427 
4 6106 705.474 1334.866 423.967 1288.012 6106 
5 5000 405.809 925  852.220 5000 
6 4268    500.472 4268 
7 3630    446.831 3630 
8 2799     2799 
9 2000     2000 
10 1900     1900 
11 1550     1550 
12 1400     1400 
13 1164     1164 
14 992     992 
15 925     925 
16 831     831 
17 710     710 
18 564     564 
19 492     492 
20 359     359 
 
Table 26 (a): Telomere bands corresponding to Gel 2_1 
 
                  
             Table 26 (b): Telomere bands corresponding to Gel 2_2 
 
Band 
Gel 2_2 
A(M) B C D E F G H I J(M) 
1 21226 1695.670 1822.003 1832.946 2055.867 1949.359 1529.107 2022.162 2022.162 21226 
2 8576 371.793 1428.791 1726.407 1695.671 1800.312 1287.315 1529.107 1855.030 8576 
3 7427  1230.973 1550 1280.134 1550 1054.026 1210.486 1675.483 7427 
4 6106  969.144 1217.277 343.625 1392.189 639.078 1048.231 1376.700 6106 
5 5000  825.986 876.741  1287.315   1258.829 5000 
6 4268   673.606  1059.854   886.187 4268 
7 3630   535.842     301.339 3630 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
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Band 
Gel 2_3 
A(M) B C D E F G H I J(M) 
1 21226 1870.475 1766.088 2000 2037.005 1959.383 2087.413 1793.966 1959.383 21226 
2 8576  1473.092 1775.332 1831.821 1702.714 2000 1650.207 1803.355 8576 
3 7427  1186.443 1356.141 1582.707 1516.559 1803.355 1599.319 1566.268 7427 
4 6106  507.754 1027.882 1058.772 1364.801 1658.844 1116.734 1451.828 6106 
5 5000   881.022  1130.039 1240.508 935.844 1322.045 5000 
6 4268     864.022 992 872.481 916.032 4268 
7 3630      692.069 666.019 839.135 3630 
8 2799       616.822 678.919 2799 
9 2000        518.535 2000 
10 1900        275.318 1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
                  Table 26 (c): Telomere bands corresponding to Gel 2_3 
 
 
 
 
           Table 26 (d): Telomere bands corresponding to Gel 2_4 
 
Band 
Gel 2_4 
A(M) B C D E F G H I J(M) 
1 21226 1609.237 1688.737 1772.164 1419.129 1932.765 1478.098 2084.282 1932.765 21226 
2 8576 1419.129  1697.809 1157.127 1743.907 1268.169 1849.776 1084.152 8576 
3 7427 1033.987  1600.638 634.888 1488.162 526.771 1164 1003.819 7427 
4 6106 831  1488.162  1319.342  825.569 909.480 6106 
5 5000   1409.532  626.591  434.447 864.465 5000 
6 4268   969.144     724.104 4268 
7 3630         3630 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
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Band 
Gel 2_5 
A(M) B C D E F G H I J(M) 
1 21226  1869.704 1781.685 2000 1400  1820.281 1800.879 21226 
2 8576  1725.319 1137.713 1869.704 526.771  1617.882  8576 
3 7427  1550 844.466    1300.343  7427 
4 6106  905.386 737.328    1014.920  6106 
5 5000       849.003  5000 
6 4268       590.575  4268 
7 3630         3630 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
 
                  Table 26 (e): Telomere bands corresponding to Gel 2_5 
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GEL 3 
 
 
 
 
 
Figure 26: U-STELA Gel 3 
 
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 3_1 
 
Figure 26 (a): U-STELA Gel 3_1 with markers 
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GEL 3_2 
 
 
Figure 26 (b): U-STELA Gel 3_2 with markers 
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GEL 3_3 
 
 
Figure 26 (c): U-STELA Gel 3_3 with markers 
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GEL 3_4 and GEL 3_5 
 
 
 
 
 
Figure 26 (d): U-STELA Gel 3_4 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
Band 
Gel 3_1 
A B C D E F G H I J 
1 21226 2633.069 2781.947 2601.083 2930.401 2885.929 2731.409 2820.484 2842.132 21226 
2 8576 2387.798 2633.069 2387.798 2649.210 2446.886 2569.485 2330.136 2569.485 8576 
3 7427 2315.939 2218.957 2000 2461.885 2178.646 2344.419 1855.030 2287.806 7427 
4 6106 1789.564 2024.595  2100.209 1900 2165.373 1778.879 1705.855 6106 
5 5000  1606.703  2000 1695.670 1888.656 1037.421 1616.353 5000 
6 4268  1356.141  1568.675 1455.893 1726.407 501.694 1280.628 4268 
7 3630  1071.133  760.278  1635.827  1149.205 3630 
8 2799  874.272    1514.017  1091.884 2799 
9 2000  564    1356.140  974.808 2000 
10 1900      1201.645  760.278 1900 
11 1550      919.797  593.129 1550 
12 1400      840.427  359 1400 
13 1164      660.716   1164 
14 992      637.372   992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
             Table 27 (a): Telomere bands corresponding to Gel 3_1 
 
 
Band 
Gel 3_2 
A B C D E F G H I A 
1 21226 2074.695 1924.521 2037.005 1900 2049.492 2165.373 2012.259 1900 21226 
2 8576 1949.359 1742.775 1797.374 1550 1559.593 2000 1888.314 1786.319 8576 
3 7427 1441.311 1105.940 803.052 1363.561 1400 1638.501 1742.775 1328.069 7427 
4 6106 980.505 543.829  749.946 455.811 1462.421 1608.453 969.144 6106 
5 5000      1319.342 1441.311 781.372 5000 
6 4268      1071.133 1243.331 588.878 4268 
7 3630      863.033 980.505 469.059 3630 
8 2799      694.841 734.709  2799 
9 2000       348.860  2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
               Table 27 (b): Telomere bands corresponding to Gel 3_2 
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Band 
Gel 3_3 
A(M) B C D E F G H I J(M) 
1 21226 1645.653 1924.521 2012.259 2024.595 2000 1900 1924.521 1675.483 21226 
2 8576 1171.986 1064.304 1832.946 1726.407 1789.564 1550 1568.675 1578.097 8576 
3 7427  710 704.747  1289.718 1502.209 1478.870 1490.494 7427 
4 6106  553.103   957.914 1352.947 1371.575 1371.575 6106 
5 5000  376.558   776.045 888.565 1071.133 1057.519 5000 
6 4268     649.466 659.184 714.874 870.889 4268 
7 3630     323.199  531.935 664.098 3630 
8 2799        553.103 2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
                       Table 27 (c): Telomere bands corresponding to Gel 3_3 
 
 
Band 
Gel 3_4.5 
A(M) B C D E F G H I 
1 21226 1550 1736.777 2037.005 1855.030 2205.438 1811.125 2246.244 2358.791 
2 8576 1332.748 1260.943 1789.564 1675.483 1587.575 1716.100 1559.309 1822.003 
3 7427 1237.878 1044.078 1616.353 1391.411 1300.343 1578.097  1391.411 
4 6106 914.051  1400 1185.688 1030.808 1391.411  992 
5 5000   610.446  606.069 1134.599  765.498 
6 4268      903.232  365.717 
7 3630         
8 2799         
9 2000         
10 1900         
11 1550         
12 1400         
13 1164         
14 992         
15 925         
16 831         
17 710         
18 564         
19 492         
20 359         
 
                  Table 27 (d): Telomere bands corresponding to Gel 3_4 
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BAND 
Gel 3_4.5 
J(M) K L M N O(M) 
1 21226 2087.413 1578.097 1078.006 1587.575 21226 
2 8576 1888.656 1178.414  632.803 8576 
3 7427 1655.537 887.243   7427 
4 6106 1260.943    6106 
5 5000     5000 
6 4268     4268 
7 3630     3630 
8 2799     2799 
9 2000     2000 
10 1900     1900 
11 1550     1550 
12 1400     1400 
13 1164     1164 
14 992     992 
15 925     925 
16 831     831 
17 710     710 
18 564     564 
19 492     492 
20 359     359 
 
      Table 27 (e): Telomere bands corresponding to Gel 3_5 
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GEL 4 
 
	  	  
 
 
Figure 27: U-STELA Gel 4  
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 4_1 
 
Figure 27 (a): U-STELA Gel 4_1 with markers 
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GEL 4_2 
 
 
Figure 27 (b): U-STELA Gel 4_2 with markers 
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GEL 4_3 
 
 
Figure 27 (c): U-STELA Gel 4_3 with markers 
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GEL 4_4 
 
 
Figure 27 (d): U-STELA Gel 4_4 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
 
     Table 28 (a): Telomere bands corresponding to Gel 4_1 
 
 
              Table 28 (b): Telomere bands corresponding to Gel 4_2 
 
 
Band 
Gel 4_1 
A(M) B C D E F(M) 
1 21226 6491.379 3686.409 9045.587 6652.258 21226 
2 8576 5214.839 2998.397 6106 6042.116 8576 
3 7427 3658.096 2734.864 3261.496 5382.005 7427 
4 6106 3311.755 2610.968 3044.602 4598.067 6106 
5 5000 2734.864 2298.437 2507.172 4170.412 5000 
6 4268 2285.156 2070.764 2338.745 3772.671 4268 
7 3630 2011.624 1924.521 2131.643 3115.248 3630 
8 2799 1798.274 1730.324 1701.994 2820.484 2799 
9 2000 1575.799 1619.757 1276.558 2656.758 2000 
10 1900 1438.006 1525.289 770.753 2379.760 1900 
11 1550 1276.558 1164  2169.026 1550 
12 1400 1080.718 534.015  2011.623 1400 
13 1164    1655.804 1164 
14 992    1593.238 992 
15 925    1258.558 925 
16 831    630.111 831 
17 710    526.771 710 
18 564     564 
19 492     492 
20 359     359 
Band 
Gel 4_2 
A(M) B C D E F G H I J(M) 
1 21226 2986.956 2667.778 2604.492 2749.052 2408.998 2573.414 2604.492 2452.768 21226 
2 8576 2749.052 2438.090 2423.500 2620.171 2175.320 2296.0596 2296.0596 2255.086 8576 
3 7427 2175.320 2162.303 2048.597 2188.416 1900 2123.717 2048.597 2048.597 7427 
4 6106 2098.376 1373.517 1789.564 1655.537 1616.353 1866.172 1811.125 1924.521 6106 
5 5000 1912.222 1240.508 1494.668 1068.445 1347.535 1420.505 1505.574 1675.483 5000 
6 4268 1736.777 1171.433 550.569  1118.388 1338.984 925 1494.668 4268 
7 3630 1616.353 1032.457   398.766 1240.508 714.874 1171.433 3630 
8 2799 1137.713 964.637    1093.132 595.124 925 2799 
9 2000 898.357 678.051    978.223 516.297  2000 
10 1900 814.117     590.575   1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
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Band 
Gel 4_3 
A(M) B C D E F G H I J(M) 
1 21226 2855.537 3011.948 3011.948 3052.372 3011.948 2991.938 3072.787 2836.566 21226 
2 8576 2062.055 2522.807 2799 2855.537 2698.228 2714.767 2836.566 2538.271 8576 
3 7427 1765.320 2218.957 2522.807 2417.161 2387.798 2387.798 2538.271 2126.036 7427 
4 6106 1658.844 2139.068 2358.791 2152.180 2260.014 2330.136 2373.249 1878.630 6106 
5 5000  1900  1046.306 1949.359 2024.595 2192.001 1649.489 5000 
6 4268  1775.332   1706.422 1815.952 2113.083 1567.632 4268 
7 3630  1039.359    1677.714 1847.025 1391.116 3630 
8 2799  851.488    1501.475 1445.246 586.060 2799 
9 2000  482.963    1417.926 1209.319  2000 
10 1900      889.647 843.233  1900 
11 1550      591.709   1550 
12 1400      528.338   1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
 
                       Table 28 (c): Telomere bands corresponding to Gel 4_3 
 
 
 
 
 
 
                   Table 28 (d): Telomere bands corresponding to Gel 4_4 
 
 
 
Band 
Gel 4_4 
A(M) B C D E F G H I J(M) 
1 21226 2919.521 3154.115 2960.837 2960.837 3110.102 3176.355 2483.399 2799 21226 
2 8576 2599.198 2455.264 2628.982 2279.999 2838.610 2899.079 2228.631 2319.301 8576 
3 7427 2241.364 2267.047 2483.399 1855.030 2644.002 2628.982 1716.100 1979.588 7427 
4 6106 1919.592 2081.367 2081.368  2359.279 2190.866 1364.80 1716.100 6106 
5 5000 1811.125 1939.386 1665.480  2000 1866.172 606.863 1518.766 5000 
6 4268 1665.480 1448.314 1081.747  1822.003 1587.575  1356.140 4268 
7 3630 626.216 1400   1518.766 1313.655  1067.429 3630 
8 2799  1264.426   1288.806 846.983   2799 
9 2000  652.984   890.418    2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 925         925 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
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GEL 5 
 
 
 
 
          Figure 28: U-STELA Gel 5  
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 5_1 
 
 
Figure 28 (a): U-STELA Gel 5_1 with markers 
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GEL 5_2 
 
 
     Figure 28 (b): U-STELA Gel 5_2 with markers 
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GEL 5_3 
 
 
Figure 28 (c): U-STELA Gel 5_3 with markers 
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GEL 5_4 
 
 
Figure 28 (d): U-STELA Gel 5_4 with markers 
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GEL 5_5 
 
Figure 28 (e): U-STELA Gel 5_5 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
Band 
Gel 5_1 
A(M) B C D E F G H I J(M) 
1 21226 1939.386 1706.422 2070.764 1979.588 2035.075 2094.904 2107.079 992 21226 
2 8576 1004.277 1649.489 1889.285 1716.100 1288.012 1706.422 1900  8576 
3 7427  1350.859 1677.714 1612.593 299.126 1342.839 1785.401  7427 
4 6106  908.718 1411.004 1257.693  836.735 1042.025  6106 
5 5007  748.237  1149.771   963.122  5007 
6 4268    1061.428   583.421  4268 
7 3585    641.431     3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 947         947 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
                   Table 29 (a): Telomere bands corresponding to Gel 5_1 
 
 
Band 
Gel 5_2 
A(M) B C D E F G H I J(M) 
1 21226 1559.309 1949.359 1655.537 2013.489 1989.768 1578.097 1939.386 1757.702 21226 
2 8576 1224.814 1843.955 1486.381 1959.383 1416.865 1313.655 1811.125 1606.703 8576 
3 7427   1248.430 1280.628 892.921  1451.207 668.026 7427 
4 6106   1149.205 659.041 836.447  1178.914  6106 
5 5007   831    1017.706  5007 
6 4268       934.706  4268 
7 3585         3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 947         947 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
                         Table 29 (b): Telomere bands corresponding to Gel 5_2 
 
	  	  
255	  
 
 
Band 
Gel 5_3 
A(M) B C D E F G H I J(M) 
1 21226 1747.208 1665.480 1736.777 2133.545 2119.798 2106.141 1843.955 1843.955 21226 
2 8576 1559.309 1578.097 1616.353 1888.656 1943.812 1977.332 1597.110 1705.855 8576 
3 7427 467.487 1473.092 1527.625 1747.208 1832.946 1888.656 1420.505 1364.801 7427 
4 6106   1420.505 798.942 1695.670 1516.559 1171.433  6106 
5 5007   738.489  1441.311 1164 875.589  5007 
6 4268   652.984  1042.025 972.458 374.619  4268 
7 3585     455.693    3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 947         947 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
                  Table 29 (c): Telomere bands corresponding to Gel 5_3 
 
 
Band 
Gel 5_4 
A(M) B C D E F G H I J(M) 
1 21226 1889.285 1878.630 1805.711 1857.501 1603.499 1677.714 1857.501 1391.116 21226 
2 8576 1400 1755.364 1640.187 1558.791 1430.870 1382.289 1785.401  8576 
3 7427 305.358 1649.489 1382.289 1373.517 849.296  1603.499  7427 
4 6106  1400 1171.433 1224.814   1313.655  6106 
5 5007  1256.403 1033.987 682.526   906.637  5007 
6 4268  1116.734 855.484      4268 
7 3585  579.036 422.065      3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1550         1550 
12 1400         1400 
13 1164         1164 
14 992         992 
15 947         947 
16 831         831 
17 710         710 
18 564         564 
19 492         492 
20 359         359 
 
                    Table 29 (d): Telomere bands corresponding to Gel 5_4 
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         Table 29 (e): Telomere bands corresponding to Gel 5_5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band 
Gel 5_5 
A(M) B C D E J(M) 
1 21226 1966.095 1900 2048.597 1805.711 21226 
2 8576 1567.632 1462.421 1696.799 1716.100 8576 
3 7427  1382.875 1594.456 1527.625 7427 
4 6106  663.518 1473.092 1462.421 6106 
5 5007  344.784 1340.975 1071.387 5007 
6 4268   1215.236 705.209 4268 
7 3585   1040.128  3585 
8 2799   805.253  2799 
9 2000     2000 
10 1900     1900 
11 1550     1550 
12 1400     1400 
13 1164     1164 
14 992     992 
15 947     947 
16 831     831 
17 710     710 
18 564     564 
19 492     492 
20 359     359 
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GEL 6 
 
 
 
 
 
Figure 29: U-STELA Gel 6  
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 6_1 
 
    Figure 29 (a): U-STELA Gel 6_1 with markers 
 
	  	  
259	  
GEL 6_2 
 
Figure 29 (b): U-STELA Gel 6_2 with markers 
	  	  
260	  
GEL 6_3 
 
Figure 29 (c): U-STELA Gel 6_3 with markers 
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GEL 6_4 
 
 
Figure 29 (d): U-STELA Gel 6_4 with markers 
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GEL 6_5 
 
Figure 29 (e): U-STELA Gel 6_5 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
 
Band 
Gel 6_1 
A(M) B C D E F(M) 
1 21226 2080.670 1614.418 1791.469 1759.339 21226 
2 8576 1436.081  1520.699 1305.544 8576 
3 7427    560.162 7427 
4 6106     6106 
5 5007     5007 
6 4268     4268 
7 3585     3585 
8 2799     2799 
9 2000     2000 
10 1900     1900 
11 1550     1550 
12 1400     1400 
13 1164     1164 
14 992     992 
15 947     947 
16 831     831 
17 710     710 
18 564     564 
19 492     492 
20 359     359 
 
Table 30 (a): Telomere bands corresponding to Gel 6_1 
 
 
Band 
Gel 6_2 
A(M) B C D E F G H I J(M) 
1 21226 1678.383 1692.318 2009.626 2019.299 1823.054 1942.229 1566.461 1007.989 21226 
2 8576 1508.026 1498.778 1617.082 1706.368 1657.696 1713.437   8576 
3 7427  1475.904 1487.297 1671.459 1323.206 1557.764   7427 
4 6106  1401.784 1217.416 1557.764 841.929 1179.018   6106 
5 5007    1510.347 557.041 821.249   5007 
6 4268    1471.372     4268 
7 3585    898.774     3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 30 (b): Telomere bands corresponding to Gel 6_2 
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Band 
Gel 6_3 
A(M) B C D E F G H I J(M) 
1 21226 1891.789 1985.398 1835.296 2080.670 1646.961 1835.297 1527.705 1985.399 21226 
2 8576 1803.776 1742.349 1661.289 1900 1482.729 985.739 992 1788.219 8576 
3 7427  1661.289 1549.116 1811.605 1164   1457.857 7427 
4 6106  1549.116  1480.451    979.519 6106 
5 5007  1462.348  1446.689    54.184 5007 
6 4268  1040.744       4268 
7 3585  983.662       3585 
8 2799  754.299       2799 
9 2000  54.184       2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 30 (c): Telomere bands corresponding to Gel 6_3 
 
 
Band 
Gel 6_4 
A(M) B C D E F G H I J(M) 
1 21226 1861.129 2000 2020.168 1838.189 1853.451 2020.168 1845.804 2061.115 21226 
2 8576 1650.857 1567.487 1685.336 1793.155 1571.599 1742.006 1323.206 1785.757 8576 
3 7427 1584 1478.555 1571.599 1450.031 1429 1567.487 359 1497.882 7427 
4 6106 1518.974 1419.869 1473.762   492   6106 
5 5007 1468.985 537.759 1357.571      5007 
6 4268 1348.897  1257.065      4268 
7 3585 986.011  988.003      3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 30 (d): Telomere bands corresponding to Gel 6_4 
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Band 
Gel 6_5 
A(M) B C D E F G H I J(M) 
1 21226 1974.517 1685.336 1488.905 1949.359 2000 2000 1523.457 1884.355 21226 
2 8576 1720.535 957.610 1293.985 1763.746 1355.326 1756.469  1830.606 8576 
3 7427 1637.263 622.483  1630.509  1657.696  1597.151 7427 
4 6106 1566.461   1505.459  1470.210   6106 
5 5007 858.595   1470.210  933.834   5007 
6 4268 492   1319.927     4268 
7 3585    982.832     3585 
8 2799    903.821     2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 30 (e): Telomere bands corresponding to Gel 6_5 
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GEL 7 
 
 
 
 
Figure 30: U-STELA Gel 7  
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 7_1 
 
Figure 30 (a): U-STELA Gel 7_1 with markers 
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GEL 7_2 
 
Figure 30 (b): U-STELA Gel 7_2 with markers 
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GEL 7_3 
 
Figure 30 (c): U-STELA Gel 7_3 with markers 
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GEL 7_4 
 
Figure 30 (d): U-STELA Gel 7_4 with markers 
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GEL 7_5 
 
 
Figure 30 (e): U-STELA Gel 7_5 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
 
Band 
Gel 7_1 
A(M) B C D E F G H I J(M) 
1 21226 1696.862 1872.183 1966.095 1988.634 1730.561 2060.930 1808.851 1932.765 21226 
2 8576 1475.538 1467.217 1556.031 1756.273 1512.147 1890.682 1680.259 1551.417 8576 
3 7427 918.869 1442.533 1225.245 1599.651 1434.398 1579.304 1584 1489.512 7427 
4 6106   972.798 39.537  1524.023 1461.695 1447.982 6106 
5 5007      887.106 1280.298 984.755 5007 
6 4268       1123.367 797.095 4268 
7 3585       536.323 519.252 3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 31 (a): Telomere bands corresponding to Gel 7_1 
 
 
 
Table 31 (b): Telomere bands corresponding to Gel 7_2 
Band 
Gel 7_2 
A(M) B C D E F G H I J(M) 
1 21226 2000 1900 2037.697 1939.386 1969.459 1890.424 1959.383 1989.768 21226 
2 8576 1871.416 1666.093 1900 1752.440 1797.278 1505.869 1815.532 1900 8576 
3 7427 0.0042 1216.302 1770.239 1584 1505.869  1734.819 1657.696 7427 
4 6106   1657.696    1579.304 1308.746 6106 
5 5007   971.491    1484.775 962.513 5007 
6 4268   949.201    1437.665 663.518 4268 
7 3585       980.553 0.0528 3585 
8 2799       882.289  2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
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Band 
Gel 7_3 
A(M) B C D E F G H I J(M) 
1 21226 1942.229 1600.088 1985.398 2023.727 1700.109 2047.735 1743.608 1942.229 21226 
2 8576 1852.599 970.424 1524.669 1788.219 1472.759 1779.206 1434.398 1649.341 8576 
3 7427 1717.377 736.782 1467.217 1616.340  1255.872 1246.367 1506.456 7427 
4 6106 1544.196  1354.995 1354.995    1046.306 6106 
5 5007 1344.740  878.234 928.153     5007 
6 4268 497.334        4268 
7 3585         3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 31 (c): Telomere bands corresponding to Gel 7_3 
 
 
Band 
Gel 7_4 
A(M) B C D E F G H I J(M) 
1 21226 1890.682 1853.865 2069.544 1863.002 1863.002 1808.851 1890.682 1881.409 21226 
2 8576 1509.109  1672.019 1696.862 553.955 1457.110 1556.031  8576 
3 7427 992  1515 1503.241   1261.678  7427 
4 6106    1437.376   139.471  6106 
5 5007    903.821   0.00581  5007 
6 4268         4268 
7 3585         3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 31 (d): Telomere bands corresponding to Gel 7_4 
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Band 
Gel 7_5 
A(M) B C D E F(M) 
1 21226 1970.903 1978.138 1942.229 1913.974 21226 
2 8576 1768.357 1855.065 1872.909 1768.357 8576 
3 7427  1645.835 1751.508 1591.601 7427 
4 6106  509.535 1490.302  6106 
5 5007     5007 
6 4268     4268 
7 3585     3585 
8 2799     2799 
9 2000     2000 
10 1900     1900 
11 1584     1584 
12 1515     1515 
13 1429     1429 
14 1164     1164 
15 992     992 
16 947     947 
17 831     831 
18 710     710 
19 564     564 
20 492     492 
 
Table 31 (d): Telomere bands corresponding to Gel 7_5 
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GEL 8 
 
 
 
Figure 31: U-STELA Gel 8  
For purposes of counting the bands, the gel was divided into 
sections, which are shown below. 
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GEL 8_1 
 
Figure 31 (a): U-STELA Gel 8_1 with markers 
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GEL 8_2 
 
Figure 31 (b): U-STELA Gel 8_2 with markers 
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GEL 8_3 
 
 
Figure 31 (c): U-STELA Gel 8_3 with markers 
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GEL 8_4 
 
 
Figure 31 (d): U-STELA Gel 8_4 with markers 
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GEL 8_5 
 
 
Figure 31 (e): U-STELA Gel 8_5 with markers 
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The corresponding bands counted using Vision Works LS Analysis software 
are shown below: 
Band 
Gel 8_1 
A(M) B C D E F(M) 
1 21226 1919.592 1979.588 1874.879 1979.588 21226 
2 8576 963.336 1537.659 1506.972 1939.386 8576 
3 7427 723.673 1429 1446.825 1817.547 7427 
4 6106   1164 1626.732 6106 
5 5007   777.333 1216.302 5007 
6 4268   560.344 803.719 4268 
7 3585    636.649 3585 
8 2799     2799 
9 2000     2000 
10 1900     1900 
11 1584     1584 
12 1515     1515 
13 1429     1429 
14 1164     1164 
15 992     992 
16 947     947 
17 831     831 
18 710     710 
19 564     564 
20 492     492 
 
Table 32 (a): Telomere bands corresponding to Gel 8_1 
 
 
Table 32 (b): Telomere bands corresponding to Gel 8_2 
Band 
Gel 8_2 
A(M) B C D E F G H I J(M) 
1 21226 1863.966 1710.085 1974.517 1768.357 1974.517 1936.900 1819.883 1734.819 21226 
2 8576 1776.842 1524.023 1802.543 1669.641 1569.953 1622.369 1685.703 1685.703 8576 
3 7427 1519.505 1276.101 1479.455 1463.332  1519.505 1460.663 1487.583 7427 
4 6106 1322.036 860.755  1231.761  1444.745 831 683.274 6106 
5 5007 1172.262   882.659  1164  578.613 5007 
6 4268    666.019  794.465   4268 
7 3585    524.011     3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
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Band 
Gel 8_3 
A(M) B C D E F G H I J(M) 
1 21226 1738.870 2011.828 1788.219 1722.725 1942.229 1873.599 1882.359 1813.417 21226 
2 8576 1573.954 1755.167 1559.004 1504.306 1838.969 1738.870 1472.675 1683.015 8576 
3 7427 1506.972 1467.468 1294.281 1294.281 1628.954 1491.045 1369.626 1524.669 7427 
4 6106 1434.070 1053.300 0.00581 1180.583 1475.285 1408.928 1231.761 1294.281 6106 
5 5007 780.304   905.119 1449.389 985.116  953.618 5007 
6 4268 521.122    1303.467   847.875 4268 
7 3585     1180.583   502.725 3585 
8 2799     978.279    2799 
9 2000     805.253    2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 32 (c): Telomere bands corresponding to Gel 8_3 
 
 
Band 
Gel 8_4 
A(M) B C D E F G H I J(M) 
1 21226 1838.969 1813.417 1722.725 1651.907 1598.845 1771.616 1796.579 1856.204 21226 
2 8576 1537.659 1519.505 1524.023 1462.280 1501.645 1698.788 1418.570 1667.388 8576 
3 7427 1457.110  1483.144 1243.328 1470.069 1584  1451.958 7427 
4 6106 1172.558  1012.026 1053.300 1032.457 1280.298   6106 
5 5007 889.2552  835.031 782.474 942.428 1074.564   5007 
6 4268     847.244 971.491   4268 
7 3585      839.082   3585 
8 2799      628.981   2799 
9 2000      570.875   2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 32 (d): Telomere bands corresponding to Gel 8_4 
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Band 
Gel 8_5 
A(M) B C D E F G H I J(M) 
1 21226 2115.236 1788.219 2056.811 2022.534 2033.896 2000 1942.229 2068.366 21226 
2 8576 1815.532 1461.695 1691.540 1770.239 1806.382 1691.540 1824.729 839.732 8576 
3 7427 1761.317  1461.695 1549.116  1632.757 1641.028  7427 
4 6106 1641.028  848.557 1447.982  1519.827 1118.388  6106 
5 5007 1549.116   810.173  989.445 951.897  5007 
6 4268 1312.719     871.025 884.791  4268 
7 3585 1164        3585 
8 2799         2799 
9 2000         2000 
10 1900         1900 
11 1584         1584 
12 1515         1515 
13 1429         1429 
14 1164         1164 
15 992         992 
16 947         947 
17 831         831 
18 710         710 
19 564         564 
20 492         492 
 
Table 32 (e): Telomere bands corresponding to Gel 8_5 
 
 
The number of bands below 1500 bp were counted for each sample (8 reactions per 
sample) from the data shown above. The resultant number of bands less than 1500 bp 
for each sample are shown in the table below: 
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Patient ID/Sample number Bands < 1500 bp 
S1 11 
S2 23 
S3 8 
S4 8 
S5 15 
S6 27 
S7 11 
S8 10 
S9 25 
S10 26 
S11 22 
S12 16 
S13 11 
S14 16 
S15 19 
S16 23 
S17 19 
S18 22 
S19 30 
S 20 19 
S 21 31 
S 22 23 
S 23 32 
S24 18 
S25 12 
S26 16 
S27 15 
S28 18 
	  	  
285	  
S29 26 
S30 22 
 
                     Table 33: Number of telomere bands below 1500 bp for each sample 
 
 
These were then calibrated based on the initial PCR DNA template concentration and 
presented as the number of telomeres below 1500 bp per genome equivalent of 
template DNA. 
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B. Graph showing mean telomere length (with 95% confidence interval) by gender 
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         Figure 32: Mean telomere length (with 95% confidence intervals) by gender 
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C: Telomere associated SNPs 
 
CHR SNP BP N P 
10 rs9415039 73192704 1481 2.58x10-6 
1 rs2801201 204726496 1474 8.02x10-6 
3 rs12696304 170963963 1487 9.73x10-6 
8 rs2167801 107563248 1485 1.17x10-5 
3 rs7625734 170991616 1486 1.25x10-5 
1 rs12083865 173962432 1484 1.32x10-5 
3 rs9831661 171011232  1484 1.38x10-5 
9 rs2680198 107051048 1481 1.41x10-5 
3 rs10936601 171011152 1473 1.43x10-5 
10 rs7090665 73713808 1485 1.73x10-5 
12 rs7133043 66226912 1481 1.83x10-5 
6 rs10806605 69569072 1483 2.35x10-5 
2 rs624895 12779844 1485 2.48x10-5 
13 rs1513031 103514088 1487 2.65x10-5 
2 rs477599 12784768 1487 2.88x10-5 
11 rs7110007 75679600 1487 2.93x10-5 
3 rs7372527 46064344 1486 3.12x10-5 
10 rs1149692 71386160 1478 3.13x10-5 
5 rs9327948 105095600 1484 3.67x10-5 
10 rs4418740 87471960 1486 3.91x10-5 
13 rs1849450 103512256 1487 4.06x10-5 
14 rs2268433 89936096 1473 4.24x10-5 
13 rs9586352 103464672 1483 4.51x10-5 
2 rs654004 12777856 1482 4.64x10-5 
10 rs1014637 132419824 1480 4.72x10-5 
12 rs1879405 117485592 1426 4.72x10-5 
18 rs2298628 45709920 1483 4.82x10-5 
8 rs13258014 4152868 1487 4.85x10-5 
 
Table 34: List of top SNPs (P<1x10-5) associating with telomere length in the 
BHF-FHS cohort 
 
{SNPs are given along with chromosomal (CHR) and base pair (bp) positions 
(estimated from HapMap build35). The number of individuals (N) included in 
the analysis for each SNP alongwith the P-value of the association are shown.} 
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CHR SNP BP N P 
15 rs8032144 96175496 1421 2.28x10-6 
1 rs12130746 212361952 1415 2.40x10-6 
12 rs7960152 99078240 1322 2.58x10-6 
9 rs10817041 110416280 1420 4.37x10-6 
16 rs2052873 70062800 1421 4.43x10-6 
9 rs10817042 110436016 1419 1.22x10-5 
13 rs17073170 28764736 1419 1.26x10-5 
16 rs16973260 70092352 1415 1.73x10-5 
16 rs16972808 70036216 1422 1.78x10-5 
12 rs4759709 129526352 1418 2.06x10-5 
18 rs1876978 64418208 1412 3.37x10-5 
7 rs2160059 10802988 1422 3.54x10-5 
1 rs1325939 119296008 1419 3.64x10-5 
7 rs17163856 10791039 1420 3.66x10-5 
16 rs12922830 70004768 1415 3.81x10-5 
7 rs6954256 10886998 1418 4.48x10-5 
5 rs13354399 153169632 1421 4.66x10-5 
10 rs11011867 20534772 1420 4.96x10-5 
 
Table 35: List of top SNPs (P<1x10-5) associating with telomere length in the 
UKBS cohort 
 
{SNPs are given along with chromosomal (CHR) and base pair (bp) positions 
(estimated from HapMap build35). The number of individuals (N) included in 
the analysis for each SNP alongwith the P-value of the association are shown.} 
 
